0001615774-16-005455.txt : 20160516 0001615774-16-005455.hdr.sgml : 20160516 20160516161009 ACCESSION NUMBER: 0001615774-16-005455 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160516 DATE AS OF CHANGE: 20160516 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYnd Analytics, Inc. CENTRAL INDEX KEY: 0000822370 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 870419387 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35527 FILM NUMBER: 161653822 BUSINESS ADDRESS: STREET 1: 85 ENTERPRISE STREET 2: SUITE 410, CITY: ALISO VIEJO STATE: CA ZIP: 92656 BUSINESS PHONE: (714) 545 3288 MAIL ADDRESS: STREET 1: 85 ENTERPRISE STREET 2: SUITE 410, CITY: ALISO VIEJO STATE: CA ZIP: 92656 FORMER COMPANY: FORMER CONFORMED NAME: CNS RESPONSE, INC. DATE OF NAME CHANGE: 20070313 FORMER COMPANY: FORMER CONFORMED NAME: STRATIVATION, INC. DATE OF NAME CHANGE: 20051115 FORMER COMPANY: FORMER CONFORMED NAME: SalesTactix, Inc. DATE OF NAME CHANGE: 20040805 10-Q 1 s103228_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2016

¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from __________________ to ______________________.

Commission file number 001-35527

MYnd Analytics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		87-0419387
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

26522 La Alameda, Suite 290

Mission Viejo, California 92691

(Address of principal executive offices) (Zip Code)

(949) 420-4400

(Registrant’s telephone number, including area code)

(Former name, former address, former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x

No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x

No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨

Non-accelerated filer	¨ (Do not check if smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨

No x

As of May 13, 2016, the issuer had 107,467,409 shares of common stock, par value $0.001 per share, issued and outstanding.

MYnd Analytics, Inc.

INDEX

		Page

PART I	FINANCIAL INFORMATION	2

Item 1.	Financial Statements	2

	Unaudited Condensed Consolidated Statements of Operations for the three and six months ended March 31, 2016 and 2015	2

	Condensed Consolidated Balance Sheets as of March 31, 2016 (unaudited) and September 30, 2015	3

	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended March 31, 2016 and 2015	4

	Unaudited Condensed Consolidated Statements of Stockholders’ Deficit for the six months ended March 31, 2016	5

	Notes to Unaudited Condensed Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	41

Item 4.	Controls and Procedures	41

PART II	OTHER INFORMATION	42

Item 1.	Legal Proceedings	42

Item 1A.	Risk Factors	42

Item 2.	Unregistered Sales of Equity Security and Use of Proceeds	42

Item 6.	Exhibits	42

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

MYND ANALYTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the three months ended March 31,						For the six months ended March 31,
	2016			2015			2016			2015
REVENUES
Neurometric Services	$	20,700		$	20,900		$	45,400		$	43,700

Cost of neurometric services revenue		1,400			1,800			2,700			2,900
Research		22,700			22,900			45,300			46,700
Product development		183,000			191,900			306,400			437,500
Sales and marketing		133,000			175,200			256,100			264,900
General and administrative		370,600			409,200			749,600			851,900

Total operating expenses		710,700			801,000			1,360,100			1,603,900

OPERATING LOSS		(690,000	)		(780,100	)		(1,314,700	)		(1,560,200	)

OTHER INCOME (EXPENSE):
Interest expense, net		(239,600	)		(54,600	)		(739,800	)		(106,000	)
Loss on extinguishment of debt		-			-			(2,337,400	)		-
Gain on derivative liabilities		786,900			139,200			798,200			99,300
Total other income (expense)		547,300			84,600			(2,279,000	)		(6,700	)
LOSS BEFORE PROVISION FOR INCOME TAXES		(142,700	)		(695,500	)		(3,593,700	)		(1,566,900	)
Provision for income taxes		-			800			300			4,000
NET LOSS	$	(142,700	)	$	(696,300	)	$	(3,594,000	)	$	(1,570,900	)

BASIC AND DILUTED LOSS PER SHARE:
From continuing operations	$	(0.00	)	$	(0.01	)	$	(0.04	)	$	(0.02	)

WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic and Diluted		102,669,022			101,667,409			102,543,215			101,667,409

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

MYND ANALYTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	Unaudited as at March 31,			Audited as at September 30,
	2016			2015
ASSETS
CURRENT ASSETS:
Cash	$	440,200		$	432,100
Accounts receivable (net of allowance for doubtful accounts of $1,200 and $1,200 as of March 31, 2016, and September 30, 2015, respectively)		6,800			11,800
Prepaid insurance		111,700			57,400
Prepaid other assets		58,900			46,900
Total current assets		617,600			548,200
Furniture and equipment, net		7,700			1,700
Intangible assets		9,000			-
Other assets		25,600			17,200
TOTAL ASSETS	$	659,900		$	567,100

LIABILITIES AND STOCKHOLDERS’ DEFICIT:
CURRENT LIABILITIES:
Accounts payable (including $10,000 and $10,000 to related parties as of March 31, 2016, and September 30, 2015, respectively)	$	744,200		$	852,000
Accrued liabilities		182,600			156,300
Accrued compensation		433,000			418,500
Accrued compensation – related parties		259,700			226,100
Deferred revenue - grant funds		45,900			45,900
Current portion of capital lease		1,700			2,400
Total current liabilities		1,667,100			1,701,200

LONG-TERM LIABILITIES
Secured convertible debt – related parties (net of discounts $363,100 and $209,900 as of March 31, 2016 and September 30, 2015, respectively)		3,346,900			2,240,100
Secured convertible debt - other (net of discounts $30,700 and $28,900 as of March 31, 2016, and September 30, 2015, respectively)		619,300			525,700
Accrued interest		192,400			103,600
Derivative liability		1,441,700			833,000
Long term portion of capital lease		5,400			-
Total long-term liabilities		5,605,700			3,702,400
TOTAL LIABILITIES		7,272,800			5,403,600
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; authorized 500,000,000 shares and issued and outstanding 102,717,409 shares and 102,417,409 shares as of March 31, 2016 and September 30, 2015, respectively		102,700			102,400
Additional paid-in capital		59,471,300			57,654,000
Accumulated deficit		(66,186,900	)		(62,592,900	)
Total stockholders’ deficit		(6,612,900	)		(4,836,500	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	659,900		$	567,100

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

MYND ANALYTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the six months ended March 31,
	2016			2015
OPERATING ACTIVITIES:
Net loss	$	(3,594,000	)	$	(1,570,900	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,700			4,400
Loss on derivative liability valuation		(798,200	)		(67,300	)
Valuation of warrants – investor relations		-			21,600
Stock based compensation		70,900			162,200
Grant of common stock		6,900			-
Loss on extinguishment of debt		2,337,400			-
Financing expenses		738,600			72,700
Changes in operating assets and liabilities:
Accounts receivable		5,000			3,900
Prepaids and other		(66,300	)		(56,500	)
Accounts payable and accrued liabilities		(81,600	)		12,300
Security deposits		(9,400	)		-
Deferred compensation		48,100			73,900
Net cash used in operating activities		(1,339,900	)		(1,343,700	)
INVESTING ACTIVITIES:
Purchase of fixed assets		(1,000	)		-
Intangible assets		(9,000	)		-
Net cash used in investing activities		(10,000	)		-
FINANCING ACTIVITIES:
Repayment of a capital lease		(2,000	)		(1,900	)
Net proceeds from issuance of secured convertible debt		1,360,000			415,000
Net cash provided by (used in) financing activities		1,358,000			413,100
NET INCREASE (DECREASE) IN CASH		8,100			(930,600	)
CASH- BEGINNING OF THE QUARTER		432,100			1,240,600
CASH- END OF THE QUARTER	$	440,200		$	310,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	1,300		$	1,500
Income taxes	$	300		$	4,000

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

MYND ANALYTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE SIX MONTHS ENDED MARCH 31, 2016

	Common Stock				Additional Paid-in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance at September 30, 2015 (Audited)		102,417,409	$	102,400	$	57,654,000	$	(62,592,900	)	$	(4,836,500	)
Stock-based compensation		—		—		70,900		—			70,900
Extension Warrants issued to note holders		—		—		1,196,000		—			1,196,000
Note Warrants issued to note holders		—		—		543,800		—			543,800
Stock issued to vendor		300,000		300		6,600		—			6,900
Net loss		—		—		—		(3,594,000	)		(3,594,000	)
Balance at March 31, 2016		102,717,409	$	102,700	$	59,471,300	$	(66,186,900	)	$	(6,612,900	)

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

MYND ANALYTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NATURE OF OPERATIONS

At our annual meeting of stockholders held on October 28, 2015, our stockholders approved a proposal to change the Company’s name to MYnd Analytics, Inc. from CNS Response, Inc. The Company’s charter was officially amended on November 2, 2015.

MYnd Analytics, Inc. (“MYnd,” “CNS,” “we,” “us,” “our,” or the “Company”), formerly known as CNS Response Inc., was incorporated in Delaware on March 20, 1987, under the name Age Research, Inc. Prior to January 16, 2007, the Company (then called Strativation, Inc.) was a “shell company” with nominal assets and our sole business was to identify, evaluate and investigate various companies to acquire or with which to merge. On January 16, 2007, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CNS Response, Inc., a California corporation formed on January 11, 2000 (“CNS California”), and CNS Merger Corporation, a California corporation and the Company’s wholly-owned subsidiary (“MergerCo”) pursuant to which the Company agreed to acquire CNS California in a merger transaction wherein MergerCo would merge with and into CNS California, with CNS California being the surviving corporation (the “Merger”). On March 7, 2007, the Merger closed, CNS California became a wholly-owned subsidiary of the Company, and on the same date the corporate name was changed from Strativation, Inc. to CNS Response, Inc. At the annual meeting held on October 28, 2015, stockholders approved a change in our name from CNS Response, Inc. to MYnd Analytics, Inc. On November 2, 2015, the Company filed an amendment to its Articles of Incorporation which, among other things, effected the name change to MYnd Analytics, Inc.

The Company is a predictive analytics company that provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (“PTSD”) and other non-psychotic disorders. The Company uses its proprietary neurometric platform, PEER Online, to generate Psychiatric EEG Evaluation Registry (“PEER”) Reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. Management intends to conduct a series of clinical trials, termed in aggregate the SMART-MD trials. The protocols used in this series of trials will be substantially similar to the protocol approved by the Walter Reed Institutional Review Board (the "Walter Reed IRB") during our 2013-2014 clinical trial at Walter Reed National Military Medical Center (“Walter Reed”) and Fort Belvoir Community Hospital (“Fort Belvoir”) (collectively, the “Walter Reed PEER Trial”). The protocol utilizes our neurometric platform to provide PEER Reports to clinicians treating patients with a primary diagnosis of depression with various comorbidities allowed, if present, to include PTSD and mild traumatic brain injury (“mTBI). The first trial in the series is the Canadian Forces Trial followed by parallel trials in Southern California, the SoCal Trial, and other U.S. locations. The protocols for the Canadian Forces Trial and the SoCal Trial have been approved by their respective institutional review boards and are ready for initiation and the recruitment of study subjects. The objective of the SMART-MD trials is to provide additional information to demonstrate the clinical and economic utility of our neurometric platform. We are in discussions to conduct additional studies with other groups and organizations. We are also focusing our direct-to-consumer marketing efforts using social media within California to boost our commercialization of the PEER Online platform and its PEER Reports.

Going Concern Uncertainty

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has a limited operating history and its operations are subject to certain challenges, expenses, difficulties, delays, complications, risks and uncertainties frequently encountered in the operation of a business with a limited operating history. These risks include the ability to obtain adequate financing on a timely basis, if at all, the failure to develop or supply technology or services to meet the demands of the marketplace, the failure to attract and retain qualified personnel, competition within the industry, government regulation and the general strength of regional and national economies.

The Company’s continued operating losses and limited capital raise substantial doubt about its ability to continue as a going concern. The Company has limited cash resources for its operations and will need to raise additional funds to meet its obligations as they become due. As of March 31, 2016, we had an accumulated deficit of $66,186,900. For the six months ended March 31, 2016 and 2015, we had net losses from operations of $1,314,700 and $1,560,200 respectively. Net cash used in operating activities for the six months ended March 31, 2016 and 2015, were $1,339,900 and $1,343,700 respectively.

To date, the Company has financed its cash requirements primarily from debt and equity financings. The Company will need to raise additional funds immediately to continue its operations and needs to raise substantial additional funds before the Company can increase demand for its PEER Online services. Until it can generate a sufficient amount of revenues to finance its cash requirements, which it may never do, the Company must continue to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The Company’s liquidity and capital requirements depend on several factors, including the rate of market acceptance of its services, the future profitability of the Company, the rate of growth of the Company’s business and other factors described elsewhere in this Quarterly Report on Form 10-Q. The Company continues to explore additional sources of capital, but there is substantial doubt as to whether any financing arrangement will be available in amounts and on terms acceptable to the Company to permit it to continue operations. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Between September 22, 2014, and March 31, 2016, the Company issued secured convertible debt in the aggregate principal amount of $4,360,000. During the fiscal year ended September 30, 2015, the aggregate gross proceeds to the Company were $1,350,000 from the debt offering. Additionally, for the six months ended March 31, 2016, the Company issued secured convertible debt in the aggregate principal amount of $1,360,000.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) and are in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, doubtful accounts, intangible assets, income taxes, valuation of equity instruments, accrued liabilities, contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates.

Cash

The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit of $250,000. At March 31, 2016 cash exceeds the federally insured limit by $190,200. The Company believes that the risk of loss is minimal. To date, the Company has not experienced any losses related to cash deposits with financial institutions.

Derivative Liabilities

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of March 31, 2016, the Company’s only derivative financial instruments were a series of convertible notes having embedded derivative liabilities based on the conversion price of the note relative to the market price of a share of Common Stock on the valuation date. See Notes 3 & 4.

Fair Value of Financial Instruments

ASC 825-10 defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company. The Company considers the carrying amount of cash, accounts receivable, other receivables, accounts payable and accrued liabilities, to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization.

The Company also analyzes all financial instruments with features of both liabilities and equity under ASC 480-10, ASC 815-10 and ASC 815-40.

The Company adopted ASC 820-10 on January 1, 2008. ASC 820-10 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments; and

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using the Black-Scholes option-pricing model with the following assumption inputs:

	March 31, 2016			September 30, 2015
Annual dividend yield		-			-
Expected life (years)		1.75			0.5
Risk-free interest rate		0.73	%		0.08	%
Expected volatility		225.53	%		48	%

	Carrying Value		Fair Value Measurements at
	As of		March 31, 2016
	March 31,		Using Fair Value Hierarchy
	2016		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		1,441,700		-		-		1,441,700
Total	$	1,441,700	$	-	$	-	$	1,441,700

	Carrying Value		Fair Value Measurements at
	As of		September 30, 2015
	September 30,		Using Fair Value Hierarchy
	2015		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		833,000		-		-		833,000
Total	$	833,000	$	-	$	-	$	833,000

For a roll-forward analysis of embedded derivative liabilities refer to Note 4. Derivative Liabilities

At March 31, 2016 and September 30, 2015, the Company had derivative liabilities of $1,441,700 and $833,000 respectively. For the six months ending March 31, 2016 and 2015, the Company had gains on the fair valuation of derivative liabilities of $798,200 and a $99,300 on fair valuation of derivative liabilities respectively. As of March 31, 2016, the Company did not identify any other assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10.

Accounts Receivable

The Company estimates the collectability of customer receivables on an ongoing basis by reviewing past-due invoices and assessing the current creditworthiness of each customer. Allowances are provided for specific receivables deemed to be at risk for collection which as of March 31, 2016 and September 30, 2015 were $1,200 and $1,200 respectively.

Furniture and Equipment

Furniture and Equipment, which are recorded at cost, consist of office furniture, equipment and purchased intellectual property which are depreciated, or amortized in the case of the intellectual property, over their estimated useful life on a straight-line basis. The useful life of these assets is estimated to be between three and ten years. Depreciation and amortization for the six months ended March 31, 2016 and 2015 was $2,700 and $4,400 respectively. Accumulated depreciation and amortization at March 31, 2016 and September 30, 2015 was $74,900 and $82,600, respectively.

Long-Lived Assets

As required by ASC 350-30 (formerly SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets), the Company reviews the carrying value of its long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of the asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset’s carrying value and fair value. No impairment loss was recorded for the six months ended March 31, 2016 and 2015.

Intangible Assets

Costs for software developed for internal use are accounted for through the capitalization of those costs incurred in connection with developing or obtaining internal-use software. Capitalized costs for internal-use software are included in intangible assets in the consolidated balance sheet. Capitalized software development costs are amortized over three years. Costs incurred during the preliminary project along with post-implementation stages of internal use computer software development and costs incurred to maintain existing product offerings are expensed as incurred. The capitalization and ongoing assessment of recoverability of development costs require considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility and estimated economic life. At March 31, 2016, the Company had $9,000 in capitalized software development of which $9,000 was capitalized during the three and six months ended March 31, 2016. The Company will begin amortizing the software over its estimated economic life once it has been placed into service. For the three and six months ended March 31, 2016, there has been no amortization expense for capitalized software development as it has not been placed into service.

Accounts Payable

Accounts payable consists of trade payables of which $405,700 and $476,900 are for legal services at March 31, 2016 and 2015 respectively.

Deferred Revenue

Deferred revenue represents revenue collected but not earned as of March 31, 2016. This represents a philanthropic grant for the payment of PEER Reports ordered for a clinical trial, which are otherwise not paid for by the military. These deferred revenue grant funds as of March 31, 2016 and 2015 are $45,900 for both periods.

Revenues

The Company recognizes revenue on services, being the delivery of PEER Reports to medical providers, in accordance with the Financial Accounting Standards Board (“FASB”) ASC No. 605, “Revenue Recognition.” In all cases, revenue is recognized when we have persuasive evidence of an arrangement, a determinable fee, when collection is considered to be reasonable assured and the services are delivered.

Research and Development Expenses

The Company charges all research and development expenses to operations as incurred.

Advertising Expenses

The Company charges all advertising expenses to operations as incurred. For the six months ended March 31, 2016 and 2015 advertising expenses were $85,100 and $29,000 respectively.

Stock-Based Compensation

The Company has adopted ASC 718-20 and related interpretations which establish the accounting for equity instruments exchanged for employee services. Under ASC 718-20, share-based compensation cost to option grantee, being employees and directors, and is measured at the grant date based on the calculated fair value of the award (see Note 5 for further discussion on valuations). The expense is recognized over the option grantees’ requisite service period, generally the vesting period of the award.

Income Taxes

The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded, when necessary, to reduce deferred tax assets to the amount expected to be realized.

As a result of the implementation of certain provisions of ASC 740, Income Taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as defined. ASC 740 seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company adopted the provisions of ASC 740 and have analyzed filing positions in each of the federal and state jurisdictions where required to file income tax returns, as well as all open tax years in these jurisdictions. We have identified the U.S. Federal and California as our "major" tax jurisdictions. Generally, we remain subject to Internal Revenue Service examination of our 2010 through 2014 U.S. federal income tax returns, and remain subject to California Franchise Tax Board examination of our 2010 through 2014 California Franchise Tax Returns. However, we have certain tax attribute carryforwards which will remain subject to review and adjustment by the relevant tax authorities until the statute of limitations closes with respect to the year in which such attributes are utilized.

We believe that our income tax filing positions and deductions will be sustained on audit and do not anticipate any adjustments that will result in a material change to our financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740. In addition, we did not record a cumulative effect adjustment related to the adoption of ASC 740. Our policy for recording interest and penalties associated with income-based tax audits is to record such items as a component of income taxes.

Comprehensive Income (Loss)

ASC 220-10 requires disclosure of all components of comprehensive income (loss) on an annual and interim basis. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company’s comprehensive income (loss) is the same as its reported net income (loss) for the six months ended March 31, 2016 and 2015.

Earnings (Loss) per Share

Basic earnings (loss) per share are computed by dividing income (loss) available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings (loss) per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.

Recent Accounting Pronouncements

Apart from the below-mentioned recent accounting pronouncements, there are no new accounting pronouncements that are currently applicable to the Company.

In April 2015, the FASB issued Accounting Standards Update (“ASU”) No. 2015-03 is to simplify presentation of debt issuance costs, the amendments in this Update would require that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of debt liability, consistent with debt discounts or premiums. The recognition and measurement guidance for debt issuance costs would not be affected by the amendments in this Update. The amendments in this ASU are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. The Company does not expect the adoption of the standard update to have a material impact on its consolidated financial position or results of operations.

CONVERTIBLE DEBT AND EQUITY FINANCINGS

Between September 22, 2014, and July 20, 2015, the Company entered into a Note Purchase Agreement (the “Original Note Purchase Agreement”) in connection with a bridge financing, with nine accredited investors, including lead investor RSJ Private Equity investiční fond s proměnným základním kapitálem (“RSJ PE”). Pursuant to the Original Note Purchase Agreement, the Company issued fifteen secured convertible promissory notes (each, a “September 2014 Note”) in the aggregate principal amount of $2.29 million. Of this amount, RSJ PE purchased a September 2014 Note for $750,000. The September 2014 Notes were also purchased by the following affiliates of the Company or entities under their control: RSJ PE, of which Michal Votruba is a director, purchased a September 2014 Note for $750,000, the Company’s director, John Pappajohn, purchased three September 2014 Notes for $400,000; the Follman Family Trust of which Robert Follman, a director of the Company, is a trustee, purchased a September 2014 Note for $100,000; The Tierney Family Trust, which is a greater than 5% stockholder of the Company, purchased five September 2014 Notes for $540,000, of which Thomas Tierney, a former director and Chairman of the Board of the Company (the “Board”), is a trustee; and Oman Ventures, of which Mark Oman, a greater than 5% stockholder of the Company, is the President, purchased a September 2014 Note for $200,000. Michal Votruba joined our Board on July 30, 2015

The Original Note Purchase Agreement provided for the issuance and sale of September 2014 Notes in the aggregate principal amount of up to $2.5 million, in one or more closings to occur over a six-month period beginning September 22, 2014. The Original Note Purchase Agreement also provided that the Company and the holders of the September 2014 Notes enter into a registration rights agreement covering the registration of the resale of the shares of the Common Stock underlying the September 2014 Notes.

On April 14, 2015, the Company entered into Amendment No. 1 to the Original Note Purchase Agreement with the majority of the noteholders in principal, dated as of April 14, 2015 (“Amendment No. 1”), pursuant to which: (i) the aggregate principal amount of notes provided for issuance was increased by $0.5 million to a total of $3.0 million, and (ii) the period to raise the $3.0 million was extended to September 30, 2015. The Company subsequently amended and restated the Original Note Purchase Agreement solely to update for the changes made pursuant to Amendment No. 1 (such amended and restated agreement, together with the Original Note Purchase Agreement, the “Note Purchase Agreement”).

On September 14, 2015, the Company entered into an Omnibus Amendment (the “Omnibus Amendment”) to the Note Purchase Agreement and the notes purchased and sold pursuant thereto, with the majority of the noteholders to fix the conversion price of all notes at $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the “Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.

Subsequently thereto, on September 14, 15 and 24, 2015, the Company entered into a Note Purchase Agreement, as amended by the Omnibus Amendment, with each of six accredited investors, in connection with a bridge financing. Pursuant to these Note Purchase Agreements, the Company issued an aggregate principal amount of $710,000 of secured convertible promissory notes (collectively, the “September 2015 Notes,” and together with the September 2014 Notes all other notes purchased and sold pursuant to the Note Purchase Agreement, the “Notes”), which amount also represents the gross proceeds to the Company from the September 2015 Notes. Four of the six September 2015 Notes were purchased by affiliates of the Company, or an entity under such affiliate’s control, as follows: (i) Dr. Robin Smith, Chairman of the Board, purchased a Note for $60,000; (ii) the Follman Family Trust purchased a Note for $150,000; (iii) John Pappajohn purchased a Note for $100,000 and (iv) RSJ PE, purchased a Note for $350,000.

Through December 23, 2015, and prior to further amendments to the Notes, all of the Notes were scheduled to mature on March 21, 2016, (subject to earlier conversion or prepayment), and earned interest at a rate of 5% per annum with interest payable at maturity. The Notes could not be prepaid without the prior written consent of the holder of such Note. The Notes were secured by a security interest in the Company’s intellectual property, as detailed in a security agreement. Upon a change of control of the Company, the holder of a Note had the option to have the Note repaid with a premium equal to 50% of the outstanding principal.

On December 23, 2015, the Company entered into a Second Amended and Restated Note and Warrant Purchase Agreement (which further amended and restated the Note Purchase Agreement, as modified by the Omnibus Amendment) (the "Second Amended Note & Warrant Agreement") with each of 16 accredited investors, pursuant to which (i) the aggregate principal amount of Notes available for issuance was increased from $3.0 million to up to $6.0 million, (ii) the maturity date of the Notes outstanding prior to such amendment was extended from March 21, 2016 to December 31, 2017; (iii) the time during which Notes may be issued was extended and (iv) certain warrants were issued to holders of both previously issued and Notes issued under the Second Amended Note & Warrant Agreement.

Pursuant to the Second Amended Note & Warrant Agreement, on December 23 and December 28, 2015, the Company issued to the two purchasers thereof (i) an aggregate principal amount of $1,000,000 of secured convertible promissory notes (each, a "December 2015 Note"), which amount also represents the gross proceeds to the Company from the December 2015 Notes, and (ii) a warrant to each holder of December 2015 Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their December 2015 Note (each, a "Note Warrant"). Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. Both December 2015 Notes and Note Warrants were purchased by affiliates of the Company, or an entity under such affiliate’s control, as follows: (i) on December 23, 2015, John Pappajohn, a member of the Board, purchased a December 2015 Note for $250,000 and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock; and (ii) on December 28, 2015, RSJ PE, of which, Michal Votruba, a member of the Board, is the Director for Life Sciences for the RSJ/Gradus Fund, purchased a December 2015 Note for $750,000 and was issued a Note Warrant to purchase 15,000,000 shares of Common Stock.

Between February 23, 2016 and March 31, 2016, the Company issued to the three accredited investor purchasers thereof (i) an aggregate principal amount of $360,000 in Notes and (ii) and a warrant to each holder of such Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their respective Note (each, also a "Note Warrant"). A total of 7,200,000 shares of Common Stock in the aggregate underlie these Note Warrants. Two of the purchasers were affiliates of the Company as follows: (i) Geoffrey E. Harris, a member of the Board, purchased a Note on February 23, 2016, for $10,000 and was issued a Note Warrant to purchase 200,000 shares of Common Stock and; (ii) John Pappajohn, a member of the Board, purchased a 2015 Note on March 31, 2016, for $250,000, and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock.

The table below provides additional detail regarding the Notes as of March 31, 2016, with respect to the carrying value and discount on the Balance Sheet.

		As of March 31, 2016
Note Type and Investor	Due Date	Balance		Discount			Carrying Value
Senior Secured 5% Notes Convertible at $0.05 (the “Notes”)			($)		($)			($)
Related Parties:
RSJ Private Equity	12/31/2017	$	1,850,000	$	(211,100	)	$	1,638,900
John Pappajohn	12/31/2017		800,000		(147,300	)		652,700
Tierney Family Trust	12/31/2017		540,000		-			540,000
Follman Family Trust	12/31/2017		250,000		-			250,000
Oman Ventures	12/31/2017		200,000		-			200,000
Robin L. Smith	12/31/2017		60,000		-			60,000
Geoffrey E. Harris	12/31/2017		10,000		(4,700	)		5,300
Total Related Parties			3,710,000		(363,100	)		3,346,900
Others:
11 Accredited Investors	12/31/2017		650,000		(30,700	)		619,300
Total Secured Convertible Promissory Notes		$	4,360,000	$	(393,800	)	$	3,966,200

Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share. No Note may be prepaid without the prior written consent of the holder of such Note. The Notes are secured by a security interest in the Company's intellectual property, as detailed in the amended and restated security agreement. Upon a change of control of the Company (as described in the Notes), the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.

DERIVATIVE LIABILITIES

At September 30, 2015 the Notes totaled $3.0 million and the derivative liability value was determined to be $833,000. For the fiscal year ended September 30, 2015, gains on derivatives liabilities totaled $162,800.

On December 23, 2015, the Company entered into the Second Amended Note & Warrant Agreement, with each of 16 accredited investors, pursuant to which (i) the aggregate principal amount of Notes available for issuance was increased from $3.0 million to up to $6.0 million, (ii) the maturity date of currently outstanding Notes was extended from March 21, 2016 to December 31, 2017; (iii) the time during which Notes may be issued was extended and (iv) certain warrants were issued to holders of both previously issued and newly issued Notes. Consequently, the existing notes totaling $3 million, plus $121,900 of accrued interest thereon, for an aggregate total debt of $3,121,900 was revalued on December 23, 2015, and on the prior trading day, December 22, 2015, to determine the impact on derivative valuation. On December 22, 2015, the derivative liability of the aggregate debt was determined to be $60,200, which resulted in a write down of $772,800 from the derivative liability balance of $833,000 at September 30, 2015, which resulted in a Gain on Derivative Liabilities of $772,800.

On December 23, 2015, all the Notes were revalued with the maturity date extended to December 31, 2017. The derivative liability value was determined to be $1,022,400 and the offset was booked to other income as a Loss on Extinguishment of Debt, adjustment amount of $962,300.

Pursuant to the Second Amended Note & Warrant Agreement, on December 23 and December 28, 2015, the Company issued to the two purchasers of December 2015 Notes in the aggregate principal amount of $1,000,000 of secured convertible promissory notes. Between February 23, 2016 and March 31, 2016, the Company issues three additional Notes to three purchasers in the aggregate principal amount of $360,000 of secured convertible promissory notes.

Consequently, on March 31, 2016, notes in the aggregate principal amount of $4.36 million were revalued, and the derivative liability value was determined to be $1,441,700; the offset was booked to other income as a Gain on Derivative Liability of $786,900.

The range of Black-Scholes option-pricing model assumption inputs for all the valuation dates are in the table below:

	September 30, 2015 through to March 31, 2016 Low			September 30, 2015 through to March 31, 2016 High
Annual dividend yield		—			—
Expected life (years)		0.2			2.00
Risk-free interest rate		0.08	%		1.06	%
Expected volatility		47.83	%		225.32	%

The following tables include a roll-forward of liabilities classified within Levels 1, 2 and 3:

	Six Months Ended March 31, 2016
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2015	$	-	$	-	$	833,000
$3M of convertible debt prior to amendment		-		-		(772,800	)
$3M of convertible debt as amended		-		-		962,300
Issuance of warrants and other derivatives		-		-		444,600
Change in fair value		-		-		(25,400	)
Stock warrant and other derivative liabilities at March 31, 2016	$	-	$	-	$	1,441,700

	Six Months Ended March 31, 2015
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2014	$	-	$	-	$	153,100
Change in fair value		-		-		(67,300	)
Stock warrant and other derivative liabilities at March 31, 2015	$	-	$	-	$	85,800

The net changes in Derivative Liabilities for transactions which were booked to other income resulted in a net gain on derivative liabilities of $798,200 and $67,300 for the six months ended March 31, 2016 and 2015 respectively.

The net changes in Extinguishment of Debt for transactions which were booked to other income resulted in a net loss on extinguishment of debt of $2,337,400 for the six months ended March 31, 2016. For the same period in 2015 we had no similar expenses.

As of March 31, 2016 and September 30, 2015 we had derivative liabilities of $1,441,700 and $833,000 respectively.

STOCKHOLDERS’ DEFICIT

Common and Preferred Stock

At the Company’s annual stockholders meeting held on October 28, 2015, stockholders approved to amend the Company’s Articles of Incorporation to increase the number of shares of Common Stock authorized for issuance from 180,000,000 to 500,000,000 shares.

As of March 31, 2016, the Company is authorized to issue 515,000,000 shares of stock, of which 500,000,000 are Common Stock; the remaining 15,000,000 shares, with a par value of $0.001 per shares are blank-check preferred stock which the Board is expressly authorized to issue without stockholder approval, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

As of March 31, 2016, 102,717,409 shares of Common Stock were issued and outstanding. No shares of preferred stock were issued or outstanding.

On August 20, 2015, the Board approved an award of 750,000 shares of the Company's restricted Common Stock to Dr. Smith in connection with her appointment as Chairman of the Company's Board. These shares, which are fully vested, were valued at $0.055 per share, the closing price of the shares on the day of grant, and were valued in aggregate at $41,250. The issuance of the shares was processed on October 30, 2015.

On January 15, 2016, the company engaged Dian Griesel International (DGI) for a 12 month long consulting agreement to provide public and investor relations services. The fee for the services is $5,000 per month, plus out-of-pocket expenses. As an origination fee for the agreement, the Board approved the issuance of 300,000 shares of common stock to Ms. Griesel on January 15, 2016. The aggregate value of these shares on the date of grant was $6,900.

Stock-Option Plans

On August 3, 2006, CNS California adopted the CNS California 2006 Stock Incentive Plan (the “2006 Plan”). The 2006 Plan provides for the issuance of awards in the form of restricted shares, stock options (which may constitute incentive stock options (ISO) or non-statutory stock options (NSO), stock appreciation rights and stock unit grants to eligible employees, directors and consultants and is administered by the Board. A total of 667,667 shares of stock were ultimately reserved for issuance under the 2006 Plan. As of March 31, 2016, 70,825 options were exercised and there were 501,924 options and 6,132 restricted shares outstanding under the amended 2006 Plan with a residual 87,786 shares which will not be issued as the 2006 Plan has been frozen. The outstanding options have exercise prices to purchase shares of Common Stock ranging from $3.60 to $32.70.

On March 22, 2012, our Board approved the MYnd Analytics, Inc. 2012 Omnibus Incentive Compensation Plan (the “2012 Plan”), reserved 333,334 shares of stock for issuance and on December 10, 2012, the Board approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 333,334 shares to 5,500,000 shares. On March 26, 2013, the Board further approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 5,500,000 shares to 15,000,000 shares. The 2012 Plan, as amended, was approved by our stockholders at the 2013 annual meeting held on May 23, 2013.

On January 8, 2015, the Board granted an option to purchase 250,000 shares of its Common Stock pursuant to the 2012 Plan, at an exercise price of $0.25 per share to a consultant. The option vesting is contingent upon the achievement of agreed upon goals.

On August 20, 2015, the Board approved an award of options to purchase 250,000 shares of the Company’s common stock for each of the Company's directors, for an aggregate grant of 1,750,000 options. The options are exercisable at a price per share of $0.055, the closing price of the Company's common stock on the date of grant, and will vest pro-rata over 36 months.

As of March 31, 2016, under the 2012 Plan as amended, options to purchase 13,728,087 shares of Common Stock and 750,000 restricted shares remain outstanding. No options have been exercised under the 2012 Plan and 521,913 shares remain available for issuance.

Stock-based compensation expenses are generally recognized over the employees’ or service provider’s requisite service period, generally the vesting period of the award. Stock-based compensation expense included in the accompanying statements of operations for the three and six months ended March 31, 2016 and 2015 is as follows:

	For the three months ended March 31,
	2016		2015
Research		10,400		10,400
Product Development		7,700		15,500
Sales and marketing		14,900		53,400
General and administrative		7,200		20,500
Total	$	40,200	$	99,800

	For the six months ended March 31,
	2016		2015
Research		20,800		20,800
Product Development		16,800		34,000
Sales and marketing		14,900		63,300
General and administrative		18,400		44,100
Total	$	70,900	$	162,200

Total unrecognized stock-based compensation as of March 31, 2016, amounted to $145,443.

A summary of stock option activity is as follows:

	Number of Shares		Weighted Average Exercise Price
Outstanding at September 30, 2015		14,230,011	$	0.75
Granted		-
Exercised		-		-
Forfeited		-
Outstanding at March 31, 2016		14,230,011	$	0.75

Following is a summary of the status of options outstanding at March 31, 2016:

Exercise Price ($)		Number of Shares		Expiration Date		Weighted Average Exercise Price ($)
$	0.055		1,750,000		08/2025	$	0.055
	0.04718		8,795,308		12/2022 – 01/2023		0.04718
	0.25		2,715,109		03/2023 – 01/2025		0.25
	0.26		425,000		07/2024		0.26
	3.00		42,670		03/2022		3.00
	3.60		28,648		08/2016		3.60
	3.96		32,928		08/2016		3.96
	9.00		4,525		11/2016		9.00
	12.00		28,535		03/2019 – 07/2020		12.00
	14.10		10,000		03/2021		14.10
	15.30		1,373		09/2018		15.30
	16.50		262,441		03/2020		16.50
	17.70		953		08/2016		17.70
	24.00		4,667		12/2017		24.00
	26.70		32,297		09/2017		26.70
	28.80		11,767		04/2018		28.80
	32.70		83,790		08/2017		32.70
$	Total		14,230,011		Average	$	0.75

Warrants to Purchase Common Stock

The warrant activity for the period starting October 1, 2015, through March 31, 2016, is described as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding at September 30, 2015		781,524		$	0.53
Granted		87,200,000			0.05
Exercised		-			-
Expired		(35,002	)		1.00
Outstanding at March 31, 2016		87,946,522		$	0.05

Following is a summary of the status of warrants outstanding at March 31, 2016:

Exercise Price		Number of Shares			Expiration Date	Weighted Average Exercise Price
$	0.04718		38,152		03/2018	$	0.04718
	0.05		27,200,000	(1)	12/31/2020		0.05
	0.05		60,000,000	(2)	12/31/2020		0.05
	0.25		332,200		04/2016 – 07/2017		0.25
	0.275		324,000		06/2018 – 03/2019		0.275
	1.00		32,168		10/2015 – 01/2017		1.00
	7.50		3,334		05/2016		7.50
$	9.00		16,668		07/2017		9.00
	Total		87,946,522			$	0.05

(1) Between December 23, 2015, and March 31, 2016 the Company entered into a Second Amended Note and Warrant Purchase Agreement pursuant to which the Company issued five Notes (including the December 2015 Notes) to the four purchasers for an aggregate principal amount of $1,360,000 and issued five Note Warrants to purchase an aggregate of 27,200,000 shares of the Company's Common Stock. The Note Warrants were issued to purchasers of Notes in an amount equal to 100% of the shares underlying their December 2015 Notes. Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. 2 million Note Warrants were issued to one accredited investor and 25.2 million Note Warrants were issued to Directors; for further detail refer to Note 6. Related Party Transactions.

(2) On December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, Extension Warrants to purchase an aggregate of 60,000,000 shares of Common Stock. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder's previously outstanding Notes. 11 million Extension Warrants were issued to 10 accredited investors and 49 million Extension Warrants were issued to Directors and Affiliates; for further detail refer to Note 6. Related Party Transactions.

On December 23, 2015, we valued the Extension Warrants to purchase 60 million shares of Common Stock using the Black-Scholes model and determined their value to be $1,196,000, which was booked as an Extinguishment of Debt expense.

The range of Black-Scholes option-pricing model assumption inputs for the six months ended March 31, 2016, were as follows:

	December 23, 2015 through March 31,2016
Annual dividend yield		-
Expected life (years)		5.00
Risk-free interest rate		1.21% ~ 1.74	%
Expected volatility		255.50% ~ 272.56	%

At March 31, 2016, there were warrants outstanding to purchase 87,946,522 shares of the Company’s Common Stock. The exercise prices of the outstanding warrants range from $0.04718 to $9.00 with a weighted average exercise price of $0.05. The warrants expire at various times starting 2016 through 2020.

RELATED PARTY TRANSACTIONS

Termination of Governance Agreements

On March 28, 2015, the Company entered into a separate termination agreement with each of Equity Dynamics and SAIL, in each case to immediately terminate the respective November 28, 2012 governance agreement (collectively, the “Governance Agreements”) that the Company had entered into with each of Equity Dynamics and SAIL (collectively, the “Termination Agreements”). Equity Dynamics is an entity owned by John Pappajohn, a director of the Company, and SAIL is one of the Company’s principal stockholders of which former director, Walter Schindler, was the managing partner. Pursuant to the Governance Agreements, the Company had agreed, subject to providing required notice to stockholders, to appoint four individuals nominated by Equity Dynamics and three individuals nominated by SAIL to the Company’s Board, and to create vacancies for that purpose, if necessary. In addition, at each meeting of stockholders of the Company at which directors were nominated and elected, the Company had agreed to nominate for election the four designees of Equity Dynamics and the three designees of SAIL, and further had agreed to take all necessary action to support such election, and to oppose any challenges to such designees. The Governance Agreements also restricted the Company’s ability to increase the number of directors to more than seven without the consent of Equity Dynamics and SAIL. Pursuant to the Termination Agreements, the Governance Agreements were terminated in their entirety as of March 28, 2015, and are of no further force or effect.

Note Purchase Agreement, Notes and Omnibus Amendment and Second Amendment Note & Warrant Agreement

Between September 22, 2014, and July 20, 2015, the Company entered into a the Original Note Purchase Agreement in connection with a bridge financing, with nine accredited investors, including lead investor RSJ PE. Pursuant to the Original Note Purchase Agreement, the Company issued fifteen September 2014 Note in the aggregate principal amount of $2.27 million. Of this amount, RSJ PE purchased a September 2014 Note for $750,000. The September 2014 Notes were also purchased by the following affiliates of the Company or entities under their control: RSJ PE, of which Michal Votruba is a director, which purchased a September 2014 Note for $750,000; the Company’s director, John Pappajohn, purchased three September 2014 Notes for $400,000; the Follman Family Trust of which Robert Follman, a director of the Company, is a trustee, purchased a September 2014 Note for $100,000; The Tierney Family Trust, which is a greater than 5% stockholder of the Company, purchased four September 2014 Notes for $540,000, of which Thomas Tierney, a former director and Chairman of the Board, is a trustee; and Oman Ventures, of which Mark Oman, a greater than 5% stockholder of the Company, is the President, purchased a September 2014 Note for $200,000. Michal Votruba joined our Board on July 30, 2015.

For details of the Original Note Purchase Agreement, Amendment No.1 on April 14, 2015, the Omnibus Amendment on September 14, 2015 and subsequent Second Amended Note & Warrant Agreement on December 23, 2015 please refer to Note 3. Convertible Debt and Equity Financing.

On September 14, 2015, the Company entered into an Omnibus Amendment and subsequently thereto, on September 14, 15 and 24, 2015, the Company entered into a Note Purchase Agreement, as amended by the Omnibus Amendment, with each of six accredited investors, in connection with a bridge financing. Pursuant to these Note Purchase Agreements, the Company issued an aggregate principal amount of $710,000 of secured convertible September 2015 Notes, which amount also represents the gross proceeds to the Company from the September 2015 Notes. Four of the six September 2015 Notes were purchased by affiliates of the Company, or an entity under such affiliate’s control, as follows: (i) Dr. Robin Smith, Chairman of the Board, purchased a Note for $60,000; (ii) the Follman Family Trust, of which, Robert Follman, a director of the Company, is a trustee, purchased a Note for $150,000; (iii) John Pappajohn, a director of the Company, purchased a Note for $100,000 and (iv) RSJ PE, purchased a Note for $350,000.

On December 23, 2015, the Company entered into a Second Amended Note & Warrant Agreement pursuant to which, on December 23 and December 28, 2015, the Company issued to the two purchasers thereof, who are both affiliates of the Company, (i) an aggregate principal amount of $1,000,000 of December 2015 Notes, which amount also represents the gross proceeds to the Company from the December 2015 Notes, and (ii) a Note Warrant issued to each holder of December 2015 Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their December 2015 Note and is exercisable at $0.05 per share. The affiliates who purchased the December 2015 Notes were as follows: (i) John Pappajohn, a director of the Company, purchased a Note for $250,000 and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock and (ii) RSJ PE, who purchased a Note for $750,000 and was issued a Note Warrant to purchase 15,000,000 shares of Common Stock.

During the three months ended March, 31, 2016, pursuant to the Second Amended Note & Warrant Agreement the Company issued to the three accredited investor purchasers thereof (i) an aggregate principal amount of $360,000 in Notes and (ii) and a Note Warrant to each holder of such Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their respective Note. A total of 7,200,000 shares of Common Stock in the aggregate underlie these Note. Two of the purchasers were affiliates of the Company as follows: (i) Geoffrey E. Harris, a member of the Board, purchased a Note on February 23, 2016, for $10,000 and was issued a Note Warrant to purchase 200,000 shares of Common Stock and; (ii) John Pappajohn, a member of the Board, purchased a 2015 Note on March 31, 2016, for $250,000, and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock.

Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days.

5-Year Extension Warrants with an non-cashless exercise price of $0.05	Secured Convertible Promissory Notes		Warrants to purchase Shares of Common Stock

RSJ Private Equity	$	1,850,000	22,000,000
Robin L. Smith		60,000		1,200,000
John Pappajohn		550,000		6,000,000
Tierney Family Trust		540,000		10,800,000
Oman Ventures		200,000		4,000,000
Follman Family Trust		250,000		5,000,000
Total Secured Convertible Promissory Notes	$	3,450,000		49,000,000

Director and Officer Indemnification Agreement

On December 7, 2015, the Company entered into indemnification agreements with each of its Directors and Executive Officers. The agreements provide for, among other things: the indemnification of these Directors and Officers by the Company to the fullest extent permitted by the laws of the State of Delaware; the advancement to such persons by the Company of certain expenses; related procedures and presumptions of entitlement; and other related matters.

Transactions with John Pappajohn, Director

On September 22, 2014, March 18, 2015, June 2, 2015 and September 15, 2015, Mr. Pappajohn purchased four Notes for $200,000, $100,000, $100,000 and $100,000 respectively. Pursuant to the Omnibus Amendment, the Notes are convertible into shares of Common Stock at $0.055 per share: (i) automatically upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily within 15 days prior to maturity.

On September 6, 2015, Mr. Pappajohn irrevocably assigned $200,000 in principal of his September 2014 Notes to four outside parties in the amount of $50,000 each.

On September 15, 2015, Mr. Pappajohn purchased a September 2015 Note for $100,000. The September 2015 Notes are convertible into share of Common Stock (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price, such that the conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock).

On December 23, 2015, and on March 31, 2016, Mr. Pappajohn purchased two Notes (including December 2015 Notes) for $250,000 each pursuant to the abovementioned Second Amended Note & Warrant Purchase Agreement. Additionally, in connection with the Second Amended Note & Warrant Purchase Agreement, Mr. Pappajohn was issued Warrants to purchase an aggregate of 16,000,000 shares of Common Stock at $0.05 per share, consisting of two Note Warrants to purchase in aggregate a total of 10,000,000 shares of Common Stock, and an Extension Warrant to purchase 6,000,000 shares of Common Stock.

Transactions with Robert J. Follman, Director

On October 19, 2012, an October 2012 Note in the aggregate principal amount of $200,000 was issued in exchange for cash to the Trust of Robert J. Follman and Carole A. Follman, dated August 14, 1979 (the “Follman Trust”), an accredited investor, of which Robert J. Follman is a trustee. As of February 25, 2013, Mr. Follman was elected as a Director of the Company. On June 14, 2013, the Follman Trust converted their October 2012 Note and interest thereon into 4,491,310 shares of Common Stock at a conversion price $0.04718 per share.

The Follman Trust made multiple additional investments pursuant to a series of subscription agreements all of which were the result of private placements of unregistered stock at $0.25 per share. All individual transactions were in tranches of $100,000 for the purchase of 400,000 shares and the Company received gross cash proceeds of $100,000 on each occasion. These transactions occurred on the following dates: August 16 and September 11 of 2013 and January 17, February 14 and July 8 of 2014. In aggregate the Follman Trust has purchased 2,000,000 shares at $0.25 per share for $500,000 gross cash proceeds to the Company.

On March 17, 2015 and September 15, 2015, the Follman Trust purchased Notes for $100,000 and $150,000, respectively. Pursuant to the Omnibus Amendment, these Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily, within 15 days prior to maturity.

Additionally, on December 23, 2015, in connection with the Second Amended Note & Warrant Purchase Agreement, the Follman Trust was issued an Extension Warrant to purchase 5,000,000 shares of Common Stock at $0.05 per share.

Transaction with Robin L. Smith, Chairman

On September 14, 2015, Dr. Smith, our Chairman of the Board, purchased a Note for $60,000. Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Additionally, on December 23, 2015, in connection with the Second Amended Note & Warrant Purchase Agreement, Dr. Smith was issued an Extension Warrant to purchase 1,200,000 shares of Common Stock at $0.05 per share.

Transaction with Geoffrey E. Harris, Director and Chairman, Audit Committee

On February 23, 2016, Geoffrey E. Harris, purchased a Note for $10,000 pursuant to the Second Amended Note & Warrant Purchase Agreement and was issued a Note Warrant to purchase an aggregate of 200,000 shares of Common Stock at $0.05 per share.

Transactions with George Carpenter, President and Chief Executive Officer

On September 25, 2013, the Board approved a consulting agreement effective May 1, 2013, for marketing services provided by Decision Calculus Associates, an entity operated by Mr. Carpenter’s spouse, Jill Carpenter. For the period from May 1, 2013 through to March 25, 2015, we had paid $280,000 to Decision Calculus Associates (“DCA”). For the period from March through July of 2015, DCA was not engaged by the Company. Effective August 2015 DCA has been re-engaged at a fee of $10,000 per month. From August 2015 through March 31, 2016, DCA has been paid $70,000 with a further $10,000 balance due in accounts payable.

Transactions with the SAIL Capital Partners and SAIL Holdings

Mr. Schindler served as a Director between November 29, 2012 and June 11, 2015, and was the Managing Partner of SAIL Capital Partners, which was a greater than 5% stockholder of the Company, and is the general partner of all the SAIL entities except for SAIL Holding, LLC which is controlled directly by Mr. Schindler.

On January 5, 2015, the Company entered into a three-month long consulting engagement with Dr. Eric Warner, Managing Partner, Europe, Middle East & Africa, SAIL Capital Partners Ltd. The objectives of the engagement include the establishment of a revenue-generating licensing agreement in the United Kingdom (U.K.) and initiation a pilot study of our PEER Online technology. Dr. Warner has been paid $10,000 per month for a total of $30,000. On January 8, 2015, the Board granted Dr. Warner an option to purchase 250,000 shares of Common Stock with an exercise price of $0.25 per share; the option vesting is conditioned on the execution of a licensing agreement and a PEER Online pilot study. The fair value of the option, which was determined using the Black-Scholes model, was $28,300 and was expensed over the term of the engagement.

Transactions with Tierney Family Trust, Greater than 5% Stockholder

Mr. Tierney, who resigned from the Board on May 22, 2015, had served on the Board since February 2013, and had served as Chairman of the Board since March 2013. Mr. Tierney is a trustee of the Thomas T. and Elizabeth C. Tierney Family Trust (the “Tierney Family Trust”), which is a greater than 5% stockholder.

On September 22, 2014, January 8, 2015, March 17, 2015, June 3, 2015 and July 3, 2015 the Tierney Family Trust purchased five Notes for $200,000, $100,000, $115,000, $100,000 and $25,000, respectively, for an aggregate total of $540,000. Pursuant to the Omnibus Amendment, all such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Additionally, on December 23, 2015, in connection with the Second Amended and Restated Note & Warrant Purchase Agreement, the Tierney Family Trust was issued an Extension Warrant to purchase 10,800,000 shares of Common Stock at $0.05 per share.

Transactions with Mark and Jill Oman, Greater than 5% Stockholder

On September 22, 2014, Oman Ventures LLC, of which Mr. Oman, a greater than 5% stockholder is the President, purchased a Note for $200,000. Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Additionally, on December 23, 2015, in connection with the Second Amended and Restated Note & Warrant Purchase Agreement, Oman Ventures LLC was issued an Extension Warrant to purchase 4,000,000 shares of Common Stock at $0.05 per share.

Transactions with RSJ PE

Michal Votruba joined our Board on July 30, 2015. Mr. Votruba is a director of RSJ PE, which acted as the lead investor in the private placement financing of September 2014 Notes.

On September 26, 2014, and September 24, 2015, investor RSJ PE purchased a two Notes for $750,000 and $350,000 respectively. Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

On December 28, 2015, RSJ PE purchased a December 2015 Note for $750,000 pursuant to the abovementioned Second Amended Note & Warrant Purchase Agreement. Additionally, in connection with the Second Amended Note & Warrant Purchase Agreement, RSJ PE was issued Warrants to purchase an aggregate of 37,000,000 shares of Common Stock at $0.05 per share, consisting of a Note Warrant to purchase 15,000,000 shares of Common Stock and an Extension Warrant to purchase 22,000,000 shares of Common Stock.

LOSS PER SHARE

In accordance with ASC 260-10 (formerly SFAS 128, “Computation of Earnings Per Share”), basic net income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. For the three and six months ended March 31, 2016 and 2015, the Company has excluded all common equivalent shares from the calculation of diluted net loss per share as such securities are anti-dilutive.

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended March 31, 2016 and 2015 is as follows:

	Three months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(142,700	)	$	(696,300	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.00	)	$	(0.01	)

Basic and Diluted weighted average shares outstanding		102,669,022			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		83,271,628			1,892,742
Warrants		80,938,825			781,833
Options		14,230,011			12,645,994

	Six months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(3,594,000	)	$	(1,570,900	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.04	)	$	(0.02	)

Basic and Diluted weighted average shares outstanding		102,543,215			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		73,234,048			1,771,371
Warrants		43,892,108			871,027
Options		14,230,011			12,531,746

COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the ordinary course of business. Other than as set forth below, the Company is not currently party to any legal proceedings, the adverse outcome of which, in the Company’s management’s opinion, individually or in the aggregate, would have a material adverse effect on the Company’s results of operations or financial position.

Since June 2009, the Company has been involved in litigation against Leonard J. Brandt, a stockholder, former Director and the Company’s former Chief Executive Officer (“Brandt”) in the Delaware Chancery Court, the Supreme Court of the State of Delaware, the United States District Court for the Central District of California and the Superior Court for the State of California, Orange County. Other than current actions described below, the Company has prevailed in all actions or the matters have been dismissed.

On April 11, 2011, Brandt and his family business partnership Brandt Ventures, GP, filed an action in the Superior Court for the State of California, Orange County against the Company, one of its stockholders, SAIL Venture Partner, LP, and Mr. David Jones, a former member of the Board, alleging breach of a promissory note agreement entered into by Brandt Ventures, GP and the Company and alleging that Mr. Brandt was wrongfully terminated as Chief Executive Officer in April, 2009. The Company was served with a summons and complaint in the action on July 19, 2011.

On November 1, 2011, Mr. Brandt and Brandt Ventures filed an amended complaint amending their claims and adding new claims against the same parties. On March 12, 2012, the court sustained demurrers to certain of the counts against each defendant. On March 22, 2012, the plaintiffs filed a second amended complaint modifying certain of their claims, but did not add new claims. On February 6, 2013, the plaintiffs moved for leave to amend the second amended complaint and file a third amended complaint. On March 6, 2013, the Court granted leave to amend, but awarded fees and costs for the defendants to again make dispositive motions. The third amended complaint adds a claim for breach of the promissory note and seeks to foreclose on the collateral securing the note obligation. In addition, Mr. Brandt is seeking approximately $170,000 of severance and compensatory and punitive damages in connection with his termination. In interrogatory responses served on January 26, 2013, Mr. Brandt for the first time identified that he seeks damages in connection with his termination exceeding $9,000,000. Mr. Brandt has proffered no credible evidence to support damages in this amount, and the Company believes this claim for damages is without merit. The plaintiffs also seek rescission of a $250,000 loan made by Brandt Ventures, GP to the Company which was converted into Common Stock in accordance with its terms and restitution of the loan amount.

A trial date had originally been set for May 2014. However, plaintiffs’ counsel requested a continuance until August 2014, to which the Company agreed. On June 18, 2014, at plaintiffs’ counsel’s request, the Company entered into a Standstill and Tolling Agreement, whereby the parties agreed to seek a stay of the litigation and plaintiffs agreed to provide the Company with an executed dismissal of all the claims without prejudice, with the ability to re-file the third amended complaint, without change, on or before June 18, 2015. The Company had the right to file the executed stipulation of dismissal if the Court lifted the stay. On May 7, 2015, the parties agreed to continue the Standstill and Tolling Agreement until May 6, 2016, on the same terms. On May 12, 2015, the Court agreed to stay the case for another six months. On November 4, 2015 the Court lifted the stay, and set the case for trial on March 7, 2016. On February 3, 2016, the Company filed the executed stipulation of dismissal, thereby ending the current action in Orange County. The parties have recently entered into extensions of the Standstill and Tolling Agreement that permit Mr. Brandt to start a new action and re-file the third amended complaint, without change, on or before May 23, 2016. The Company continues to believe that Mr. Brandt's allegations set forth in the third amended complaint, like the prior complaints, are without merit. The Company has not accrued any amounts related to this matter. The just-dismissed action was captioned Leonard J. Brandt and Brandt Ventures, GP v. CNS Response, Inc., Sail Venture Partners and David Jones, case no. 30-2011-00465655-CU-WT-CJC.

The Company has expended substantial resources to pursue the defense of legal proceedings initiated by Mr. Brandt. The Company does not know whether Mr. Brandt will institute additional claims against the Company and the defense of any such claims could involve the expenditure of additional resources by the Company.

Lease Commitments

The Company had its Headquarters and Neurometric Services business premises located at 85 Enterprise, Aliso Viejo, California 92656 from February 2010 through January 2016. The Company relocated its new Headquarters and Neurometric Services business to 26522 La Alameda, Suite 290, Mission Viejo, CA 92691, which is 2,290 sqft in size. We signed a 24 month lease for our new location on January 22, 2016. The lease period commenced on February 1, 2016 and terminates on January 31, 2018. The rent for the first four months is $2,290 per month, which is abated by 50%; for months 5 through 12 the rent increases to $4,580 per month and for the final 12 months the rent will increase by 5% to $4,809 per month.

On February 2, 2016, we signed a 23.5 month lease for 1,092 sqft of office space to house our EEG testing center. The premises are located at 25201 Paseo De Alicia, Laguna Hills, CA 92653. The lease period commenced on February 15, 2016 and terminates on January 31, 2018. The rent for first half month of February was prorated at $928.20; for the next 11 months the rent is $1,856 per month, and for the remaining twelve months the rent will increase by 3% to $1,911 per month. The landlord abated the rent for March 2016.

The Company incurred rent expense from operations of $16,200 and $12,200 for the three months ended March 31, 2016 and 2015, respectively; and $28,400 and $24,400 for the six months ended March 31, 2016 and 2015, respectively.

On April 24, 2013, we entered into a financial lease to acquire additional EEG equipment costing $8,900. The term of the lease is 36 months ending May 2016 with a monthly payment of $325. As of March 31, 2016 the remaining lease obligation is $600 all of which is due in fiscal year 2016.

On January 20, 2016, we entered into a financial lease to acquire Canon Copier costing $6,700. The term of the lease is 60 months ending January 2021 with a monthly payment of $135. As of March 31, 2016 the remaining lease obligation is $7,800, of the remaining lease obligation is 2016 $1,600; with $1,200 for the years 2017-2020; 2021 $1,400.

	Payments due by period
Contractual Obligations	Total		Less than 1 year		1 to 3 years		3 to 5 years		More than 5 years

Operating Lease Obligations	$	140,400	$	75,100	$	65,300	$	-	$	-
Capital Lease Obligations		8,400		2,200		4,800		1,400		-
Total	$	148,800	$	77,300	$	70,100	$	1,400	$	-

SUBSEQUENT EVENTS

Events subsequent to March 31, 2016 have been evaluated through the date these financial statements were issued, to determine whether they should be disclosed to keep the financial statements from being misleading. The following events have occurred since March 31, 2016.

On April 5, 2016, the Board approved grants of the Company's Common Stock under the 2012 Plan, with immediate vesting, as follows: 1,000,000 shares to our Chairman of the Board, Dr. Robin Smith; 500,000 shares to our Director and Chairman of the Audit Committee, Geoffrey Harris; and 250,000 shares to each of our remaining five Directors.

Also on April 5, 2016, the Board granted 1,000,000 shares of the Company’s Common Stock under the 2012 Plan to each of George Carpenter, the Company's President and Chief Executive Officer, and Paul Buck, the Company's Chief Financial Officer. 50% of these shares vested on the date of grant with the remaining 50% vesting pro-rata over 12 months starting on the date of grant, respectively.

Lastly, on April 5, 2016 the Board granted options to purchase 1,450,000 shares of the Company’s Common Stock under the 2012 Plan to staff members and options to purchase 200,000 shares of the Company’s Common Stock to our consultant, DCA. These shares vest pro-rata over 12 months starting on the date of grant.

The abovementioned grants of shares and options to Board members, executive officers, staff and consultant are valued $0.0255 per share, which was the closing price on the OTC.QB of the Company’s Common Stock on April 5, 2016.

Subsequent to March 31, 2016, the Company issued multiple Notes and Note Warrants pursuant to the Second Amended Note and Warrant Purchase Agreement to affiliates of the Company as follows:

On April 7, 2016, the Company issued to the Follman Trust, of which Robert Follman, a member of the Company’s Board, is a trustee: (i) a Note in the aggregate principal amount of $200,000, and (ii) a Note Warrant to purchase 4,000,000 shares of the Company’s Common stock at $0.05 per share.

On April 11, 2016, the Company issued to John Pappajohn, a member of the Board: (i) a Note in the aggregate principal amount of $250,000, and (ii) a Note Warrant to purchase 5,000,000 shares of the Company’s Common stock at $0.05 per share.

On April 21, 2016, the Company issued to Dr. Robin Smith, our Chairman of the Board: (i) a Note in the aggregate principal amount of $40,000, and (ii) a Note Warrant to purchase 800,000 shares of the Company’s Common stock at $0.05 per share.

On May 4, 2016, the Company issued to George Carpenter, the Company’s CEO, and his wife Jill: (i) a Note in the aggregate principal amount of $50,000, and (ii) a Note Warrant to purchase 1,000,000 shares of the Company’s Common stock at $0.05 per share.

In aggregate, since March 31, 2016, the Company has issued Notes totaling $540,000, which also represents gross proceeds to the Company, and has issued Note Warrants to purchase 10,800,000 shares of the Company’s Common Stock at $0.05 per share.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operation should be read in conjunction with our unaudited condensed consolidated financial statements as of, and for, the three and six months ended March 31, 2016 and 2015, and our Annual Report on Form 10-K for the year ended September 30, 2015, filed with the U.S. Securities and Exchange Commission on January 5, 2016.

Forward-Looking Statements

This discussion summarizes the significant factors affecting the unaudited condensed consolidated operating results, financial condition and liquidity and cash flows of MYnd Analytics, Inc. (“we,” “us,” “our,” or the “Company”) for the three and six months ended March 31, 2016 and 2015. Except for historical information, the matters discussed in this management’s discussion and analysis or plan of operation and elsewhere in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new products or services; our statements concerning litigation or other matters; statements concerning projections, predictions, expectations, estimates or forecasts for our business, financial and operating results and future economic performance; statements of management’s goals and objectives; trends affecting our financial condition, results of operations or future prospects; our financing plans or growth strategies; and other similar expressions concerning matters that are not historical facts. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes” and “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to:

our inability to raise additional funds to support operations and capital expenditures;

our inability to achieve greater and broader market acceptance of our products and services in existing and new market segments;

our inability to successfully compete against existing and future competitors;

our inability to manage and maintain the growth of our business;

our inability to protect our intellectual property rights; and

other factors discussed under the headings “Risk Factors” and “Business” in our Annual Report on Form 10-K for the year ended September 30, 2015 and this Quarterly Report on Form 10-Q.

Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview

The Company is a predictive analytics company that provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (“PTSD”) and other non-psychotic disorders. The Company uses its proprietary neurometric platform, PEER Online, to generate Psychiatric EEG Evaluation Registry (“PEER”) Reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. Management intends to conduct a series of clinical trials, termed in aggregate the SMART-MD trials. The protocols to be used in this series of trials will be substantially similar to the protocol approved by the Walter Reed Institutional Review Board (the "Walter Reed IRB") during our 2013-2014 clinical trial at Walter Reed National Military Medical Center (“Walter Reed”) and Fort Belvoir Community Hospital (“Fort Belvoir”) (collectively, the “Walter Reed PEER Trial”). This protocol utilizes our neurometric platform to provide PEER Reports to clinicians treating patients with a primary diagnosis of depression with various comorbidities allowed, if present, to include PTSD and mild traumatic brain injury (“mTBI). The first trial in the series is the Canadian Forces Trial, which is expected to commence in the next quarter, which will be followed by parallel trials in Southern California, the SoCal Trial, as well as other U.S. locations. The protocols for the Canadian Forces Trial and the SoCal Trial have been approved by their respective institutional review boards and are ready for initiation and the recruitment of study subjects. The objective of the SMART-MD trials will be to provide additional information to demonstrate the clinical and economic utility of our neurometric platform. We also expect to conduct additional studies with other groups and organizations. We are also focusing our direct-to-consumer marketing efforts using social media within California to boost our commercialization of the PEER Online platform and its PEER Reports.

Working Capital

We are unable to pay all our obligations as they become due and we are in arrears on paying certain of our creditors. If we are not able to raise additional funds within the next several months, and we cannot find additional sources of funds and/or reach accommodations with certain of our creditors, we will likely be required to cease our operations.

Since our inception, we have never been profitable and we have generated significant net losses. As of March 31, 2016, we had an accumulated deficit of approximately $66.2 million compared to our accumulated deficit as of March 31, 2015, which was approximately $60.8 million. We incurred operating losses of approximately $1.3 million and $1.6 million for the six months ended March 31, 2016 and 2015, respectively, and incurred net losses of $3.6 million and $1.6 million for those respective periods. Large, non-cash, accounting transactions significantly impacted the net losses for the 2016 and 2015 six-month periods in question, including:

For the six-month period ended March 31, 2016, our net loss was exacerbated by non-cash charges totaling approximately $2.3 million as a result of accounting for the extinguishment of debt, non-cash interest and derivative liability transactions. These non-cash charges are primarily the result of amendments to the terms of our convertible notes payable along with the issuance of warrants pursuant to our fund raising.

For the six-month period ended March 31, 2015 we had non-cash income of $6,700.

Assuming we are able to continue our operations, we expect our net losses to continue for at least the next eighteen months to two years. We anticipate that a substantial portion of any capital resources and efforts would be focused on conducting our proposed clinical trials, followed by the scale-up of our commercial organization, further research, product development and other general corporate purposes, including the payment of legal fees incurred as a result of our litigation. We anticipate that future research and development projects would be funded by grants or third-party sponsorship, along with funding by the Company.

As of March 31, 2016, our current liabilities of approximately $1.67 million exceeded our current assets of approximately $0.62 million by approximately $1.05 million. During fiscal 2016 to date we have raised $1.9 million from the private placement of secured debt convertible at $0.05 per share along with 100% warrant coverage. During fiscal year 2015 we raised $1.35 million through this private placement of debt.

On December 23, 2015, the Company entered into a second amended and restated note and warrant purchase agreement with each of 16 accredited investors, pursuant to which (i) the aggregate principal amount of notes available for issuance was increased from $3.0 million to up to $6.0 million, (ii) the maturity date of currently outstanding notes was extended from March 21, 2016 to December 31, 2017; (iii) the time during which notes may be issued was extended and (iv) certain warrants were issued to holders of both previously issued and newly issued notes.

Pursuant to the second amended note and warrant agreement, between December 23, 2015 and the date of this report, the Company has issued to seven purchasers thereof (i) an aggregate principal amount of $1,900,000 in nine secured convertible promissory notes, which amount also represents the gross proceeds to the Company therefrom, and (ii) a warrant to the purchaser of each note, to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying its respective purchased notes. For details of the second amended note and warrant agreement financing see "Private Placement Transactions" below.

We will need additional funding to conduct the planned clinical trials and to conduct a marketing campaign to significantly increase the demand for our PEER Online services. We are actively exploring additional sources of capital. However, we cannot offer assurances that additional funding will be available on acceptable terms, or at all. Even if we were to raise additional funds, any additional equity funding may result in significant dilution to existing stockholders, and, if we incur additional debt financing, a substantial additional portion of our operating cash flow may be dedicated to the payment of principal and interest on such indebtedness, thus limiting the funds available for our business activities. If adequate funds are not available, it will likely force us to cease operations or would otherwise have a material adverse effect on our business, financial condition and/or results of operations.

Private Placement Transactions

Between September 22, 2014, and July 20, 2015, the Company entered into a Note Purchase Agreement (the “Original Note Purchase Agreement”) in connection with a bridge financing, with nine accredited investors, including lead investor RSJ Private Equity investiční fond s proměnným základním kapitálem (“RSJ PE”). Pursuant to the Original Note Purchase Agreement, the Company issued fifteen secured convertible promissory notes (each, a “September 2014 Note”) in the aggregate principal amount of $2.27 million. The September 2014 Notes were also purchased by the following affiliates of the Company or entities under their control: RSJ PE, of which Michal Votruba is a director, which purchased a September 2014 Note for $750,000; the Company’s director, John Pappajohn, who purchased three September 2014 Notes for $400,000; the Follman Family Trust, which purchased a September 2014 Note for $100,000; The Tierney Family Trust, which is a greater than 5% stockholder of the Company, which purchased five September 2014 Notes for $540,000; and Oman Ventures, of which Mark Oman, a greater than 5% stockholder of the Company, is the President, which purchased a September 2014 Note for $200,000. Michal Votruba joined our Board on July 30, 2015.

Subsequently thereto, on September 14, 15 and 24, 2015, the Company entered into a Note Purchase Agreement, as amended by the Omnibus Amendment, with each of six accredited investors, in connection with a bridge financing. Pursuant to these Note Purchase Agreements, the Company issued an aggregate principal amount of $710,000 of secured convertible promissory notes (collectively, the “September 2015 Notes,” and together with the September 2014 Notes all other notes that may be purchased and sold, from time to time in the future, pursuant to the Note Purchase Agreement, and any further amendments or modifications thereto, the “Notes”), which amount also represents the gross proceeds to the Company from the September 2015 Notes. Four of the six September 2015 Notes were purchased by affiliates of the Company, or an entity under such affiliate’s control, as follows: (i) Dr. Robin Smith, Chairman of the Board of Directors of the Company, purchased a Note for $60,000; (ii) the Follman Family Trust purchased a Note for $150,000; (iii) John Pappajohn purchased a Note for $100,000 and (iv) RSJ PE purchased a Note for $350,000.

On December 23, 2015, the Company entered into a Second Amended Note & Warrant Agreement (which further amended the Note Purchase Agreement, as modified by the Omnibus Amendment) (the "Second Amended Note & Warrant Agreement"), with each of 16 accredited investors, pursuant to which (i) the aggregate principal amount of Notes available for issuance was increased from $3.0 million to up to $6.0 million, (ii) the maturity date of currently outstanding Notes was extended from March 21, 2016 to December 31, 2017; (iii) the time during which Notes may be issued was extended and (iv) certain warrants were issued to holders of both previously issued and newly issued Notes.

Pursuant to the Second Amended Note & Warrant Agreement, between December 23, 2015 and the date of this report, the Company has issued to the seven purchasers thereof (i) an aggregate principal amount of $1,900,000 in nine Notes, which amount also represents the gross proceeds to the Company from such Notes, and (ii) a Note Warrant to each holder of such Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their respective Note (each, a "Note Warrant"). Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. Eight of these Notes and Note Warrants were purchased by affiliates of the Company, or an entity under such affiliate’s control, as in the following table:

Date	Noteholder	Affiliation	Note Amount		Common Stock Warrants Issued
12/23/15	John Pappajohn	Director	$	250,000		5,000,000
12/28/15	RSJ Private Equity	Director		750,000		15,000,000
02/23/16	Geoffrey Harris	Director		10,000		200,000
03/31/16	John Pappajohn	Director		250,000		5,000,000
04/07/16	Follman Trust	Director is a trustee		200,000		4,000,000
04/11/16	John Pappajohn	Director		250,000		5,000,000
04/21/16	Robin Smith	Chairman		40,000		800,000
05/04/16	George & Jill Carpenter	Chief Executive Officer		50,000		1,000,000
	Total		$	1,800,000		36,000,000

Also on December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, warrants to purchase an aggregate of 60,000,000 shares of Common Stock (the "Extension Warrants", together with the Note Warrants, the "Warrants"). All Warrants have identical terms. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder's previously outstanding Notes. Accordingly, Extension Warrants to purchase a total of 60,000,000 shares of Common Stock were issued, consisting of (i) Extension Warrants to purchase 11,000,000 shares of Common Stock issued to 10 accredited investors, and (ii) Extension Warrants to purchase 49,000,000 shares of Common Stock issued to Directors and Affiliates. For further details regarding these transactions, refer to Note 6. Related Party Transactions of the Unaudited Condensed Consolidated Financial Statements.

Pursuant to the Second Amended Note & Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (A) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (B) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share. No Note may be prepaid without the prior written consent of the holder of such Note. The Notes are secured by a security interest in the Company's intellectual property. Upon a change of control of the Company, the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.

Capitalization

At our annual meeting of stockholders held on October 28, 2015, our stockholders approved a proposal to amend the Company’s Certificate of Incorporation in order to increase the number of shares of Common Stock authorized for issuance under our Charter from 180,000,000 to 500,000,000. The table below summaries our capitalization as of May 14, 2016:

	Shares
Shares of Common Stock Authorized		500,000,000
Shares of Preferred stock Authorized (none issued and outstanding)		15,000,000
Total Authorized Shares		515,000,000

Shares of Common Stock Issued and Outstanding		107,467,409
Common Stock issuable upon the exercise of outstanding stock options at March 31, 2016		14,230,011	(1)
Common Stock issuable upon the exercise of outstanding stock options subsequent to March 31, 2016		1,650,000	(2)
Common Stock issuable upon the exercise of outstanding warrants at March 31, 2016		87,946,522	(1)
Common Stock issuable upon the exercise of outstanding warrants subsequent to March 31, 2016		10,800,000	(2)
Common Stock reserved for conversion of $4.9M Secured Convertible Notes at $0.05 per share		98,000,000	(3)
Total securities outstanding and reserved for issuance at May 14, 2016		320,093,942	(3)

For more detail on the exercise prices and expiration dates of the options and warrants please refer to the Stock Option Plans and Warrants to Purchase Common Stock sections of Note 5. Stockholders’ Deficit of the Unaudited Condensed Consolidated Financial Statements

For more detail on the exercise prices of the options and warrants please refer to Note 9.Subsequent Events of the Unaudited Condensed Consolidated Financial Statement

Does not include stock issued on the conversion of interest earned at 5% per annum on the Secured Convertible Notes

At our annual meeting of stockholders held on October 28, 2015, our stockholders also approved an amendment to amend the Company’s Charter for the purposes of effecting a reverse stock split of our Common Stock at a later time and at any time until the next meeting of the Company’s stockholders which are entitled to vote on such actions, by a ratio of not less than 1-for-10 and not more than 1-for-200, and to authorize the Board of Directors to determine, at its discretion, the timing of the amendment and the specific ratio of the reverse stock split. There has been no such stock split as of the date of this filing.

Recent Developments

Canadian Forces/NATO

The Company is moving forward with the cooperation and support of Canadian Military mental health leaders for the purpose of conducting a clinical trial of the PEER technology. The Canadian Military has identified two study sites to support the proposed clinical trial using a protocol for PEER substantially similar to that used for the Walter Reed Trial. The Canadian study protocol has been reviewed and approved by the Research Ethics Board of University of Ottawa, equivalent to an institutional review board. We are advised by the Canadian Military that funding for the study has been secured. In anticipation of commencing the study, we have shipped EEG equipment to the Canadian Military for use in the study.

Marketing Initiatives

We conducted a marketing campaign throughout the month of October 2015 which resulted in a 10 fold increase in leads at 6% of our prior cost when compared to our prior marketing initiative. These leads have been referred to psychiatrists and other practitioners who use our PEER Online Technology. To date, the adoption of PEER Reports continues to be minimal, and the Company has generated no significant revenue from PEER Reports.

Our management believes that by investing in marketing automation we may be able to increase yield and reduce the time from a potential user’s awareness of our technology to their ultimate order of a PEER Report. We have initiated a targeted social media advertising campaign in the Southern California region to build regional demand, for purpose of referring EEG testing to the Company’s MYnd Analytics Center (“MAC Center”), which opened in March 2016. Initially, we expect that The MAC Center will offer two benefits to consumers and prescribers: 1) It will allow for easy scheduling and EEG administration in a central location, and 2) will provide a consistent high quality experience for all, while reducing physician workload. We plan on recruiting a physician to be co-located at the MAC Center. Furthermore, we anticipate opening a second MAC Center in Northern California, where our Medical Director is located.

Commercial Adoption Plan

As a result of the response to our October 2015 marketing initiative, and in conjunction with the planned start of the Canadian military study, the Company will commence a series of commercial studies starting in Southern California with the SoCal Study. The series of anticipated studies, termed in aggregate the SMART-MD Study, are expected to be based on the protocol and study endpoints used for the Walter Reed Trial. With several military bases and a high concentration of veterans in the region, we believe we are well positioned to recruit enrollees into the SoCal Study. We are currently exploring additional legs of the SMART-MD study with additional study partners and study sites in other regions of the country. This project will be led by Dr. Daniel Iosifescu, MD, Director of the Mood and Anxiety Disorders Program and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital, New York. The study protocol for the SoCal Study has been reviewed and approved by the Western Institutional Review Board. We anticipate enrolling 468 subjects into the study and tracking them for a period of twelve weeks. We estimate this project will take between 18 and 24 months to complete, once commenced, and will cost approximately $2.0 million. We currently do not have the funds necessary to complete this study and will need to raise additional funds to complete the study.

As we are recruiting for the SMART-MD Study, we will seek to generate media coverage and demand from regular patients. If we are able to secure sufficient additional financing, and our SMART-MD Study is successful, we intend to expand our direct-to-consumer marketing to the top 10 metro areas in the United States. We are currently developing a consumer-facing mobile app (web/ iOS/ Android), which management expects will automate patient-reported outcomes and support patient engagement. If we are successful in increasing patient-reported outcomes, we expect to be able to expand the PEER Online database, thereby improving its predictive accuracy.

Payer Reimbursement

We have been focused on invoicing payers to receive reimbursement for EEG recordings, the conversion of analog EEG to a digital Quantitative EEG (QEEG), and ultimately, the processing and delivery of a PEER Report. To date, we have limited experience with payer reimbursement and have been successful in obtaining reimbursement for a limited number of EEG recordings and QEEG conversions from payer organizations. Allowed reimbursement for the EEG and QEEG averaged approximately $275 for each of the two procedures, over the last 12 months. The PEER Report does not currently have a separate and distinct Current Procedural Terminology (CPT) code. We have submitted the PEER Report under CPT Code 99090 – Data Analysis – and to date have rarely been reimbursed. We currently bill each patient $400 for the PEER Report.

United Healthcare issued an “emerging technology” approval for PEER Online in 2011, with guidance that PEER technology was one clinical study away from full reimbursement approval. We anticipate, but cannot guarantee, that the SMART-MD Study will satisfy United Healthcare’s requirement for an additional study, thereby permitting the potential for full reimbursement for PEER Reports. However, even if our SMART-MD Study is successful, there is no guarantee that it will satisfy United Healthcare’s requirement for an additional study, or even if it does, that United Healthcare will approve full reimbursement for PEER Reports, if at all. If our efforts are successful, we believe that payers could receive substantial benefit by encouraging the use of PEER Online, as they could benefit from a savings on medical expenses for patients who are successfully treated for their behavioral disorders.

One of the key elements in obtaining payer reimbursement is to become a registered CMS (Medicare/ Medicaid) provider. We are applying to become an accredited provider to CMS as an independent diagnostic testing facility, although our efforts may not be successful. If our application to become a registered CMS provider is approved, there is no guarantee that PEER Reports will be reimbursed.

FDA Inspection

In February 2016, we hosted an FDA inspection for five days. The inspection focused primarily on procedures, processes, communications and data associated with the Walter Reed Trial. The inspector did not cite any significant issue for action by the Company.

Financial Operations Overview

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as revenues and expenses during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from those estimates under different assumptions or conditions.

Our significant accounting policies are described in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this report. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our unaudited condensed consolidated financial statements.

Revenue Recognition

We have generated limited revenues since our inception. Revenues for our Neurometric Service product are recognized when a PEER Report is delivered to a Client-Physician.

Stock-based Compensation Expense

Stock-based compensation expense, which is a non-cash charge, results from stock option grants. Compensation cost is measured at the grant date based on the calculated fair value of the award. We recognize stock-based compensation expense on a straight-line basis over the vesting period of the underlying option. The amount of stock-based compensation expense expected to be amortized in future periods may decrease if unvested options are subsequently cancelled or may increase if future option grants are made.

Long-Lived Assets and Intangible Assets

Property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If the Company determines that the carrying value of the asset is not recoverable, a permanent impairment charge is recorded for the amount by which the carrying value of the long-lived or intangible asset exceeds its fair value. Intangible assets with finite lives are amortized on a straight-line basis over their useful lives of ten years.

Costs for software developed for internal use are accounted for through the capitalization of those costs incurred in connection with developing or obtaining internal-use software. Capitalized costs for internal-use software are included in intangible assets in the consolidated balance sheet. Capitalized software development costs are amortized over three years. Costs incurred during the preliminary project along with post-implementation stages of internal use computer software development and costs incurred to maintain existing product offerings are expensed as incurred. The capitalization and ongoing assessment of recoverability of development costs require considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility and estimated economic life. The Company will begin amortizing the software over its estimated economic life once it has been placed into service.

Derivative accounting for convertible debt and warrants

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of September 30, 2015, the Company’s only derivative financial instruments were a series of convertible notes having a beneficial conversion feature based on the conversion price of the note relative to the market price of a share of Common Stock on the valuation date. See Notes 4 & 5.

Results of Operations for the three months ended March 31, 2016 and 2015

Our operations consist solely of our Neurometric Services business which is focused on the delivery of PEER Reports that enable psychiatrists and other physicians/prescribers to make more informed, patient-specific decisions when treating individual patients for behavioral (psychiatric and/or addictive) disorders based on the patient’s own physiology.

The following table presents consolidated statement of operations data for each of the periods indicated as a percentage of revenues.

	Three months ended
	March 31,
	2016			2015

Revenues		100	%		100	%
Cost of revenues		7			9
Gross profit		93			91
Research		110			110
Product development		884			918
Sales and marketing		643			838
General and administrative expenses		1,790			1,958
Operating loss		(3,334	)		(3,733	)
Other income (expense), net		2,644			401
Net loss		(690	)%		(3,332	)%

Revenues

	Three months ended				Percent
	March 31,				Change
	2016		2015
Neurometric Service Revenues	$	20,700	$	20,900		(0	)%

The number of paid PEER Reports delivered as part of our Neurometric Services business was 48 reports for both three-month periods ended March 31, 2016 and 2015. The average revenue was $415 per PEER Report for the quarter ended March 31, 2016. The total numbers of free PEER Reports processed were 4 and 3 for the quarters ended March 31, 2016 and 2015 respectively. These free PEER Reports are used for training, database-enhancement and compassionate-use purposes.

Cost of Revenues

	Three months ended				Percent
	March 31,				Change
	2016		2015
Cost of revenues
Neurometric Services	$	1,400	$	1,800		(22	)%

The cost of Neurometric Services revenues consisting of payroll costs (including stock-based compensation) and consulting costs, which were as follows:

	Three months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Consulting fees		1,400		1,800		(400	)
Total Costs of Revenues	$	1,400	$	1,800	$	(400	)

Consulting costs associated with the processing of second generation PEER Reports are between $10 and $60 per report for EEG artifacting and neuro review services, and approximately $75 for EEG the collecting of the EEG.

Comparing the three month period ended March 31, 2016, with the corresponding period in 2015:

(1) Consulting fees decreased slightly for the quarter ended March 31, 2016 as we processed more EEGs with in-house resources.

Research

	Three months ended				Percent
	March 31,				Change
	2016		2015
Research
Neurometric Services	$	22,700	$	22,900		(1	)%

Research expenses consist of payroll costs (including stock-based compensation), consulting fees and other miscellaneous costs which were as follows:

	Three months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salary and benefit costs	$	10,400	$	10,400	$	-
(2) Consulting fees		10,000		10,000		-
(3) Other miscellaneous costs		2,300		2,500		(200	)
Total Research	$	22,700	$	22,900	$	(200	)

Comparing the three-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salary and benefit costs, which are solely comprised of stock-based compensation stayed the consistent for the 2016 and 2015 periods; and

(2)

Consulting costs remained the same for both periods as we have a consulting agreement with Dr. Schiller for the medical monitoring of the clinical trials, the training of clinical trial investigators and new PEER Online users. Additionally Dr. Schiller is also advising the Company on clinical trial design and product development; and

(3)

Other miscellaneous costs for the 2016 and 2015 periods were substantially similar.

Product Development

	Three months ended				Percent
	March 31,				Change
	2016		2015
Product Development
Neurometric Services	$	183,000	$	191,900		(5	)%

Product Development expenses consist of payroll costs (including stock-based compensation), consulting fees, system development costs, travel and miscellaneous costs which were as follows:

	Three months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	121,300	$	120,300	$	1,000
(2) Consulting fees		37,600		37,900		(300	)
(3) System development costs		13,100		9,200		3,900
(4) Other miscellaneous costs		11,000		24,500		(13,500	)
Total Product Development	$	183,000	$	191,900	$	(8,900	)

Comparing the three-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salaries and benefits increased by a net $1,000 in the quarter ended March 31, 2016 due to a slight increase in benefit costs; and

(2)

Consulting fees remained substantially the same for the two periods in question. We have a consulting agreement with White Star Investment Management who provide us with compliance, quality and regulatory services as well as advisory services for clinical trial design and data management systems.

(3)

System development and maintenance costs increased slightly in the quarter ended March 31, 2016, due to increased system maintenance costs and some minor system enhancements. Costs associated with the development of our Outcomes Application are currently being capitalized and will be depreciated over the application’s expected economic life; and

(4)

Other miscellaneous expenses decreased by $13,500 in the quarter ended March 31, 2016, as costs incurred for the prior 2015 period, did not reoccur. These 2015 period costs were substantially associated with the Walter Reed Trial which has been closed.

Sales and Marketing

	Three months ended				Percent
	March 31,				Change
	2016		2015
Sales and Marketing
Neurometric Services	$	133,000	$	175,200		(24	)%

Sales and marketing expenses associated with our Neurometric Services business consist primarily of payroll and benefit costs, including stock-based compensation, advertising and marketing, consulting fees and miscellaneous expenses. The reason for the change in these expenses is discussed below.

	Three months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	33,500	$	80,500	$	(47,000	)
(2) Consulting fees		44,000		78,900		(34,900	)
(3) Advertising and marketing costs		45,000		8,300		36,700
(4) Other miscellaneous costs		10,500		7,500		3,000
Total Sales and marketing	$	133,000	$	175,200	$	(42,200	)

Comparing the three-month period ended March 31, 2016, with the corresponding period in 2015:

	(1)	Salaries and benefits for the quarter ended March 31, 2016, decreased by $47,000 from the 2015 period as certain stock-based compensation had become fully amortized prior to the 2016 period;

(2)

Consulting fees for the quarter ended March 31, 2016, decreased by $34,900, from the 2015 period. During the 2015 period we spent $30,000 on a U.K. based consultant in a failed attempt to sign a service contract with a U.K. based healthcare group; additionally we incurred public relations costs for being on the CBS television show, “The Doctors”, which aired in January 2015.

	(3)	Advertising and marketing expenses increased for the quarter ended March 31, 2016, by a net $36,700. During the 2016 period we incurred approximately $45,000 in social media advertising costs focused on the Southern California market. This expenditure has resulted in the generation of over 1,000 leads per month for potential patients. This increase in advertising expenditure in the 2016 period was partially offset by a reduction in the 2015 period expenditures as we did not utilize the services of a public relations agency during the 2016 period.

(4)

Miscellaneous expenditures increased for the quarter ended March 31, 2016, by a net $3,000. The 2016 period increase was due to the subscription of a lead-automation software application to assist with the efficient tracking of leads generated by our social media advertising campaign; additionally we also incurred some costs related to establishing the MAC Center. These 2016 period cost increases were partially offset by a decrease in travel related expenditure to attend a conference in the 2015 period.

General and administrative

	Three months ended				Percent
	March 31,				Change
	2016		2015
General and administrative
Neurometric Services	$	370,600	$	409,200		(9	)%

General and administrative expenses for our Neurometric Services business are largely comprised of payroll and benefit costs, including stock-based compensation, legal fees, other professional and consulting fees, patent costs, general administrative and occupancy costs, dues and subscriptions, conference, travel and miscellaneous costs. The reason for the change in these expenses is discussed below.

	Three months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	179,900	$	183,700	$	(3,800	)
(2) Legal fees		14,900		67,800		(52,900	)
(3) Other professional and consulting fees		24,000		21,500		2,500
(4) Patent costs		44,300		30,700		13,600
(5) Marketing and investor relations costs		17,900		3,300		14,600
(6) Conference and travel costs		12,700		28,000		(15,300	)
(7) Dues & subscriptions fees		17,300		20,200		(2,900	)
(8) General administrative and occupancy costs		59,600		54,000		5,600
Total General and administrative costs	$	370,600	$	409,200	$	(38,600	)

Comparing the three-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salaries and benefit expenses decreased by $3,800 for the quarter ended March 31, 2016; The decrease was largely due to the reduction in the amortization of stock-based compensation from the 2015 period. The actual payroll expenditures remained unchanged during the two periods; and

(2)

Legal fees decreased by $52,900 for the 2016 period. This reduction was substantially due to a renegotiation of our fees associated with our lobbying efforts. This reduction was partially offset by a $9,600 expenditure in litigation fees in the 2016 period: and

(3)

Other professional and consulting fees had a minor change for the 2016 and 2015 periods which was related to the timing of our tax work;

(4)

Patent costs increased by $13,600 due to the timing and volume of patent and trademark applications and maintenance costs;

(5)

Marketing and investor relations costs increased by $14,600 for the 2016 period as we engaged a public relations firm, Dian Griesel International.

(6)

Conference and travel expenditures decreased by $15,300 for the 2016 period. This is largely because international travel and a road show, which occurred in the 2015 period, did not repeat in the 2016 period.

(7)

Dues and subscription expenditures had a minor reductions in the 2016 period; and

(8)

General administrative and occupancy expenses increased by $5,600 in the quarter ended March 31, 2016, largely due to relocation costs associated with Corporate Office moving to its new location and an increase in Directors’ and Officers’ Insurance premiums.

Other Income and Expense

	Three months ended				Percent
	March 31,				Change
	2016		2015
Other Income (Expense)
Neurometric Services income (expense), net	$	547,300	$	84,600		547	%

For the three-month periods ended March 31, 2016 and 2015, changes in net non-operating Other Income (Expense) for Neurometric Services were as follows:

For the 2016 period, we incurred non-cash interest charges totaling $239,600 of which $49,900 was accrued interest on our convertible promissory notes at 5% per annum; the balance of $189,700 was comprised of warrant discount amortization and warrant and note conversion derivative liability charges; only $500 were for actual net interest paid in cash during the period. For the 2015 period, we incurred non-cash interest charges totaling $54,600 of which $22,100 was accrued interest on our convertible promissory notes at 5% per annum; the balance was comprised of $32,000 of beneficial conversion discount amortization on convertible promissory notes; only $500 were for actual net interest paid in cash during the period.

Under ASC 815, all derivative instruments are required to be measured periodically at fair value and the resultant change in fair value of non-hedging derivative instruments are to be recognized in current earnings. For the quarter ended March 31, 2016, we revalued our derivative liabilities for the beneficial conversion feature of the convertible promissory notes which resulted in a net non-cash gain on derivative liabilities of $786,900. For the quarter ended March 31, 2015, we revalued our derivative liabilities for the promissory note beneficial conversion feature which resulted in a non-cash gain on derivative liabilities of $139,200.

Net Loss

	Three months ended						Percent
	March 31,						Change
	2016			2015
Neurometric Services net loss	$	(142,700	)	$	(696,300	)		(80	)%

The net loss for our Neurometric Services business of $142,700 for the three-month period ended March 31, 2016, compared to the approximately $696,300 loss in the prior year’s corresponding period is primarily due to the large non-cash accounting charges in our Other Income (Expense) expense category described above.

The Company’s operating loss of $690,000 for the 2016 period is a reduction of $90,100 from the $780,100 loss in the 2015 period. This is due to substantial reductions in expenditures across all cost centers. These reductions were due in part to the Walter Reed Trial being suspended, as well as continuing efforts to reduce expenditures across the board.

Results of Operations for the six months ended March 31, 2016 and 2015

The following table presents consolidated statement of operations data for each of the periods indicated as a percentage of revenues.

	Six months ended
	March 31,
	2015			2015

Revenues		100	%		100	%
Cost of revenues		6			7
Gross profit		94			93
Research		100			107
Product development		675			1,001
Sales and marketing		564			606
General and administrative expenses		1,651			1,949
Operating loss		(2,896	)		(3,570	)
Other income (expense), net		(5,020	)		(25	)
Net loss		(7916	)%		(3,595	)%

Revenues

	Six months ended				Percent
	March 31,				Change
	2016		2015
Neurometric Service Revenues	$	45,400	$	43,700		4	%

The number of third party paid PEER Reports delivered as part of our Neurometric Services business increased to 108 for the six-month period ended March 31, 2016, up from 102 for the same period in the prior year. Our standard price per PEER Report is $400 for our commercial patients plus the fee for Company recorded EEGs and any ancillary services. The average revenue was $410 per PEER Report for the 2016 period. The total numbers of free PEER Reports processed were 9 and 4 for the six-month periods ended March 31, 2016 and 2015 respectively. These free PEER Reports are used for training, database-enhancement and compassionate-use purposes.

Cost of Revenues

	Six months ended				Percent
	March 31,				Change
	2016		2015
Cost of revenues
Neurometric Services	$	2,700	$	2,900		(7	)%

The cost of Neurometric Services revenues consisting of payroll costs (including stock-based compensation) and consulting costs, which were as follows:

	Six months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Consulting fees		2,700		2,900		(200	)
Total Costs of Revenues	$	2,700	$	2,900	$	(200	)

Comparing the six months ended March 31, 2016, with the corresponding period in 2015:

(1) Consulting fees decreased slightly for the six months ended March 31, 2016 as we processed more EEGs with in-house resources.

Research

	Six months ended				Percent
	March 31,				Change
	2016		2015
Research
Neurometric Services	$	45,300	$	46,700		(3	)%

Research expenses consist of payroll costs (including stock-based compensation), consulting fees and other miscellaneous costs which were as follows:

	Six months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salary and benefit costs	$	20,800	$	20,800	$	-
(2) Consulting fees		20,000		20,000		-
(3) Other miscellaneous costs		4,500		5,900		(1,400	)
Total Research	$	45,300	$	46,700	$	(1,400	)

Comparing the six-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salary and benefit costs, which are solely comprised of stock-based compensation stayed the consistent for the 2016 and 2015 periods; and

(2)

(3)

Other miscellaneous costs for the 2016 period showed a slight decline as travel and insurance expenses for the 2015 period were marginally higher than in the 2016 period.

Product Development

	Six months ended				Percent
	March 31,				Change
	2016		2015
Product Development
Neurometric Services	$	306,400	$	437,500		(30	)%

Product Development expenses consist of payroll costs (including stock-based compensation), consulting fees, system development costs, travel and miscellaneous costs which were as follows:

	Six months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	225,100	$	238,900	$	(13,800	)
(2) Consulting fees		40,600		138,500		(97,900	)
(3) System development costs		24,500		45,100		(20,600	)
(4) Other miscellaneous costs		16,200		15,000		1,200
Total Product Development	$	306,400	$	437,500	$	(131,100	)

Comparing the six-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salaries and benefits decreased by a net $13,800 in the 2016 period; this decrease was primarily related to stock compensation becoming fully amortized during the 2016 period; and

(2)

Consulting fees decreased by $97,900 for the 2016 period: this was substantially due to the Walter Reed Trial being suspended. Consequently, during the 2015 period we reduced the expenditure on our Clinical Research Organization and released clinical trial coordinators who were contracted through the Henry Jackson Foundation to work on the trial; and

(3)

System development and maintenance costs decreased by $20,600 in the 2016 period, due to the stage in the development cycle and in order to conserve cash; in the 2015 period, system development and maintenance costs were elevated due to further development of our Salesforce.com based applications, including the development of a patient referral portal to handle incoming inquiries, the development of a system dashboard and the migration of our data to a more robust and secure hosting service operated by Microsoft; and

(4)

Other miscellaneous expenses had a marginal net increase of $1,200 in the 2016 period.

Sales and Marketing

	Six months ended				Percent
	March 31,				Change
	2016		2015
Sales and Marketing
Neurometric Services	$	256,100	$	264,900		3	%

	Six months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	68,600	$	117,500	$	(48,900	)
(2) Consulting fees		77,100		108,900		(31,800	)
(3) Advertising and marketing costs		93,400		29,000		64,400
(4) Other miscellaneous costs		17,000		9,500		7,500
Total Sales and marketing	$	256,100	$	264,900	$	(8,800	)

Comparing the six-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salaries and benefits for the 2016 period, decreased by $48,900 as some stock compensation had become fully amortized; and

(2)

Consulting fees for the 2016 period decreased by $31,800: this is primarily due to the non-recurrence of consulting fees amounting to $30,000 paid to a U.K. based consultant during the 2015 period in a failed attempt to sign a service contract with a U.K. based healthcare group; additionally we incurred some public relations costs for being on the CBS television show, “The Doctors”, which aired in January 2015.

(3)

Advertising and marketing expenses increased for 2016 period by a net $64,400; of this increase approximately $66,400 was due to social media advertising focused on the Southern California market which has resulted in a substantial increase in lead generation to over 1,000 potential patient leads per month.

(4)

Miscellaneous expenditures increased for the 2016 period by a net $7,500. The 2016 period increase was due to the subscription of a lead-automation software application to assist with the efficient tracking of leads generated by our social media advertising campaign; additionally we also incurred some costs related to establishing the MAC Center. These 2016 period cost increases were partially offset by a decrease in travel related expenditure to attend a conference in the 2015 period.

General and administrative

	Six months ended				Percent
	March 31,				Change
	2016		2015
General and administrative
Neurometric Services	$	749,600	$	851,900		(12	)%

	Six months ended
	March 31,
Key Expense Categories	2016		2015		Change
(1) Salaries and benefit costs	$	353,100	$	363,600	$	(10,500	)
(2) Legal fees		53,000		120,500		(67,500	)
(3) Other professional and consulting fees		74,000		71,500		2,500
(4) Patent costs		51,300		58,500		(7,200	)
(5) Marketing and investor relations costs		21,800		48,600		(26,800	)
(6) Conference and travel costs		30,200		42,900		(12,700	)
(7) Dues & subscriptions fees		40,800		38,500		2,300
(8) General administrative and occupancy costs		125,400		107,800		17,600
Total General and administrative costs	$	749,600	$	851,900	$	(102,300	)

Comparing the six-month period ended March 31, 2016, with the corresponding period in 2015:

(1)

Salaries and benefit expenses decreased by $10,500 for the 2016 period; this was primarily due to a net $18,900 reduction in stock compensation as stock options became fully vested; the remainder of the difference was offset by a minor increases in payroll taxes and benefit expenses. The actual salary expenditures remained unchanged during the two periods; and

(2)

Legal fees decreased by $67,500 for the 2016 period. This reduction was substantially due to a renegotiation of our fees associated with our lobbying efforts. This reduction was partially offset by a $12,100 increase in expenditure in litigation fees in the 2016 period and an increase in legal fees due to the documentation of our private placement financing activities; and

(3)

Other professional and consulting fees had minimal change for the 2016 and 2015 periods; the minor increase was due to the timing of tax services; and

(4)

Patent costs decreased by $7,200 due to the timing and volume of patent and trademark applications and maintenance costs;

(5)

Marketing and investor relations costs decreased by a net $26,800 for the 2016 period: The decrease was primarily due to the engagement of RedChip Companies, Inc. for investor relations services during the 2015 period which cost approximately $22,500 in fees and $21,600 as the fair value of issued warrants. This 2015 period expenditure has been partially offset by the engagement of a public relations firm, Dian Griesel International, during the 2016 period;

(6)

Conference and travel costs decreased by a net $12,700 for the 2016 period. This is largely because international travel and a road show, which occurred in the 2015 period, did not reoccur in the 2016 period. The reduction of cost was partially offset by management traveling to New York for the Annual Stockholders’ Meeting during the 2016 period.

(7)

Dues and subscription costs increased marginally by $2,300 for 2016 period largely due to fees associated with our Annual Stockholders Meeting held in October 2015; and

(8)

General, administrative and occupancy expenses increased by $17,600 in the 2016 period, largely due to printing costs associated with the Annual Stockholders’ Meeting, an increase in D&O and Workers’ Compensation insurances and costs associated with the move of our corporate office to our new location.

Other Expense

	Six months ended						Percent
	March 31,						Change
	2016			2015
Other Expense
Neurometric Services expense, net	$	(2,279,000	)	$	(6,700	)		33915	%

For the six-month periods ended March 31, 2016 and 2015, changes in net non-operating Other Income (Expense) for Neurometric Services were as follows:

For the 2016 period, we incurred non-cash interest charges totaling $739,800 of which $88,800 was accrued interest on our convertible promissory notes at 5% per annum; the balance of $651,000 was comprised of warrant discount amortization and warrant and note conversion derivative liability charges; only $1,300 was for actual net interest paid in cash during the period. For the 2015 period, we incurred non-cash interest charges totaling $106,000 of which $42,700 was accrued interest on our convertible promissory notes at 5% per annum; the balance was comprised of $61,900 of beneficial conversion discount amortization on convertible promissory notes; only $1,400 was for actual net interest paid in cash during the period.

	·	Under ASC 815, all derivative instruments are required to be measured periodically at fair value and the resultant change in fair value of non-hedging derivative instruments are to be recognized in current earnings. For the 2016 period, we revalued our derivative liabilities for the beneficial conversion feature of the convertible promissory notes which resulted in a net non-cash gain on derivative liabilities of $798,200. For 2015 period, we revalued our derivative liabilities for the promissory note beneficial conversion feature which resulted in a non-cash loss on derivative liabilities of $99,300.

For the 2016 period, we incurred a non-cash loss of $2,337,400 as a result of the accounting for the extinguishment of debt. The debt extinguishment accounting was precipitated by the changes in the fair value of existing notes pursuant to the Amended Note & Warrant Purchase Agreement which extended the maturity date of the existing Notes and provided 100% warrant coverage of the shares underlying the Notes. No similar transaction occurred in the 2015 period.

Net Loss

	Six months ended						Percent
	March 31,						Change
	2016			2015
Neurometric Services net loss	$	(3,594,000	)	$	(1,570,900	)		295	%

The net loss for our Neurometric Services business of $3.6 million for the six-month period ended March 31, 2016, compared to the approximately $1.6 million loss in the corresponding period in the prior year is primarily due to the large non-cash accounting charges in our Other Income (Expense) expense category described above.

The Company’s operating loss of $1.3 million for the six-month period ended March 31, 2016, is a reduction of $0.2 million from the $1.6 million loss in the corresponding period in the prior year. This is due to substantial reductions in expenditures across all cost centers. These reductions were due in part to the Walter Reed Trial being suspended as well as continuing efforts to reduce expenditures across the board.

Liquidity and Capital Resources

Since our inception, we have never been profitable and we have generated significant losses. As of March 31, 2016, we had an accumulated deficit of approximately $66.2 million compared to our accumulated deficit as of March 31, 2015, which was approximately $60.8 million. We have not yet achieved profitability and anticipate that we will continue to incur losses for the foreseeable future. Our management expects that with our proposed clinical trials, sales and marketing and general and administrative costs, our expenditures will continue to grow and, as a result, we will need to generate significant product revenues to achieve profitability. We may never achieve profitability.

As of March 31, 2016, we had $440,200 in cash and cash equivalents and a working capital deficit of approximately $1.05 million. This is compared to our cash position of $310,000 in cash and cash equivalents as of March 31, 2015, and a working capital deficit of $3.15 million. The reduction in our working capital deficit is primarily due to the reclassification of our secured convertible debt and associated derivative liabilities to long-term liabilities as the maturity date of the debt was extended to December 2017. Furthermore, our cash on hand and prepaid assets increased in the 2016 period, thereby further reducing our working capital deficit.

The Company has been funded through multiple rounds of private placements primarily from members of our Board or our affiliates. For details please refer to Item 2. Private Placement Transactions and Notes 3 and 6 to the Unaudited Condensed Consolidated Financial Statements.

Since September 22, 2014, we have raised $4.9 million of Secured Convertible Notes. These Notes are automatically convertible upon an equity offering of $5 million or more, or can be voluntarily converted at the option of the Noteholder 15 days before the maturity date of December 31, 2017. We do not now have, and, unless the notes are automatically or voluntarily converted, are not likely to have on the maturity date thereof, the cash necessary to repay the Notes when they become due. If we are unable to repay the Notes when due, the holders could pursue any remedies available to them, which could result in a complete foreclosure on their security interest in the assets of the Company in which case, the common stock of the Company would likely have no value.

Operating Capital and Capital Expenditure Requirements

Our continued operating losses and limited capital raise substantial doubt about our ability to continue as a going concern. We have limited ability to meet our current obligations as they become due and we are in arrears with certain of our creditors. Because of our substantial indebtedness, we are insolvent and need to raise additional funds and restructure our debt in order to continue our operations. Our financial statements include an opinion of our auditors that our continued operating losses and limited capital raise substantial doubt about our ability to continue as an ongoing concern.

We need additional funds to conduct our SoCal Study clinical trial and to continue our operations and will need substantial additional funds before we can implement our initiatives to increase demand for our PEER Online services. We are continuing to explore additional sources of capital; however, we do not know whether additional funding will be available on acceptable terms, or at all, especially given the economic conditions that currently prevail. Furthermore, any additional equity funding may result in significant dilution to existing stockholders and, if we incur debt financing, a substantial portion of our operating cash flow may be dedicated to the repayment of principal and interest on such indebtedness, thus limiting funds available for our business activities.

We expect to continue to incur operating losses in the future. We anticipate that our cash on hand and cash generated through our operations will not be sufficient to fund our operations beyond the next few months. If adequate funds are not available, it would have a material adverse effect on our business, financial condition and/or results of operations, and could cause us to have to cease operations.

The amount of capital we will need to conduct our operations and the time at which we will require such capital may vary significantly depending upon a number of factors, such as:

the amount and timing of costs we incur in connection with our clinical trials and product development activities, including enhancements to our PEER Online database and costs we incur to further validate the efficacy of our technology;

the amount and timing of costs we incur in connection with the expansion of our commercial operations, including our selling and marketing efforts;

whether we incur additional consulting and legal fees in our efforts to conducting a Non-Significant Risk study under an FDA requirements, which will enable us to obtain a 510(k) clearance from the FDA; and

if we expand our business by acquiring or investing in complimentary businesses.

Sources of Liquidity

Since our inception, substantially all of our operations have been financed from equity and debt financings. From June, 2010, through to November, 2012, we raised $9.6 million through five rounds of private placements of convertible secured notes with 34 accredited investors. All the aforementioned notes were converted, along with the interest thereon, by September 30, 2013. Of these notes, $5.6 million, or 58% in principal amount, were purchased by directors, officers and affiliates of the Company.

Since February, 2013, through July 2014 we raised $4.8 million through the private placement of equity at $0.25 per share of Common Stock. Of these equity offerings $2.1 million, or 44%, were purchased by directors, officers and affiliates of the Company.

Between September 2014, and May 2016 we have raised $4.9 million through the private placement of secured convertible debt with an exercise price of $0.05 per share of Common Stock and the issuance of 100% warrant coverage on the common stock underlying the secured convertible debt exercisable at $0.05 per share. Of this funding $4.45 million, or 91%, was provided by directors, an officer and affiliates of the Company.

For details of these financings please See Note 3 and Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

Cash Flows

Net cash used in operating activities was $1,339,900 for the six months ended March 31, 2016, compared to $1,343,700 for the same period in 2015. Consequently, the net reduction in cash used for operations between the two periods was only $3,800.

During the six months ended March 31, 2016, the Company purchased $1,000 of office furniture for the MAC Center and invested $9,000 in an intangible asset, which is the development of a software application to collect patient outcomes. During the corresponding period in 2015, the Company had no investment activities.

Financing activities for the six-month period ended March 31, 2016, consisted of $1.36 million in cash proceeds received from private placements pursuant to the Second Amended Note & Warrant Purchase Agreement from four accredited investors of which three are affiliated with the Company as follows: $500,000 from John Pappajohn, a director; $750,000 from RSJ PE, of which Michal Votruba, a director, is a director; and $10,000 from Geoffrey Harris, a director. During the corresponding period in 2015 the Company raised $415,000 from affiliates as follows: $215,000 from The Tierney Family Trust, a greater than 5% stockholder, of which Thomas Tierney our former Chairman is a trustee; $100,000 from The Follman Family Trust, of which our director Robert Follman is a trustee; and $100,000 from John Pappajohn, a director. The Company used $2,000 and $1,900 during the 2016 and 2015 periods respectively, to repay capital leases.

Income Taxes

Current and non-current deferred taxes have been recorded on a net basis in the accompanying balance sheet. As of September 30, 2015, the Company had Federal net operating loss carryforwards of approximately $32.8 million and State net operating loss carryforwards of approximately $55.6 million. Both the Federal and State net operating loss carryforwards will begin to expire in 2035. Our ability to utilize net operating loss carryforwards may be limited in the event that a change in ownership, as defined in the Internal Revenue Code, occurs in the future. The Company has placed a valuation allowance against the deferred tax assets in excess of deferred tax liabilities due to the uncertainty surrounding the realization of such excess tax assets. Management periodically evaluates the recoverability of the deferred tax assets and the level of the valuation allowance. At such time as it is determined that it is more likely than not that the deferred tax assets are realizable, the valuation allowance will be reduced accordingly.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements or financing activities with special purpose entities.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management, including our principal executive officer (PEO) and principal financial officer (PFO), conducted an evaluation of the effectiveness of our disclosure controls and procedures, as defined by paragraph (e) of Exchange Act Rule 13a-15, as of March 31, 2016, the end of the period covered by this report. Based on this evaluation, our PEO and PFO concluded that our disclosure controls and procedures were effective as of March 31, 2016.

A “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

A “significant deficiency” is a deficiency, or combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of our financial reporting.

To the knowledge of our management, including our PEO and PFO, there were none of the aforementioned deficiencies leading to a misstatement of our results of operations for the six months ended March 31, 2016, or statement of financial position as of March 31, 2016.

Changes in Internal Control Over Financial Reporting

During the quarterly period ending March 31, 2016, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

Please see Note 8 of our Notes to Unaudited Condensed Consolidated Financial Statements for a description of our litigation with Leonard Brandt, which disclosure is incorporated herein by reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors included in the Risk Factors section in our Annual Report on Form 10-K for the year ended September 30, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Private Placement Transactions

From September 22, 2014, through May 4, 2016, the Company entered into the Note Purchase and Warrant Purchase Agreements in connection with a bridge financing, with 18 accredited investors. Pursuant to the Second Amended Note & Warrant Purchase Agreement, the Company issued 32 secured convertible promissory notes and warrants in the aggregate principal amount of $4.9 million.

Refer to Note 3. Convertible Debt and Equity Financings, Note 6. Related Party Transactions and Note 9.Subsequent Events of our Unaudited Condensed Consolidated Financial Statements for details of the abovementioned transaction, which detail is incorporated herein by reference to such notes.

The issuance of the securities described above was not registered under the Securities Act. No general solicitation or advertising was used in connection with the issuance. In making the issuance to accredited investors without registration under the Securities Act, the Company relied upon the exemption from registration contained in Section 4(a)(2) of the Securities Act and/or Regulation D thereunder.

Item 6. Exhibits

The following exhibits are filed as part of this report or incorporated by reference herein:

Exhibit Number		Exhibit Title
31.1		Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema
101.CAL		XBRL Taxonomy Extension Calculation Linkbase
101.DEF		XBRL Taxonomy Extension Definition Linkbase
101.LAB		XBRL Taxonomy Extension Label Linkbase
101.PRE		XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MYnd Analytics, Inc.

Date: May 16, 2016		/s/ George Carpenter
	By:	George Carpenter
	Its:	Chief Executive Officer (Principal Executive Officer)

		/s/ Paul Buck
	By:	Paul Buck
	Its:	Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 s103228_ex31-1.htm EXHIBIT 31-1

EXHIBIT 31.1

Certification of CEO Pursuant to

Securities Exchange Act Rules 13a-14 and 15d-14

as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, George Carpenter, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MYnd Analytics, Inc. for the quarter ended March 31, 2016;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2016

	/s/ George Carpenter
	Name: George Carpenter
	Title: Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 s103228_ex31-2.htm EXHIBIT 31-2

EXHIBIT 31.2

Certification of CFO Pursuant to

Securities Exchange Act Rules 13a-14 and 15d-14

as Adopted Pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Paul Buck, certify that:

1. I have reviewed this quarterly report on Form 10-Q of MYnd Analytics, Inc. for the quarter ended March 31, 2016;

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 16, 2016

	/s/ Paul Buck
	Name: Paul Buck
	Title: Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 s103228_ex32-1.htm EXHIBIT 32-1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in connection with the filing of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (the “Report”) by MYnd Analytics, Inc. (the “Registrant”), the undersigned hereby certifies that to the best of his knowledge:

1. the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 16, 2016	/s/ George Carpenter
	George Carpenter
	Chief Executive Officer (Principal Executive Officer)

Date: May 16, 2016	/s/ Paul Buck
	Paul Buck
	Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 cnso-20160331.xml XBRL INSTANCE FILE 0000822370 2015-10-01 2016-03-31 0000822370 2016-05-13 0000822370 cnso:ConvertibleNotesPayable2Member cnso:TwentyAccreditedInvestorsMember 2015-10-01 2016-03-31 0000822370 2016-01-01 2016-03-31 0000822370 2014-10-01 2015-03-31 0000822370 2016-03-31 0000822370 cnso:ConvertibleNotesPayable2Member cnso:TwentyAccreditedInvestorsMember 2014-10-01 2015-09-30 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:FurnitureAndFixturesMember 2016-03-31 0000822370 us-gaap:FurnitureAndFixturesMember 2015-09-30 0000822370 2015-09-30 0000822370 us-gaap:FurnitureAndFixturesMember 2015-10-01 2016-03-31 0000822370 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2015-10-01 2016-03-31 0000822370 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2016-03-31 0000822370 2014-10-01 2015-09-30 0000822370 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-09-30 0000822370 us-gaap:FairValueInputsLevel1Member 2015-09-30 0000822370 us-gaap:FairValueInputsLevel2Member 2015-09-30 0000822370 us-gaap:FairValueInputsLevel3Member 2015-09-30 0000822370 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0000822370 us-gaap:FairValueInputsLevel1Member 2016-03-31 0000822370 us-gaap:FairValueInputsLevel2Member 2016-03-31 0000822370 us-gaap:FairValueInputsLevel3Member 2016-03-31 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-10-01 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:RSJPrivateEquityMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:DirectorMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:Director3Member us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:Director2Member us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:PresidentMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:RsjPrivateEquityAndEightAccreditedInvestorsMember us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2014-09-22 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-04-13 2015-04-14 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-09-14 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:ConvertibleNotesPayable1Member cnso:SixAccreditedInvestorsMember 2015-09-24 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:DirectorMember cnso:ConvertibleNotesPayable1Member 2015-09-24 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:Director2Member cnso:ConvertibleNotesPayable1Member 2015-09-24 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:BoardOfDirectorsChairmanMember cnso:ConvertibleNotesPayable1Member 2015-09-24 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:RSJPrivateEquityMember cnso:ConvertibleNotesPayable1Member 2015-09-24 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-04-14 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:SixteenAccreditedInvestorsMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable3Member 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable3Member us-gaap:DirectorMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable3Member cnso:RSJPrivateEquityMember 2015-12-28 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember us-gaap:DirectorMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:RSJPrivateEquityMember 2015-12-28 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable3Member 2015-10-01 2016-03-31 0000822370 us-gaap:NoteWarrantMember cnso:ThreeAccreditedInvestorMember 2016-03-31 0000822370 us-gaap:NoteWarrantMember cnso:Director8Member 2016-02-24 0000822370 us-gaap:NoteWarrantMember us-gaap:DirectorMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:RSJPrivateEquityMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director3Member 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director2Member 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:PresidentMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:BoardOfDirectorsChairmanMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director8Member 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:ElevenAccreditedInvestorsMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:RSJPrivateEquityMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director3Member 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director2Member 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:PresidentMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember us-gaap:BoardOfDirectorsChairmanMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:Director8Member 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 us-gaap:ConvertibleNotesPayableMember cnso:ElevenAccreditedInvestorsMember 2016-03-31 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable3Member 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-12-21 2015-12-23 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-12-23 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2014-10-01 2015-09-13 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-09-30 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:SixteenAccreditedInvestorsMember 2015-12-21 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-12-21 2015-12-22 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-12-22 0000822370 us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockMember 2015-08-19 2015-08-20 0000822370 us-gaap:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockMember 2015-08-20 0000822370 cnso:StockIncentivePlan2006Member 2006-08-03 0000822370 cnso:StockIncentivePlan2006Member us-gaap:MinimumMember 2006-08-03 0000822370 cnso:StockIncentivePlan2006Member us-gaap:MaximumMember 2006-08-03 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2012-03-22 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2012-12-10 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2013-03-26 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2015-01-08 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2015-01-07 2015-01-08 0000822370 us-gaap:ManagementMember us-gaap:EmployeeStockOptionMember cnso:Dollar0.055Member 2015-08-19 2015-08-20 0000822370 us-gaap:ManagementMember us-gaap:EmployeeStockOptionMember cnso:Dollar0.055Member 2015-08-20 0000822370 cnso:StockIncentivePlan2006Member 2016-03-31 0000822370 cnso:StockIncentivePlan2006Member 2015-10-01 2016-03-31 0000822370 us-gaap:RestrictedStockMember cnso:StockIncentivePlan2006Member 2016-03-31 0000822370 us-gaap:RestrictedStockMember cnso:OmnibusIncentiveCompensationPlan2012Member 2016-03-31 0000822370 cnso:OmnibusIncentiveCompensationPlan2012Member 2016-03-31 0000822370 us-gaap:WarrantMember 2016-03-31 0000822370 us-gaap:WarrantMember us-gaap:MinimumMember 2016-03-31 0000822370 us-gaap:WarrantMember us-gaap:MaximumMember 2016-03-31 0000822370 cnso:ConsultingAgreementMember cnso:DianGrieselInternationalMember 2016-01-14 2016-01-15 0000822370 cnso:ConsultingAgreementMember cnso:DianGrieselMember 2016-01-14 2016-01-15 0000822370 cnso:ConsultingAgreementMember cnso:DianGrieselMember 2016-01-15 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:OneAccreditedInvestorMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:TenAccreditedInvestorsMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:DirectorsAndAffiliatesMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember 2015-12-21 2015-12-23 0000822370 us-gaap:ResearchMember 2016-01-01 2016-03-31 0000822370 cnso:ProductDevelopmentMember 2016-01-01 2016-03-31 0000822370 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-03-31 0000822370 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0000822370 us-gaap:ResearchMember 2015-01-01 2015-03-31 0000822370 cnso:ProductDevelopmentMember 2015-01-01 2015-03-31 0000822370 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-03-31 0000822370 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-03-31 0000822370 2015-01-01 2015-03-31 0000822370 us-gaap:ResearchMember 2015-10-01 2016-03-31 0000822370 cnso:ProductDevelopmentMember 2015-10-01 2016-03-31 0000822370 us-gaap:SellingAndMarketingExpenseMember 2015-10-01 2016-03-31 0000822370 us-gaap:GeneralAndAdministrativeExpenseMember 2015-10-01 2016-03-31 0000822370 us-gaap:ResearchMember 2014-10-01 2015-03-31 0000822370 cnso:ProductDevelopmentMember 2014-10-01 2015-03-31 0000822370 us-gaap:SellingAndMarketingExpenseMember 2014-10-01 2015-03-31 0000822370 us-gaap:GeneralAndAdministrativeExpenseMember 2014-10-01 2015-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.055Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.04718Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.25Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.26Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3.6Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3.96Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar9Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar12Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar14.1Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar15.3Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar16.5Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar17.7Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar24Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar26.7Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar28.8Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar32.7Member 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.055Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.04718Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.04718Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.25Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.25Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar0.26Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3.6Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar3.96Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar9Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar12Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar12Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar14.1Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar15.3Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar16.5Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar17.7Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar24Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar26.7Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar28.8Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember cnso:Dollar32.7Member 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember 2016-03-31 0000822370 us-gaap:WarrantMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.04718Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.05Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.05OneMember 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.25Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.275Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar1Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar7.5Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar9Member 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.04718Member 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.05Member 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.05OneMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.25Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.25Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.275Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar0.275Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar1Member us-gaap:MaximumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar1Member us-gaap:MinimumMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar7.5Member 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember cnso:Dollar9Member 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember 2016-03-31 0000822370 cnso:TerminationAgreementsMember cnso:GovernanceAgreementsMember 2015-03-28 0000822370 cnso:TerminationAgreements1Member cnso:GovernanceAgreementsMember 2015-03-28 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:Director7Member us-gaap:ConvertibleNotesPayableMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2014-09-22 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2015-03-18 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2015-06-02 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:ConvertibleNotesPayable1Member us-gaap:DirectorMember 2015-09-15 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:DirectorMember 2015-10-01 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember us-gaap:PrivatePlacementMember 2015-09-06 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember us-gaap:PrivatePlacementMember 2015-09-05 2015-09-06 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2015-09-15 0000822370 cnso:ConvertibleNotesPayable1Member us-gaap:DirectorMember 2015-10-01 2016-03-31 0000822370 cnso:ConvertibleNotesPayable2Member cnso:Director2Member 2012-10-19 0000822370 cnso:ConvertibleNotesPayable2Member cnso:Director2Member 2013-06-14 0000822370 cnso:ConvertibleNotesPayable2Member cnso:Director2Member 2013-06-13 2013-06-14 0000822370 cnso:Director2Member us-gaap:PrivatePlacementMember cnso:UnregisteredStockMember 2013-08-16 2014-07-08 0000822370 cnso:Director2Member us-gaap:PrivatePlacementMember cnso:UnregisteredStockMember 2014-07-08 0000822370 cnso:Director2Member us-gaap:PrivatePlacementMember cnso:UnregisteredStockMember 2015-10-01 2016-03-31 0000822370 cnso:Director2Member us-gaap:PrivatePlacementMember cnso:UnregisteredStockMember 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:Director2Member us-gaap:ConvertibleNotesPayableMember 2015-03-17 0000822370 cnso:Director2Member cnso:AmendmentOriginNotePurchaseAgreementMember cnso:ConvertibleNotesPayable1Member 2015-09-15 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:Director2Member 2015-10-01 2016-03-31 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember us-gaap:BoardOfDirectorsChairmanMember 2015-10-01 2016-03-31 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:ConvertibleNotesPayable1Member us-gaap:BoardOfDirectorsChairmanMember 2015-09-14 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:ConvertibleNotesPayable1Member cnso:Director8Member 2016-02-24 0000822370 cnso:MarketingServicesConsultingAgreementMember cnso:DecisionCalculusAssociatesMember 2013-05-01 2015-03-25 0000822370 cnso:MarketingServicesConsultingAgreementMember cnso:DecisionCalculusAssociatesMember 2015-08-01 2016-03-31 0000822370 cnso:MarketingServicesConsultingAgreementMember cnso:DecisionCalculusAssociatesMember 2016-03-31 0000822370 cnso:ThreeMonthLongConsultingEngagementWithEricWarnerMember 2015-01-04 2015-01-05 0000822370 cnso:ThreeMonthLongConsultingEngagementWithEricWarnerMember 2015-01-07 2015-01-08 0000822370 cnso:Director3Member cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2014-09-22 0000822370 cnso:Director3Member cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-01-08 0000822370 cnso:Director3Member cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-03-17 0000822370 cnso:Director3Member cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-06-03 0000822370 cnso:Director3Member cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2015-07-03 0000822370 cnso:OriginalNotePurchaseAgreementMember cnso:Director3Member us-gaap:ConvertibleNotesPayableMember 2015-10-01 2016-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:PresidentMember us-gaap:ConvertibleNotesPayableMember 2014-09-22 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember cnso:RSJPrivateEquityMember 2014-09-26 0000822370 cnso:AmendmentOriginNotePurchaseAgreementMember cnso:RSJPrivateEquityMember 2015-10-01 2016-03-31 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember cnso:RSJPrivateEquityMember 2015-12-28 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:Director2Member 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember us-gaap:BoardOfDirectorsChairmanMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:Director3Member 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember us-gaap:PresidentMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member us-gaap:DirectorMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member cnso:Director3Member 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member cnso:RSJPrivateEquityMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member us-gaap:BoardOfDirectorsChairmanMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member us-gaap:PresidentMember 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member cnso:Director2Member 2015-12-23 0000822370 cnso:SecondAmendedNoteAndWarrantAgreementMember cnso:ConvertibleNotesPayable4Member 2015-12-23 0000822370 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-03-31 0000822370 us-gaap:ConvertibleDebtSecuritiesMember 2015-01-01 2015-03-31 0000822370 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000822370 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000822370 us-gaap:WarrantMember 2015-01-01 2015-03-31 0000822370 us-gaap:ConvertibleDebtSecuritiesMember 2015-10-01 2016-03-31 0000822370 us-gaap:ConvertibleDebtSecuritiesMember 2014-10-01 2015-03-31 0000822370 us-gaap:EmployeeStockOptionMember 2015-10-01 2016-03-31 0000822370 us-gaap:EmployeeStockOptionMember 2014-10-01 2015-03-31 0000822370 us-gaap:WarrantMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember 2014-10-01 2015-03-31 0000822370 cnso:LitigationCase1Member 2013-03-05 2013-03-06 0000822370 cnso:LitigationCase1Member 2013-01-25 2013-01-26 0000822370 cnso:LitigationCase1Member 2015-10-01 2016-03-31 0000822370 cnso:EegEquipmentMember 2013-04-23 2013-04-24 0000822370 cnso:HeadquartersAndNeurometricInformationServicesMember 2015-10-01 2016-03-31 0000822370 cnso:EegEquipmentMember 2013-04-24 0000822370 cnso:HeadquartersAndNeurometricInformationServicesMember 2010-02-01 2016-01-22 0000822370 cnso:EegEquipmentMember 2016-02-01 2016-02-02 0000822370 cnso:EegEquipmentMember 2016-02-02 0000822370 2016-02-01 2016-02-02 0000822370 cnso:CanonCopierMember 2016-01-19 2016-01-20 0000822370 cnso:CanonCopierMember 2016-03-31 0000822370 us-gaap:ManagementMember 2016-03-31 0000822370 us-gaap:ManagementMember 2015-09-30 0000822370 us-gaap:CommonStockMember 2015-10-01 2016-03-31 0000822370 us-gaap:AdditionalPaidInCapitalMember 2015-10-01 2016-03-31 0000822370 us-gaap:RetainedEarningsMember 2015-10-01 2016-03-31 0000822370 us-gaap:WarrantMember 2015-09-30 0000822370 us-gaap:CommonStockMember 2015-09-30 0000822370 us-gaap:CommonStockMember 2016-03-31 0000822370 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0000822370 us-gaap:AdditionalPaidInCapitalMember 2016-03-31 0000822370 us-gaap:RetainedEarningsMember 2015-09-30 0000822370 us-gaap:RetainedEarningsMember 2016-03-31 0000822370 2014-09-30 0000822370 2015-03-31 0000822370 2016-01-10 2016-03-31 0000822370 2015-01-10 2015-03-31 0000822370 us-gaap:FurnitureAndFixturesMember 2014-10-01 2015-03-31 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:ConvertibleNotesPayableMember 2014-10-01 2015-09-30 0000822370 cnso:OriginalNotePurchaseAgreementMember us-gaap:PresidentMember us-gaap:ConvertibleNotesPayableMember 2015-10-01 2016-03-31 0000822370 cnso:HeadquartersAndNeurometricInformationServicesMember 2016-03-31 0000822370 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000822370 us-gaap:WarrantMember 2015-12-21 2016-03-31 0000822370 us-gaap:WarrantMember us-gaap:MinimumMember 2015-12-21 2016-03-31 0000822370 us-gaap:WarrantMember us-gaap:MaximumMember 2015-12-21 2016-03-31 0000822370 cnso:ElevenAccreditedInvestorsMember 2016-03-31 0000822370 cnso:ElevenAccreditedInvestorsMember 2015-09-30 0000822370 us-gaap:FairValueInputsLevel1Member 2015-10-01 2016-03-31 0000822370 us-gaap:FairValueInputsLevel2Member 2015-10-01 2016-03-31 0000822370 us-gaap:FairValueInputsLevel3Member 2015-10-01 2016-03-31 0000822370 us-gaap:FairValueInputsLevel1Member 2014-10-01 2015-03-31 0000822370 us-gaap:FairValueInputsLevel2Member 2014-10-01 2015-03-31 0000822370 us-gaap:FairValueInputsLevel3Member 2014-10-01 2015-03-31 0000822370 us-gaap:FairValueInputsLevel1Member 2015-09-30 0000822370 us-gaap:FairValueInputsLevel1Member 2016-03-31 0000822370 us-gaap:FairValueInputsLevel2Member 2015-09-30 0000822370 us-gaap:FairValueInputsLevel2Member 2016-03-31 0000822370 us-gaap:FairValueInputsLevel3Member 2015-09-30 0000822370 us-gaap:FairValueInputsLevel3Member 2016-03-31 0000822370 us-gaap:FairValueInputsLevel1Member 2014-09-30 0000822370 us-gaap:FairValueInputsLevel1Member 2015-03-31 0000822370 us-gaap:FairValueInputsLevel2Member 2014-09-30 0000822370 us-gaap:FairValueInputsLevel2Member 2015-03-31 0000822370 us-gaap:FairValueInputsLevel3Member 2014-09-30 0000822370 us-gaap:FairValueInputsLevel3Member 2015-03-31 0000822370 us-gaap:SubsequentEventMember us-gaap:BoardOfDirectorsChairmanMember cnso:OmnibusIncentiveCompensationPlan2012Member 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:Director8Member 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:FiveDirectorsMember 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member us-gaap:PresidentMember 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member us-gaap:ChiefFinancialOfficerMember 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:StaffMembersMember 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:DecisionCalculusAssociatesMember 2016-04-04 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member us-gaap:BoardOfDirectorsChairmanMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:Director8Member 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:FiveDirectorsMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member us-gaap:PresidentMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member us-gaap:ChiefFinancialOfficerMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:StaffMembersMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:OmnibusIncentiveCompensationPlan2012Member cnso:DecisionCalculusAssociatesMember 2016-04-05 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:Director2Member 2016-04-07 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember cnso:RSJPrivateEquityMember 2016-04-07 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:DirectorMember 2016-04-11 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember us-gaap:DirectorMember 2016-04-11 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember us-gaap:BoardOfDirectorsChairmanMember 2016-04-21 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember us-gaap:BoardOfDirectorsChairmanMember 2016-04-21 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:ConvertibleNotesPayableMember cnso:PresidentAndHisWifeMember 2016-05-04 0000822370 us-gaap:SubsequentEventMember cnso:SecondAmendedNoteAndWarrantAgreementMember us-gaap:NoteWarrantMember cnso:PresidentAndHisWifeMember 2016-04-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft cnso:Number xbrli:pure MYnd Analytics, Inc. 0000822370 10-Q 2016-03-31 false --09-30 No No Yes Smaller Reporting Company Q2 2016 107467409

-66186900

-62592900

-3594000

-142700

-1570900

-696300

-3594000

-1339900

-1343700

4360000

750000

400000

540000

100000

200000

100000

150000

60000

350000

6000000

1850000

800000

540000

250000

200000

60000

10000

3710000

650000

3121900

3000000

750000

200000

100000

200000

100000

150000

60000

10000

200000

100000

115000

100000

25000

200000

750000

1350000

1360000

P3Y

P10Y

P3Y

2700

4400

2700

4400

74900

82600

45900

1441700

833000

1441700

833000

60200

1200

405700

476900

9000

P1Y9M

P6M

P2M

P2Y

0.0073

0.0008

0.0106

2.2553

0.48

0.4783

2.2532

833000

1441700

833000

1441700

9 6 16 10 4 3 5 15 16

2290000

2270000

2500000

710000

3000000

1000000

250000

750000

360000

10000

250000

27200000

550000

540000

1850000

60000

200000

250000

3450000

200000

250000

40000

50000

500000

0.05

0.25

0.04718

Conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the Fixed Conversion Price) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.

Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.

Pursuant to the Omnibus Amendment, the Notes are convertible into shares of Common Stock at $0.055 per share: (i) automatically upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily within 15 days prior to maturity.

The September 2015 Notes are convertible into share of Common Stock (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price, such that the conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock)

Pursuant to the Omnibus Amendment, these Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily, within 15 days prior to maturity.

Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Pursuant to the Omnibus Amendment, all such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.

Secured by a security interest in the Companys intellectual property, as detailed in a security agreement.

Secured by a security interest in the Company's intellectual property, as detailed in the amended and restated security agreement.

Upon a change of control of the Company, the holder of a Note had the option to have the Note repaid with a premium equal to 50% of the outstanding principal.

Upon a change of control of the Company (as described in the Notes), the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.

2017-12-31

2016-03-21

2017-12-31

5000000

16000000

15000000

60000000

7200000

200000

5000000

2000000

4000000

5000000

800000

1000000

0.05

-393800

-211100

-147300

-4700

-363100

-30700

363100

209900

30700

28900

3966200

1638900

652700

540000

250000

200000

60000

5300

3346900

619300

798200

786900

67300

786900

162800

-2337400

786900

962300

772800

1022400

121900

786900

500000000

515000000

15000000

0.001

102717409

102417409

102717409

102417409

0.055

750000

41250

6900

2015-10-30

667667

521913

14230011

501924

13728087

70825

6132

750000

87946522

781524

0.75

3.6

32.7

0.25

0.055

0.04718

9.00

0.055

0.04718

0.25

0.26

3.6

3.96

14.1

15.3

16.5

17.7

26.7

28.8

32.7

0.04718

0.05

0.25

0.275

7.5

333334

5500000

15000000

250000

1000000

500000

25000

1000000

1450000

200000

The option vesting is contingent upon the achievement of agreed upon goals.

50% of these shares vested on the date of grant with the remaining 50% vesting pro-rata over 12 months starting on the date of grant, respectively.

These shares vest pro-rata over 12 months starting on the date of grant.

1750000

8795308

2715109

425000

42670

28648

32928

4525

28535

10000

1373

262441

953

4667

32297

11767

83790

14230011

38152

27200000

60000000

332200

324000

32168

3334

16668

87946522

P36M

5000

30000

300000

6000000 22000000 49000000 11000000 49000000 200000 10000000 1200000 10800000 4000000

1196000

70900

40200

162200

10400

7700

14900

7200

10400

15500

53400

20500

99800

20800

16800

14900

18400

20800

34000

63300

44100

2025-08 2023-01 2022-12 2025-01 2023-03 2024-07 2022-03 2016-08 2016-08 2016-11 2020-07 2019-03 2021-03 2018-09 2020-03 2016-08 2017-12 2017-09 2018-04 2017-08 2018-03 2017-07 2016-04 2019-03 2018-06 2017-01 2015-10 2016-05 2017-07

0.055

0.04718

0.25

0.26

3.00

3.60

3.96

9.00

12.00

14.10

15.30

16.50

17.70

24.00

26.70

28.80

32.70

0.75

0.04718

0.05

0.25

0.275

7.5

0.05

87200000

35002

0.05 1

2020-12-31

3 4

50000

100000

4491310

0.25

0.0255

0.05

6900

100000

500000

300

6600

400000

2000000

300000

280000

744200

852000

70000

10000

0.25

28300 10000 P5Y

-3594000

-142700

-1570900

-696300

-0.04

0.00

-0.02

-0.01

102543215

102669022

101667409

83271628

1892742

14230011

12645994

80938825

781833

73234048

1771371

14230011

12531746

43892108

871027

170000

9000000

250000

P24M

P23M15D

P60M

4580 325 2290 928 1856 135

28400

16200

24400

12200

4809

1911

8900

P36M

1092

2290

8400

600

7800

2016-02-01 2016-02-15

2018-01-31

6700

75100

65300

140400

2200

4800

1400

77300

70100

1400

148800

45400

20700

43700

20900

2700

1400

2900

1800

45300 22700 46700 22900 306400 183000 437500 191900

256100

133000

264900

175200

749600

370600

851900

409200

1360100

710700

1603900

801000

-1314700

-690000

-1560200

-780100

-739800

-239600

-106000

-54600

-2279000

547300

-6700

84600

-3593700

-142700

-1566900

-695500

300

4000

800

-0.04

0.00

-0.02

-0.01

440200

432100

1240600

310000

6800

11800

111700

57400

58900

46900

617600

548200

7700

1700

9000

25600

17200

659900

567100

182600

156300

433000

418500

259700 226100

1700

2400

1667100

1701200

3346900 2240100 619300 525700

192400

103600

1441700

833000

5400

5605700

3702400

7272800

5403600

102700

102400

59471300

57654000

-6612900

-4836500

102400

102700

57654000

59471300

-62592900

-66186900

659900

567100

10000

0.001

21600

70900

162200

6900

-738600

-72700

-5000

-3900

66300

56500

-81600

12300

-9400

48100

73900

1000

9000

-10000

2000

1900

1360000

415000

1358000

413100

8100

-930600

1300

1500

300

4000

70900

1196000 1196000

543800

<table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt; margin-bottom: 0px"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0px"> </td> <td style="text-align: left; width: 0.5in">5.</td> <td style="text-align: justify">STOCKHOLDERS DEFICIT</td></tr> </table>   Common and Preferred Stock    At the Companys annual stockholders meeting held on October 28, 2015, stockholders approved to amend the Companys Articles of Incorporation to increase the number of shares of Common Stock authorized for issuance from 180,000,000 to 500,000,000 shares.   As of March 31, 2016, the Company is authorized to issue 515,000,000 shares of stock, of which 500,000,000 are Common Stock; the remaining 15,000,000 shares, with a par value of $0.001 per shares are blank-check preferred stock which the Board is expressly authorized to issue without stockholder approval, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.   As of March 31, 2016, 102,717,409 shares of Common Stock were issued and outstanding. No shares of preferred stock were issued or outstanding.   On August 20, 2015, the Board approved an award of 750,000 shares of the Company's restricted Common Stock to Dr. Smith in connection with her appointment as Chairman of the Company's Board. These shares, which are fully vested, were valued at $0.055 per share, the closing price of the shares on the day of grant, and were valued in aggregate at $41,250. The issuance of the shares was processed on October 30, 2015.   On January 15, 2016, the company engaged Dian Griesel International (DGI) for a 12 month long consulting agreement to provide public and investor relations services. The fee for the services is $5,000 per month, plus out-of-pocket expenses. As an origination fee for the agreement, the Board approved the issuance of 300,000 shares of common stock to Ms. Griesel on January 15, 2016. The aggregate value of these shares on the date of grant was $6,900.   Stock-Option Plans   On August 3, 2006, CNS California adopted the CNS California 2006 Stock Incentive Plan (the 2006 Plan). The 2006 Plan provides for the issuance of awards in the form of restricted shares, stock options (which may constitute incentive stock options (ISO) or non-statutory stock options (NSO), stock appreciation rights and stock unit grants to eligible employees, directors and consultants and is administered by the Board. A total of 667,667 shares of stock were ultimately reserved for issuance under the 2006 Plan. As of March 31, 2016, 70,825 options were exercised and there were 501,924 options and 6,132 restricted shares outstanding under the amended 2006 Plan with a residual 87,786 shares which will not be issued as the 2006 Plan has been frozen. The outstanding options have exercise prices to purchase shares of Common Stock ranging from $3.60 to $32.70.   On March 22, 2012, our Board approved the MYnd Analytics, Inc. 2012 Omnibus Incentive Compensation Plan (the 2012 Plan), reserved 333,334 shares of stock for issuance and on December 10, 2012, the Board approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 333,334 shares to 5,500,000 shares. On March 26, 2013, the Board further approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 5,500,000 shares to 15,000,000 shares. The 2012 Plan, as amended, was approved by our stockholders at the 2013 annual meeting held on May 23, 2013.   On January 8, 2015, the Board granted an option to purchase 250,000 shares of its Common Stock pursuant to the 2012 Plan, at an exercise price of $0.25 per share to a consultant. The option vesting is contingent upon the achievement of agreed upon goals.   On August 20, 2015, the Board approved an award of options to purchase 250,000 shares of the Companys common stock for each of the Company's directors, for an aggregate grant of 1,750,000 options. The options are exercisable at a price per share of $0.055, the closing price of the Company's common stock on the date of grant, and will vest pro-rata over 36 months.    As of March 31, 2016, under the 2012 Plan as amended, options to purchase 13,728,087 shares of Common Stock and 750,000 restricted shares remain outstanding. No options have been exercised under the 2012 Plan and 521,913 shares remain available for issuance.   Stock-based compensation expenses are generally recognized over the employees or service providers requisite service period, generally the vesting period of the award. Stock-based compensation expense included in the accompanying statements of operations for the three and six months ended March 31, 2016 and 2015 is as follows:      <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For the three months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 72%">Research</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">10,400</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">10,400</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Product Development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,700</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,500</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Sales and marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,900</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,400</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,200</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">20,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">40,200</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">99,800</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For the six months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 72%">Research</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">20,800</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">20,800</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Product Development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,800</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">34,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Sales and marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,900</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">63,300</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">18,400</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">44,100</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">70,900</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">162,200</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>   Total unrecognized stock-based compensation as of March 31, 2016, amounted to $145,443.   A summary of stock option activity is as follows:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average  Exercise  Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 72%">Outstanding at September 30, 2015</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%">14,230,011</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="text-align: left; padding-bottom: 1pt; width: 1%">$</td> <td style="text-align: right; padding-bottom: 1pt; width: 11%">0.75</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">14,230,011</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">0.75</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>   Following is a summary of the status of options outstanding at March 31, 2016:     <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price ($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 23%">0.055</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 22%">1,750,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: center; width: 24%">08/2025</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 22%">0.055</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.04718</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,795,308</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">12/2022 01/2023</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.04718</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,715,109</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2023 01/2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">07/2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">42,670</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2022</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.60</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28,648</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.60</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.96</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,928</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.96</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,525</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">11/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28,535</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2019 07/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">14.10</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">15.30</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,373</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">09/2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15.30</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">16.50</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">262,441</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">17.70</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">953</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">24.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,667</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">12/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">26.70</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,297</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">09/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">28.80</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,767</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">04/2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28.80</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">32.70</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">83,790</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">08/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">32.70</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">$</td> <td style="text-align: right; padding-bottom: 2.5pt">Total</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">14,230,011</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt">Average</td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 2.5pt; font-weight: bold">0.75</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td></tr> </table>    Warrants to Purchase Common Stock    The warrant activity for the period starting October 1, 2015, through March 31, 2016, is described as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average  Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 72%">Outstanding at September 30, 2015</td> <td style="padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%; font-weight: bold">781,524</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 1pt; width: 11%; font-weight: bold">0.53</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">87,200,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(35,002</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">1.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: right; font-weight: bold">87,946,522</td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 1pt; font-weight: bold">0.05</td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold"> </td></tr> </table>     Following is a summary of the status of warrants outstanding at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 23%">0.04718</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 22%">38,152</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: center; width: 24%">03/2018</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 22%">0.04718</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,200,000</td> <td style="text-align: left">(1)</td> <td> </td> <td style="text-align: center">12/31/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,000,000</td> <td style="text-align: left">(2)</td> <td> </td> <td style="text-align: center">12/31/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">332,200</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">04/2016 07/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.275</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">324,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">06/2018 03/2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.275</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,168</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">10/2015 01/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">7.50</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,334</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">05/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">9.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,668</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">07/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">9.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt">Total</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">87,946,522</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 2.5pt; font-weight: bold">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td></tr> </table>   (1) Between December 23, 2015, and March 31, 2016 the Company entered into a Second Amended Note and Warrant Purchase Agreement pursuant to which the Company issued five Notes (including the December 2015 Notes) to the four purchasers for an aggregate principal amount of $1,360,000 and issued five Note Warrants to purchase an aggregate of 27,200,000 shares of the Company's Common Stock. The Note Warrants were issued to purchasers of Notes in an amount equal to 100% of the shares underlying their December 2015 Notes. Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. 2 million Note Warrants were issued to one accredited investor and 25.2 million Note Warrants were issued to Directors; for further detail refer to Note 6. Related Party Transactions.   (2) On December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, Extension Warrants to purchase an aggregate of 60,000,000 shares of Common Stock. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder's previously outstanding Notes. 11 million Extension Warrants were issued to 10 accredited investors and 49 million Extension Warrants were issued to Directors and Affiliates; for further detail refer to Note 6. Related Party Transactions.   On December 23, 2015, we valued the Extension Warrants to purchase 60 million shares of Common Stock using the Black-Scholes model and determined their value to be $1,196,000, which was booked as an Extinguishment of Debt expense.    The range of Black-Scholes option-pricing model assumption inputs for the six months ended March 31, 2016, were as follows:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">December 23, 2015 through March 31,2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annual dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 76%">Expected life (years)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 21%">5.00</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Risk-free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.21% ~ 1.74 %</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">255.50% ~ 272.56 %</td> <td style="text-align: left"> </td></tr> </table>   At March 31, 2016, there were warrants outstanding to purchase 87,946,522 shares of the Companys Common Stock. The exercise prices of the outstanding warrants range from $0.04718 to $9.00 with a weighted average exercise price of $0.05. The warrants expire at various times starting 2016 through 2020.

7. LOSS PER SHARE   In accordance with ASC 260-10 (formerly SFAS 128, Computation of Earnings Per Share), basic net income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period.  For the three and six months ended March 31, 2016 and 2015, the Company has excluded all common equivalent shares from the calculation of diluted net loss per share as such securities are anti-dilutive.   A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended March 31, 2016 and 2015 is as follows:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months ended March 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Net Loss for computation of basic and diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; width: 72%">Net loss</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(142,700</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(696,300</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Basic and Diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Basic net loss per share</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.00</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.01</td> <td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Basic and Diluted weighted average shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,669,022</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,667,409</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Convertible debt</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,271,628</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,892,742</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">80,938,825</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">781,833</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,230,011</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,645,994</td> <td style="text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Six months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Net Loss for computation of basic and diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; width: 72%">Net loss</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(3,594,000</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(1,570,900</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Basic and Diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Basic net loss per share</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.04</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.02</td> <td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Basic and Diluted weighted average shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,543,215</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,667,409</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Convertible debt</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">73,234,048</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,771,371</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">43,892,108</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">871,027</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,230,011</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,531,746</td> <td style="text-align: left"> </td></tr> </table>

Basis of Presentation   The accompanying unaudited condensed consolidated financial statements of the Company have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the SEC) and are in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates   The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expense, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, doubtful accounts, intangible assets, income taxes, valuation of equity instruments, accrued liabilities, contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates.

Cash   The Company deposits its cash with major financial institutions and may at times exceed the federally insured limit of $250,000.  At March 31, 2016 cash exceeds the federally insured limit by $190,200.  The Company believes that the risk of loss is minimal. To date, the Company has not experienced any losses related to cash deposits with financial institutions.

Derivative Liabilities   The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a weighted average Black-Scholes option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of March 31, 2016, the Companys only derivative financial instruments were a series of convertible notes having embedded derivative liabilities based on the conversion price of the note relative to the market price of a share of Common Stock on the valuation date. See Notes 3 & 4.

Fair Value of Financial Instruments   ASC 825-10 defines financial instruments and requires disclosure of the fair value of financial instruments held by the Company. The Company considers the carrying amount of cash, accounts receivable, other receivables, accounts payable and accrued liabilities, to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization.    The Company also analyzes all financial instruments with features of both liabilities and equity under ASC 480-10, ASC 815-10 and ASC 815-40.   The Company adopted ASC 820-10 on January 1, 2008. ASC 820-10 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:   <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td>Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td>Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments; and</td></tr> </table> <table cellspacing="0" cellpadding="0" style="margin-top: 0pt; font-size: 10pt; margin-bottom: 0pt; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td>Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.</td></tr> </table>   The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using the Black-Scholes option-pricing model with the following assumption inputs:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annual dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 72%">Expected life (years)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">1.75</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">0.5</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Risk-free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.73</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.08</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">225.53</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">48</td> <td style="text-align: left">%</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">Carrying Value</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">Fair Value Measurements at</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">As of</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">March 31, 2016</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Using Fair Value Hierarchy</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify">Liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; width: 40%">Embedded derivative liabilities</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">Carrying Value</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">Fair Value Measurements at</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">As of</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">September 30, 2015</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">September 30,</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Using Fair Value Hierarchy</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify">Liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; width: 40%">Embedded derivative liabilities</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">833,000</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">833,000</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">833,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">833,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>   For a roll-forward analysis of embedded derivative liabilities refer to Note 4. Derivative Liabilities   At March 31, 2016 and September 30, 2015, the Company had derivative liabilities of $1,441,700 and $833,000 respectively. For the six months ending March 31, 2016 and 2015, the Company had gains on the fair valuation of derivative liabilities of $798,200 and a $99,300 on fair valuation of derivative liabilities respectively.  As of March 31, 2016, the Company did not identify any other assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10.

Accounts Receivable   The Company estimates the collectability of customer receivables on an ongoing basis by reviewing past-due invoices and assessing the current creditworthiness of each customer.  Allowances are provided for specific receivables deemed to be at risk for collection which as of March 31, 2016 and September 30, 2015 were $1,200 and $1,200 respectively.

Furniture and Equipment   Furniture and Equipment, which are recorded at cost, consist of office furniture, equipment and purchased intellectual property which are depreciated, or amortized in the case of the intellectual property, over their estimated useful life on a straight-line basis.  The useful life of these assets is estimated to be between three and ten years.  Depreciation and amortization for the six months ended March 31, 2016 and 2015 was $2,700 and $4,400 respectively.  Accumulated depreciation and amortization at March 31, 2016 and September 30, 2015 was $74,900 and $82,600, respectively.

Long-Lived Assets   As required by ASC 350-30 (formerly SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets), the Company reviews the carrying value of its long-lived assets whenever events or changes in circumstances indicate that the historical cost-carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of the asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the assets carrying value and fair value. No impairment loss was recorded for the six months ended March 31, 2016 and 2015.

Intangible Assets   Costs for software developed for internal use are accounted for through the capitalization of those costs incurred in connection with developing or obtaining internal-use software. Capitalized costs for internal-use software are included in intangible assets in the consolidated balance sheet. Capitalized software development costs are amortized over three years. Costs incurred during the preliminary project along with post-implementation stages of internal use computer software development and costs incurred to maintain existing product offerings are expensed as incurred. The capitalization and ongoing assessment of recoverability of development costs require considerable judgment by management with respect to certain external factors, including, but not limited to, technological and economic feasibility and estimated economic life. At March 31, 2016, the Company had $9,000 in capitalized software development of which $9,000 was capitalized during the three and six months ended March 31, 2016. The Company will begin amortizing the software over its estimated economic life once it has been placed into service. For the three and six months ended March 31, 2016, there has been no amortization expense for capitalized software development as it has not been placed into service.

Accounts Payable   Accounts payable consists of trade payables of which $405,700 and $476,900 are for legal services at March 31, 2016 and 2015 respectively.

Deferred Revenue   Deferred revenue represents revenue collected but not earned as of March 31, 2016. This represents a philanthropic grant for the payment of PEER Reports ordered for a clinical trial, which are otherwise not paid for by the military. These deferred revenue grant funds as of March 31, 2016 and 2015 are $45,900 for both periods.

Revenues   The Company recognizes revenue on services, being the delivery of PEER Reports to medical providers, in accordance with the Financial Accounting Standards Board (FASB) ASC No. 605, Revenue Recognition.  In all cases, revenue is recognized when we have persuasive evidence of an arrangement, a determinable fee, when collection is considered to be reasonable assured and the services are delivered.

Research and Development Expenses   The Company charges all research and development expenses to operations as incurred.

Advertising Expenses   The Company charges all advertising expenses to operations as incurred. For the six months ended March 31, 2016 and 2015 advertising expenses were $85,100 and $29,000 respectively.

Stock-Based Compensation   The Company has adopted ASC 718-20 and related interpretations which establish the accounting for equity instruments exchanged for employee services. Under ASC 718-20, share-based compensation cost to option grantee, being employees and directors, and is measured at the grant date based on the calculated fair value of the award (see Note 5 for further discussion on valuations). The expense is recognized over the option grantees requisite service period, generally the vesting period of the award.

Income Taxes   The Company accounts for income taxes under the asset and liability method.  Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.  Valuation allowances are recorded, when necessary, to reduce deferred tax assets to the amount expected to be realized.   As a result of the implementation of certain provisions of ASC 740, Income Taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as defined. ASC 740 seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes.  The Company adopted the provisions of ASC 740 and have analyzed filing positions in each of the federal and state jurisdictions where required to file income tax returns, as well as all open tax years in these jurisdictions.  We have identified the U.S. Federal and California as our "major" tax jurisdictions.  Generally, we remain subject to Internal Revenue Service examination of our 2010 through 2014 U.S. federal income tax returns, and remain subject to California Franchise Tax Board examination of our 2010 through 2014 California Franchise Tax Returns.  However, we have certain tax attribute carryforwards which will remain subject to review and adjustment by the relevant tax authorities until the statute of limitations closes with respect to the year in which such attributes are utilized.   We believe that our income tax filing positions and deductions will be sustained on audit and do not anticipate any adjustments that will result in a material change to our financial position.  Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740.  In addition, we did not record a cumulative effect adjustment related to the adoption of ASC 740.  Our policy for recording interest and penalties associated with income-based tax audits is to record such items as a component of income taxes.

Comprehensive Income (Loss)   ASC 220-10 requires disclosure of all components of comprehensive income (loss) on an annual and interim basis.  Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources.  The Companys comprehensive income (loss) is the same as its reported net income (loss) for the six months ended March 31, 2016 and 2015.

Earnings (Loss) per Share    Basic earnings (loss) per share are computed by dividing income (loss) available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings (loss) per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.

Recent Accounting Pronouncements   Apart from the below-mentioned recent accounting pronouncements, there are no new accounting pronouncements that are currently applicable to the Company.   In April 2015, the FASB issued Accounting Standards Update (ASU) No. 2015-03 is to simplify presentation of debt issuance costs, the amendments in this Update would require that debt issuance costs be presented in the balance sheet as a direct deduction from the carrying amount of debt liability, consistent with debt discounts or premiums. The recognition and measurement guidance for debt issuance costs would not be affected by the amendments in this Update. The amendments in this ASU are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. The Company does not expect the adoption of the standard update to have a material impact on its consolidated financial position or results of operations.

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using the Black-Scholes option-pricing model with the following assumption inputs:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annual dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 72%">Expected life (years)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">1.75</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">0.5</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Risk-free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.73</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.08</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">225.53</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">48</td> <td style="text-align: left">%</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">Carrying Value</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">Fair Value Measurements at</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">As of</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">March 31, 2016</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Using Fair Value Hierarchy</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify">Liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; width: 40%">Embedded derivative liabilities</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">Carrying Value</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">Fair Value Measurements at</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; font-weight: bold">As of</td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td nowrap="nowrap" style="font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="text-align: center; font-weight: bold">September 30, 2015</td> <td nowrap="nowrap" style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">September 30,</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Using Fair Value Hierarchy</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify">Liabilities</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt; width: 40%">Embedded derivative liabilities</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">833,000</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">-</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 12%">833,000</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 1pt">Total</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">833,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">833,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>

The table below provides additional detail regarding the Notes as of March 31, 2016, with respect to the carrying value and discount on the Balance Sheet.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">As of March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; font-weight: bold">Note Type and Investor</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Due Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Balance</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Discount</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Carrying Value</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid">Senior Secured 5% Notes Convertible at $0.05 (the Notes)</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="text-align: center; padding-bottom: 1pt; font-weight: bold">($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; font-weight: bold"> Related Parties:</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt; width: 40%">RSJ Private Equity</td> <td style="width: 1%"> </td> <td style="text-align: center; width: 14%">12/31/2017</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1,850,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">(211,100</td> <td style="text-align: left; width: 1%">)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">1,638,900</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">John Pappajohn</td> <td> </td> <td style="text-align: center">12/31/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">800,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(147,300</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">652,700</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">Tierney Family Trust</td> <td> </td> <td style="text-align: center">12/31/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">540,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">540,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">Follman Family Trust</td> <td> </td> <td style="text-align: center">12/31/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">250,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">250,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">Oman Ventures</td> <td> </td> <td style="text-align: center">12/31/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">200,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">200,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">Robin L. Smith</td> <td> </td> <td style="text-align: center">12/31/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Geoffrey E. Harris</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">12/31/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">10,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,700</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,300</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; text-indent: -8.6pt; padding-left: 8.65pt; font-weight: bold">Total Related Parties</td> <td> </td> <td style="text-align: center"> </td> <td style="font-weight: bold"> </td> <td style="text-align: left; font-weight: bold"> </td> <td style="text-align: right; font-weight: bold">3,710,000</td> <td style="text-align: left; font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td style="text-align: left; font-weight: bold"> </td> <td style="text-align: right; font-weight: bold">(363,100</td> <td style="text-align: left; font-weight: bold">)</td> <td style="font-weight: bold"> </td> <td style="text-align: left; font-weight: bold"> </td> <td style="text-align: right; font-weight: bold">3,346,900</td> <td style="text-align: left; font-weight: bold"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-indent: -8.6pt; padding-left: 8.65pt; font-weight: bold; text-decoration: underline">Others:</td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">11 Accredited Investors</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">12/31/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">650,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(30,700</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">619,300</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -8.6pt; padding-left: 8.65pt; font-weight: bold">Total Secured Convertible Promissory Notes</td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">4,360,000</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">(393,800</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold">)</td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">3,966,200</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td></tr> </table>

The range of Black-Scholes option-pricing model assumption inputs for all the valuation dates are in the table below:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: right"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015 through to March 31, 2016 Low</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">September 30, 2015 through to March 31, 2016 High</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Annual dividend yield</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"></td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; width: 72%">Expected life (years)</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">0.2</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">2.00</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Risk-free interest rate</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.08</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.06</td> <td style="text-align: left">%</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Expected volatility</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">47.83</td> <td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">225.32</td> <td style="text-align: left">%</td></tr> </table>

The following tables include a roll-forward of liabilities classified within Levels 1, 2 and 3:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Six Months Ended March 31, 2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 61%">Stock warrant and other derivative liabilities at September 30, 2015</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">-</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">-</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">833,000</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">$3M of convertible debt prior to amendment</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">(772,800</td> <td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-left: 9pt">$3M of convertible debt as amended</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">962,300</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-left: 9pt">Issuance of warrants and other derivatives</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">444,600</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(25,400</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Stock warrant and other derivative liabilities at March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">1,441,700</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="10" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Six Months Ended March 31, 2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 1</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 2</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Level 3</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 61%">Stock warrant and other derivative liabilities at September 30, 2014</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">-</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">-</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 10%">153,100</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Change in fair value</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(67,300</td> <td style="text-align: left; padding-bottom: 1pt">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Stock warrant and other derivative liabilities at March 31, 2015</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left">$</td> <td style="border-bottom: black 1pt solid; text-align: right">85,800</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>

Stock-based compensation expense included in the accompanying statements of operations for the three and six months ended March 31, 2016 and 2015 is as follows:      <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For the three months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 72%">Research</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">10,400</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">10,400</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Product Development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7,700</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15,500</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Sales and marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,900</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">53,400</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,200</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">20,500</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">40,200</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">99,800</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">For the six months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="width: 72%">Research</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">20,800</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">20,800</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">Product Development</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16,800</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">34,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Sales and marketing</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,900</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">63,300</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">18,400</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">44,100</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 8.65pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">70,900</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">162,200</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

A summary of stock option activity is as follows:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average  Exercise  Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 72%">Outstanding at September 30, 2015</td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%">14,230,011</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td> <td style="padding-bottom: 1pt; width: 1%"> </td> <td style="text-align: left; padding-bottom: 1pt; width: 1%">$</td> <td style="text-align: right; padding-bottom: 1pt; width: 11%">0.75</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Forfeited</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">14,230,011</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">0.75</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> </table>

Following is a summary of the status of options outstanding at March 31, 2016:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price ($)</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 23%">0.055</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 22%">1,750,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: center; width: 24%">08/2025</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 22%">0.055</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.04718</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">8,795,308</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">12/2022 01/2023</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.04718</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">2,715,109</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2023 01/2025</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">425,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">07/2024</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.26</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">42,670</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2022</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.60</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28,648</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.60</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">3.96</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,928</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3.96</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,525</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">11/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">9.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28,535</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2019 07/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">14.10</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2021</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14.10</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">15.30</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,373</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">09/2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">15.30</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">16.50</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">262,441</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">03/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">16.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">17.70</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">953</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">08/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">17.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">24.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,667</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">12/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">24.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">26.70</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,297</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">09/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">26.70</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">28.80</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">11,767</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">04/2018</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">28.80</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">32.70</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">83,790</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">08/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">32.70</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt">$</td> <td style="text-align: right; padding-bottom: 2.5pt">Total</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">14,230,011</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt">Average</td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 2.5pt; font-weight: bold">0.75</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td></tr> </table>

The warrant activity for the period starting October 1, 2015, through March 31, 2016, is described as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of  Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average  Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt; width: 72%">Outstanding at September 30, 2015</td> <td style="padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: right; width: 11%; font-weight: bold">781,524</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="padding-bottom: 1pt; width: 1%; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 1pt; width: 11%; font-weight: bold">0.53</td> <td style="text-align: left; padding-bottom: 1pt; width: 1%; font-weight: bold"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Granted</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">87,200,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Exercised</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">-</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-bottom: 1pt">Expired</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(35,002</td> <td style="text-align: left; padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">1.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="padding-bottom: 1pt">Outstanding at March 31, 2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: right; font-weight: bold">87,946,522</td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 1pt; font-weight: bold">0.05</td></tr> </table> Following is a summary of the status of warrants outstanding at March 31, 2016:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="background-color: white; vertical-align: bottom"> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 23%">0.04718</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 22%">38,152</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: center; width: 24%">03/2018</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 22%">0.04718</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">27,200,000</td> <td style="text-align: left">(1)</td> <td> </td> <td style="text-align: center">12/31/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,000,000</td> <td style="text-align: left">(2)</td> <td> </td> <td style="text-align: center">12/31/2020</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.05</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">332,200</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">04/2016 07/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.25</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">0.275</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">324,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">06/2018 03/2019</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">0.275</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">1.00</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">32,168</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">10/2015 01/2017</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1.00</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left"> </td> <td style="text-align: right">7.50</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">3,334</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: center">05/2016</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">7.50</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">$</td> <td style="text-align: right; padding-bottom: 1pt">9.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,668</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">07/2017</td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt">9.00</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt">Total</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 2.5pt double; text-align: right; font-weight: bold">87,946,522</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="text-align: right; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-weight: bold"> </td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold">$</td> <td style="text-align: right; padding-bottom: 2.5pt; font-weight: bold">0.05</td> <td style="text-align: left; padding-bottom: 2.5pt; font-weight: bold"> </td></tr> </table>

Extension warrants were issued to affiliates as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid">5-Year Extension Warrants with an non-cashless exercise price of $0.05</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Secured Convertible Promissory Notes</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Warrants to purchase Shares of Common Stock</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt; width: 72%">RSJ Private Equity</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 11%">1,850,000</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%"> </td> <td style="text-align: right; width: 11%">22,000,000</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Robin L. Smith</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">60,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,200,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">John Pappajohn</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">550,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">6,000,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Tierney Family Trust</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">540,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">10,800,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; text-indent: -8.1pt; padding-left: 8.1pt">Oman Ventures</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">200,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">4,000,000</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Follman Family Trust</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">250,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">5,000,000</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.1pt; padding-left: 8.1pt">Total Secured Convertible Promissory Notes</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font-weight: bold">$</td> <td style="border-bottom: black 1pt solid; text-align: right; font-weight: bold">3,450,000</td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: left; font-weight: bold"> </td> <td style="border-bottom: black 1pt solid; text-align: right; font-weight: bold">49,000,000</td> <td style="text-align: left; padding-bottom: 1pt; font-weight: bold"> </td></tr> </table>

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended March 31, 2016 and 2015 is as follows:    <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three months ended March 31,</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Net Loss for computation of basic and diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; width: 72%">Net loss</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(142,700</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(696,300</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Basic and Diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Basic net loss per share</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.00</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.01</td> <td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Basic and Diluted weighted average shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,669,022</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,667,409</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Convertible debt</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">83,271,628</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,892,742</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">80,938,825</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">781,833</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,230,011</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,645,994</td> <td style="text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="6" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Six months ended March 31,</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2016</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">2015</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Net Loss for computation of basic and diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; width: 72%">Net loss</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(3,594,000</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td> <td style="padding-bottom: 2.5pt; width: 1%"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 11%">(1,570,900</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Basic and Diluted net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="padding-left: 9pt">Basic net loss per share</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.04</td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right">(0.02</td> <td style="text-align: left">)</td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Basic and Diluted weighted average shares outstanding</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">102,543,215</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">101,667,409</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left">The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: left">Convertible debt</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">73,234,048</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,771,371</td> <td style="text-align: left"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td>Warrants</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">43,892,108</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">871,027</td> <td style="text-align: left"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td>Options</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">14,230,011</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">12,531,746</td> <td style="text-align: left"> </td></tr> </table>

As of March 31, 2016 the remaining lease obligation is $7,800, of the remaining lease obligation is 2016 $1,600; with $1,200 for the years 2017-2020; 2021 $1,400.   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt"> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="text-align: center"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="18" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Payments due by period</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Contractual Obligations</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">Total</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">Less than  1 year</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">1 to 3 years</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center; font-weight: bold">3 to 5 years</td> <td nowrap="nowrap" style="padding-bottom: 1pt; font-weight: bold"> </td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td> <td colspan="2" nowrap="nowrap" style="border-bottom: black 1pt solid; text-align: center">More than 5 years</td> <td nowrap="nowrap" style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; width: 25%">Operating Lease Obligations</td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">140,400</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">75,100</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">65,300</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">-</td> <td style="text-align: left; width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: left; width: 1%">$</td> <td style="text-align: right; width: 12%">-</td> <td style="text-align: left; width: 1%"> </td></tr> <tr style="background-color: white; vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Capital Lease Obligations</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">8,400</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,200</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">4,800</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,400</td> <td style="text-align: left; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: left"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr style="background-color: rgb(204,238,255); vertical-align: bottom"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">148,800</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">77,300</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">70,100</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">1,400</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.5pt double; text-align: left">$</td> <td style="border-bottom: black 2.5pt double; text-align: right">-</td> <td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table>

0.05 0.53

102417409

102717409

CNSO

190200

85100

29000

798200

99300

2 1600 1400 1200

145443

The warrants expire at various times starting 2016 through 2020.

P5Y

0.0121

0.0174

2.5550

2.7256

833000

1441700

153100

85800

-772800 962300

444600

-25400

-67300

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="text-align: justify; vertical-align: top"> <td style="width: 0.5in; text-align: left">9.</td> <td style="text-align: justify">SUBSEQUENT EVENTS</td></tr> </table>   Events subsequent to March 31, 2016 have been evaluated through the date these financial statements were issued, to determine whether they should be disclosed to keep the financial statements from being misleading. The following events have occurred since March 31, 2016.    On April 5, 2016, the Board approved grants of the Company's Common Stock under the 2012 Plan, with immediate vesting, as follows: 1,000,000 shares to our Chairman of the Board, Dr. Robin Smith; 500,000 shares to our Director and Chairman of the Audit Committee, Geoffrey Harris; and 250,000 shares to each of our remaining five Directors.   Also on April 5, 2016, the Board granted 1,000,000 shares of the Companys Common Stock under the 2012 Plan to each of George Carpenter, the Company's President and Chief Executive Officer, and Paul Buck, the Company's Chief Financial Officer. 50% of these shares vested on the date of grant with the remaining 50% vesting pro-rata over 12 months starting on the date of grant, respectively. Lastly, on April 5, 2016 the Board granted options to purchase 1,450,000 shares of the Companys Common Stock under the 2012 Plan to staff members and options to purchase 200,000 shares of the Companys Common Stock to our consultant, DCA. These shares vest pro-rata over 12 months starting on the date of grant.   The abovementioned grants of shares and options to Board members, executive officers, staff and consultant are valued $0.0255 per share, which was the closing price on the OTC.QB of the Companys Common Stock on April 5, 2016.   Subsequent to March 31, 2016, the Company issued multiple Notes and Note Warrants pursuant to the Second Amended Note and Warrant Purchase Agreement to affiliates of the Company as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td style="text-align: justify">On April 7, 2016, the Company issued to the Follman Trust, of which Robert Follman, a member of the Companys Board, is a trustee: (i) a Note in the aggregate principal amount of $200,000, and (ii) a Note Warrant to purchase 4,000,000 shares of the Companys Common stock at $0.05 per share.</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td style="text-align: justify">On April 11, 2016, the Company issued to John Pappajohn, a member of the Board: (i) a Note in the aggregate principal amount of $250,000, and (ii) a Note Warrant to purchase 5,000,000 shares of the Companys Common stock at $0.05 per share. </td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td style="text-align: justify">On April 21, 2016, the Company issued to Dr. Robin Smith, our Chairman of the Board: (i) a Note in the aggregate principal amount of $40,000, and (ii) a Note Warrant to purchase 800,000 shares of the Companys Common stock at $0.05 per share. </td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt; line-height: normal; margin-top: 0px; margin-bottom: 0px; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"></td> <td style="text-align: justify">On May 4, 2016, the Company issued to George Carpenter, the Companys CEO, and his wife Jill: (i) a Note in the aggregate principal amount of $50,000, and (ii) a Note Warrant to purchase 1,000,000 shares of the Companys Common stock at $0.05 per share.</td></tr> </table>   In aggregate, since March 31, 2016, the Company has issued Notes totaling $540,000, which also represents gross proceeds to the Company, and has issued Note Warrants to purchase 10,800,000 shares of the Companys Common Stock at $0.05 per share.

798200

786900

99300

139200

(1) On December 23, 2015, the Company entered into a Second Amended Note and Warrant Purchase Agreement pursuant to which on December 23 and December 28, 2015, the Company issued December 2015 Notes to the two purchasers for an aggregate principal amount of $1,000,000 and issued a Note Warrant to each holder of December 2015 Notes to purchase the Company's Common Stock, in an amount equal to 100% of the shares underlying their December 2015 Note. Each Note Warrant is exercisable, in whole or in part, during the period beginning on the date of its issuance, and ending on the earlier of (i) December 31, 2020 and (ii) the date that is forty-five (45) days following the date on which the daily closing price of shares of the Company's Common Stock quoted on the OTCQB Venture Marketplace (or other bulletin board or exchange on which the Company's Common Stock is traded or listed) exceeds $0.25 for at least ten (10) consecutive trading days. In connection therewith, the Company will promptly notify the Note Warrant holders in the event that the daily closing price of the Company's shares of Common Stock so exceeds $0.25 for at least ten (10) consecutive trading days. Both December 2015 Notes and Note Warrants were purchased by affiliates of the Company, or an entity under such affiliate's control, as follows: (i) on December 23, 2015, John Pappajohn, a member of the board of directors of the Company, purchased a December 2015 Note for $250,000 and was issued a Note Warrant to purchase 5,000,000 shares of Common Stock; and (ii) on December 28, 2015, RSJ PE, of which, Michal Votruba, a member of the board of directors of the Company, is the Director for Life Sciences for the RSJ/Gradus Fund, purchased a December 2015 Note for $750,000 and was issued a Note Warrant to purchase 15,000,000 shares of Common Stock. (2) On December 23, 2015, in consideration for the agreement to extend the maturity date of the Notes, the Company issued to holders of all Notes outstanding prior to the date of the Second Amended Note & Warrant Agreement, Extension Warrants to purchase an aggregate of 60,000,000 shares of Common Stock. Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder's previously outstanding Notes. 11 million Extension Warrants were issued to 10 accredited investors and 49 million Extension Warrants were issued to Directors and Affiliates; for further detail refer to Note 7. Related Party Transactions.

EX-101.SCH 6 cnso-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - CONVERTIBLE DEBT AND EQUITY FINANCINGS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - CONVERTIBLE DEBT AND EQUITY FINANCINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - DERIVATIVE LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCKHOLDERS' DEFICIT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - DERIVATIVE LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DERIVATIVE LIABILITIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - STOCKHOLDERS' DEFICIT (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS' DEFICIT (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS' DEFICIT (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS' DEFICIT (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS' DEFICIT (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - STOCKHOLDERS' DEFICIT (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 cnso-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 cnso-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 cnso-20160331_lab.xml XBRL LABEL FILE October 2012 Note [Member] Short-term Debt, Type [Axis] Twenty Accredited Investors [Member] Related Party [Axis] Original Note Purchase Agreement [Member] Type of Arrangement and Non-arrangement Transactions [Axis] 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] Furniture and Equipment [Member] Property, Plant and Equipment, Type [Axis] Minimum [Member] Range [Axis] Maximum [Member] Computer Software development [Member] Carrying Value [Member] Measurement Basis [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Amendment Note Purchase Agreement [Member] RSJ Private Equity (Michal Votruba) [Member] John Pappajohn [Member] Thomas Tierney (Tierney Family Trust) [Member] Robert Follman (Follman Family Trust) [Member] Mr. George Carpenter [Member] RSJ Private Equity & Nine Accredited Investors [Member] Secured Convertible Promissory Notes (September 2015 Notes) [Member] Six Accredited Investors [Member] Robin L. Smith [Member] Second Amended Note & Warrant Agreement [Member] Sixteen Accredited Investors [Member] Secured Convertible Promissory Notes ( December 2015 Notes) [Member] Note Warrant [Member] Class of Warrant or Right [Axis] Three Accredited Investor [Member] Geoffrey E. Harris [Member] Eleven Accredited Investors [Member] $3 Million Convertible Debt (Beginning) [Member] $250,000 Convertible Note [Member] $750,000 Convertible Note [Member] $3M Convertible Debt (Prior To Amendment) [Member] $3 Million Convertible Debt (Amended) [Member] $4M Million Convertible Debt (Ending) [Member] Restricted Stock [Member] Award Type [Axis] 2006 Stock Incentive Plan [Member] Plan Name [Axis] 2012 Omnibus Incentive Compensation Plan [Member] Management [Member] Option [Member] $0.055 [Member] Exercise Price Range [Axis] Warrant [Member] Consulting Agreement [Member] Dian Griesel International [Member] Legal Entity [Axis] Dian Griesel International [Member] One Accredited Investor [Member] Ten Accredited Investors [Member] Directors And Affiliates [Member] Research [Member] Income Statement Location [Axis] Product Development [Member] Sales And Marketing [Member] General And Administrative [Member] $0.04718 [Member] $0.25 [Member] $0.26 [Member] $3.00 [Member] $3.60 [Member] $3.96 [Member] $9.00 [Member] $12.00 [Member] $14.10 [Member] $15.30 [Member] $16.50 [Member] $17.70 [Member] $24.00 [Member] $26.70 [Member] $28.80 [Member] $32.70 [Member] $0.05 [Member] $0.05 [Member] $0.275 [Member] $1.00 [Member] $7.50 [Member] Termination Agreements With SAIL Capital Partners [Member] Related Party Transaction [Axis] Governance Agreements [Member] Termination Agreements With Equity Dynamics,Inc [Member] Michal Votruba [Member] Private Placement [Member] Sale of Stock [Axis] Unregistered Stock [Member] Class of Stock [Axis] Marketing Services Consulting Agreement [Member] Decision Calculus Associates (Jill Carpenter) [Member] Three-Month Long Consulting Engagement With Dr. Eric Warner [Member] Secured Convertible Promissory Notes [Member] Convertible Debt [Member] Antidilutive Securities [Axis] Leonard J. Brandt and Brandt Ventures, GP v. CNS Response, Inc., Sail Venture Partners and David Jones [Member] Litigation Case [Axis] EEG Equipment [Member] Headquarters and Neurometric Services [Member] Canon Copier [Member] Common Stock [Member] Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Fair Value, Hierarchy [Axis] SubsequentEventMember Subsequent Event Type [Axis] Five Directors [Member] Mr. Paul Buck [Member] Staff Members [Member] Mr. George Carpenter & His Wife Jill [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Income Statement [Abstract] REVENUES Neurometric Services OPERATING EXPENSES Cost of neurometric services revenue Research Product development Sales and marketing General and administrative Total operating expenses OPERATING LOSS OTHER INCOME (EXPENSE): Interest expense, net Loss on extinguishment of debt Gain on derivative liabilities Total other income (expense) LOSS BEFORE PROVISION FOR INCOME TAXES Provision for income taxes NET LOSS BASIC AND DILUTED LOSS PER SHARE: From continuing operations (in dollars per share) WEIGHTED AVERAGE SHARES OUTSTANDING: Basic and Diluted (in shares) Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Accounts receivable (net of allowance for doubtful accounts of $1,200 and $1,200 as of March 31, 2016, and September 30, 2015, respectively) Prepaid insurance Prepaid other assets Total current assets Furniture and equipment, net Intangible assets Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT: CURRENT LIABILITIES: Accounts payable (including $10,000 and $10,000 to related parties as of March 31, 2016, and September 30, 2015, respectively) Accrued liabilities Accrued compensation Accrued compensation - related parties Deferred revenue - grant funds Current portion of capital lease Total current liabilities LONG-TERM LIABILITIES Secured convertible debt - related parties (net of discounts $363,100 and $209,900 as of March 31, 2016 and September 30, 2015, respectively) Secured convertible debt - other (net of discounts $30,700 and $28,900 as of March 31, 2016, and September 30, 2015, respectively) Accrued interest Derivative liability Long term portion of capital lease Total long-term liabilities TOTAL LIABILITIES STOCKHOLDERS' DEFICIT: Common stock, $0.001 par value; authorized 500,000,000 shares and issued and outstanding 102,717,409 shares and 102,417,409 shares as of March 31, 2016 and September 30, 2015, respectively Additional paid-in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Statement [Table] EX-101.PRE 10 cnso-20160331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 13, 2016
Document And Entity Information
Entity Registrant Name	MYnd Analytics, Inc.
Entity Central Index Key	0000822370
Document Type	10-Q
Trading Symbol	CNSO
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		107,467,409
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
REVENUES
Neurometric Services	$ 20,700	$ 20,900	$ 45,400	$ 43,700
OPERATING EXPENSES
Cost of neurometric services revenue	1,400	1,800	2,700	2,900
Research	22,700	22,900	45,300	46,700
Product development	183,000	191,900	306,400	437,500
Sales and marketing	133,000	175,200	256,100	264,900
General and administrative	370,600	409,200	749,600	851,900
Total operating expenses	710,700	801,000	1,360,100	1,603,900
OPERATING LOSS	(690,000)	(780,100)	(1,314,700)	(1,560,200)
OTHER INCOME (EXPENSE):
Interest expense, net	$ (239,600)	$ (54,600)	(739,800)	$ (106,000)
Loss on extinguishment of debt			(2,337,400)
Gain on derivative liabilities	$ 786,900	$ 139,200	798,200	$ 99,300
Total other income (expense)	547,300	84,600	(2,279,000)	(6,700)
LOSS BEFORE PROVISION FOR INCOME TAXES	$ (142,700)	(695,500)	(3,593,700)	(1,566,900)
Provision for income taxes		800	300	4,000
NET LOSS	$ (142,700)	$ (696,300)	$ (3,594,000)	$ (1,570,900)
BASIC AND DILUTED LOSS PER SHARE:
From continuing operations (in dollars per share)	$ 0.00	$ (0.01)	$ (0.04)	$ (0.02)
WEIGHTED AVERAGE SHARES OUTSTANDING:
Basic and Diluted (in shares)	102,669,022	101,667,409	102,543,215	101,667,409

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
CURRENT ASSETS:
Cash	$ 440,200	$ 432,100
Accounts receivable (net of allowance for doubtful accounts of $1,200 and $1,200 as of March 31, 2016, and September 30, 2015, respectively)	6,800	11,800
Prepaid insurance	111,700	57,400
Prepaid other assets	58,900	46,900
Total current assets	617,600	548,200
Furniture and equipment, net	7,700	$ 1,700
Intangible assets	9,000
Other assets	25,600	$ 17,200
TOTAL ASSETS	659,900	567,100
CURRENT LIABILITIES:
Accounts payable (including $10,000 and $10,000 to related parties as of March 31, 2016, and September 30, 2015, respectively)	744,200	852,000
Accrued liabilities	182,600	156,300
Accrued compensation	433,000	418,500
Accrued compensation - related parties	259,700	226,100
Deferred revenue - grant funds	45,900	45,900
Current portion of capital lease	1,700	2,400
Total current liabilities	1,667,100	1,701,200
LONG-TERM LIABILITIES
Secured convertible debt - related parties (net of discounts $363,100 and $209,900 as of March 31, 2016 and September 30, 2015, respectively)	3,346,900	2,240,100
Secured convertible debt - other (net of discounts $30,700 and $28,900 as of March 31, 2016, and September 30, 2015, respectively)	619,300	525,700
Accrued interest	192,400	103,600
Derivative liability	1,441,700	$ 833,000
Long term portion of capital lease	5,400
Total long-term liabilities	5,605,700	$ 3,702,400
TOTAL LIABILITIES	7,272,800	5,403,600
STOCKHOLDERS' DEFICIT:
Common stock, $0.001 par value; authorized 500,000,000 shares and issued and outstanding 102,717,409 shares and 102,417,409 shares as of March 31, 2016 and September 30, 2015, respectively	102,700	102,400
Additional paid-in capital	59,471,300	57,654,000
Accumulated deficit	(66,186,900)	(62,592,900)
Total stockholders' deficit	(6,612,900)	(4,836,500)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 659,900	$ 567,100

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Allowance for doubtful accounts	$ 1,200	$ 1,200
Accounts payable due to related parties	$ 10,000	$ 10,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000
Common stock, issued	102,717,409	102,417,409
Common stock, outstanding	102,717,409	102,417,409
Management [Member]
Secured convertible debt, net of discount	$ 363,100	$ 209,900
Eleven Accredited Investors [Member]
Secured convertible debt, net of discount	$ 30,700	$ 28,900

XML 15 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
OPERATING ACTIVITIES:
Net loss	$ (3,594,000)	$ (1,570,900)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,700	4,400
Loss on derivative liability valuation	$ (798,200)	(67,300)
Valuation of warrants - investor relations		21,600
Stock based compensation	$ 70,900	$ 162,200
Grant of common stock	6,900
Loss on extinguishment of debt	2,337,400
Financing expenses	738,600	$ 72,700
Changes in operating assets and liabilities:
Accounts receivable	5,000	3,900
Prepaids and other	(66,300)	(56,500)
Accounts payable and accrued liabilities	(81,600)	$ 12,300
Security deposits	(9,400)
Deferred compensation	48,100	$ 73,900
Net cash used in operating activities	(1,339,900)	$ (1,343,700)
INVESTING ACTIVITIES:
Purchase of fixed assets	(1,000)
Intangible assets	(9,000)
Net cash used in investing activities	(10,000)
FINANCING ACTIVITIES:
Repayment of a capital lease	(2,000)	$ (1,900)
Net proceeds from issuance of secured convertible debt	1,360,000	415,000
Net cash provided by (used in) financing activities	1,358,000	413,100
NET INCREASE (DECREASE) IN CASH	8,100	(930,600)
CASH- BEGINNING OF THE QUARTER	432,100	1,240,600
CASH- END OF THE QUARTER	440,200	310,000
Cash paid during the period for:
Interest	1,300	1,500
Income taxes	$ 300	$ 4,000

XML 16 R6.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - 6 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Sep. 30, 2015	$ 102,400	$ 57,654,000	$ (62,592,900)	$ (4,836,500)
Balance at beginning (in shares) at Sep. 30, 2015	102,417,409
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		70,900		70,900
Extension warrants issued to note holders		1,196,000		1,196,000
Note warrants issued to note holders		543,800		543,800
Stock issued to vendor	$ 300	$ 6,600		6,900
Stock issued to vendor (in shares)	300,000
Net loss			$ (3,594,000)	(3,594,000)
Balance at ending at Mar. 31, 2016	$ 102,700	$ 59,471,300	$ (66,186,900)	$ (6,612,900)
Balance at ending (in shares) at Mar. 31, 2016	102,717,409

XML 17 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

6 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

1.	NATURE OF OPERATIONS

Going Concern Uncertainty

XML 18 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Cash

Derivative Liabilities

Fair Value of Financial Instruments

The Company also analyzes all financial instruments with features of both liabilities and equity under ASC 480-10, ASC 815-10 and ASC 815-40.

•

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

	March 31, 2016			September 30, 2015
Annual dividend yield		-			-
Expected life (years)		1.75			0.5
Risk-free interest rate		0.73	%		0.08	%
Expected volatility		225.53	%		48	%

	Carrying Value		Fair Value Measurements at
	As of		March 31, 2016
	March 31,		Using Fair Value Hierarchy
	2016		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		1,441,700		-		-		1,441,700
Total	$	1,441,700	$	-	$	-	$	1,441,700

	Carrying Value		Fair Value Measurements at
	As of		September 30, 2015
	September 30,		Using Fair Value Hierarchy
	2015		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		833,000		-		-		833,000
Total	$	833,000	$	-	$	-	$	833,000

For a roll-forward analysis of embedded derivative liabilities refer to Note 4. Derivative Liabilities

Accounts Receivable

Furniture and Equipment

Long-Lived Assets

Intangible Assets

Accounts Payable

Accounts payable consists of trade payables of which $405,700 and $476,900 are for legal services at March 31, 2016 and 2015 respectively.

Deferred Revenue

Revenues

Research and Development Expenses

The Company charges all research and development expenses to operations as incurred.

Advertising Expenses

The Company charges all advertising expenses to operations as incurred. For the six months ended March 31, 2016 and 2015 advertising expenses were $85,100 and $29,000 respectively.

Stock-Based Compensation

Income Taxes

Comprehensive Income (Loss)

Earnings (Loss) per Share

Recent Accounting Pronouncements

Apart from the below-mentioned recent accounting pronouncements, there are no new accounting pronouncements that are currently applicable to the Company.

XML 19 R9.htm IDEA: XBRL DOCUMENT

CONVERTIBLE DEBT AND EQUITY FINANCINGS

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

CONVERTIBLE DEBT AND EQUITY FINANCINGS

CONVERTIBLE DEBT AND EQUITY FINANCINGS

The table below provides additional detail regarding the Notes as of March 31, 2016, with respect to the carrying value and discount on the Balance Sheet.

		As of March 31, 2016
Note Type and Investor	Due Date	Balance		Discount			Carrying Value
Senior Secured 5% Notes Convertible at $0.05 (the “Notes”)		($)		($)			($)
Related Parties:
RSJ Private Equity	12/31/2017	$	1,850,000	$	(211,100	)	$	1,638,900
John Pappajohn	12/31/2017		800,000		(147,300	)		652,700
Tierney Family Trust	12/31/2017		540,000		-			540,000
Follman Family Trust	12/31/2017		250,000		-			250,000
Oman Ventures	12/31/2017		200,000		-			200,000
Robin L. Smith	12/31/2017		60,000		-			60,000
Geoffrey E. Harris	12/31/2017		10,000		(4,700	)		5,300
Total Related Parties			3,710,000		(363,100	)		3,346,900
Others:
11 Accredited Investors	12/31/2017		650,000		(30,700	)		619,300
Total Secured Convertible Promissory Notes		$	4,360,000	$	(393,800	)	$	3,966,200

XML 20 R10.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES

6 Months Ended

Mar. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES

The range of Black-Scholes option-pricing model assumption inputs for all the valuation dates are in the table below:

	September 30, 2015 through to March 31, 2016 Low			September 30, 2015 through to March 31, 2016 High
Annual dividend yield		—			—
Expected life (years)		0.2			2.00
Risk-free interest rate		0.08	%		1.06	%
Expected volatility		47.83	%		225.32	%

The following tables include a roll-forward of liabilities classified within Levels 1, 2 and 3:

	Six Months Ended March 31, 2016
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2015	$	-	$	-	$	833,000
$3M of convertible debt prior to amendment		-		-		(772,800	)
$3M of convertible debt as amended		-		-		962,300
Issuance of warrants and other derivatives		-		-		444,600
Change in fair value		-		-		(25,400	)
Stock warrant and other derivative liabilities at March 31, 2016	$	-	$	-	$	1,441,700

	Six Months Ended March 31, 2015
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2014	$	-	$	-	$	153,100
Change in fair value		-		-		(67,300	)
Stock warrant and other derivative liabilities at March 31, 2015	$	-	$	-	$	85,800

As of March 31, 2016 and September 30, 2015 we had derivative liabilities of $1,441,700 and $833,000 respectively.

XML 21 R11.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT

6 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' DEFICIT

STOCKHOLDERS’ DEFICIT

Common and Preferred Stock

As of March 31, 2016, 102,717,409 shares of Common Stock were issued and outstanding. No shares of preferred stock were issued or outstanding.

Stock-Option Plans

	For the three months ended March 31,
	2016		2015
Research		10,400		10,400
Product Development		7,700		15,500
Sales and marketing		14,900		53,400
General and administrative		7,200		20,500
Total	$	40,200	$	99,800

	For the six months ended March 31,
	2016		2015
Research		20,800		20,800
Product Development		16,800		34,000
Sales and marketing		14,900		63,300
General and administrative		18,400		44,100
Total	$	70,900	$	162,200

Total unrecognized stock-based compensation as of March 31, 2016, amounted to $145,443.

A summary of stock option activity is as follows:

	Number of Shares		Weighted Average Exercise Price
Outstanding at September 30, 2015		14,230,011	$	0.75
Granted		-
Exercised		-		-
Forfeited		-
Outstanding at March 31, 2016		14,230,011	$	0.75

Following is a summary of the status of options outstanding at March 31, 2016:

Exercise Price ($)		Number of Shares		Expiration Date	Weighted Average Exercise Price ($)

$	0.055		1,750,000	08/2025	$	0.055
	0.04718		8,795,308	12/2022 – 01/2023		0.04718
	0.25		2,715,109	03/2023 – 01/2025		0.25
	0.26		425,000	07/2024		0.26
	3.00		42,670	03/2022		3.00
	3.60		28,648	08/2016		3.60
	3.96		32,928	08/2016		3.96
	9.00		4,525	11/2016		9.00
	12.00		28,535	03/2019 – 07/2020		12.00
	14.10		10,000	03/2021		14.10
	15.30		1,373	09/2018		15.30
	16.50		262,441	03/2020		16.50
	17.70		953	08/2016		17.70
	24.00		4,667	12/2017		24.00
	26.70		32,297	09/2017		26.70
	28.80		11,767	04/2018		28.80
	32.70		83,790	08/2017		32.70
$	Total		14,230,011	Average	$	0.75

Warrants to Purchase Common Stock

The warrant activity for the period starting October 1, 2015, through March 31, 2016, is described as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding at September 30, 2015		781,524		$	0.53
Granted		87,200,000			0.05
Exercised		-			-
Expired		(35,002	)		1.00
Outstanding at March 31, 2016		87,946,522		$	0.05

Following is a summary of the status of warrants outstanding at March 31, 2016:

Exercise Price		Number of Shares			Expiration Date	Weighted Average Exercise Price

$	0.04718		38,152		03/2018	$	0.04718
	0.05		27,200,000	(1)	12/31/2020		0.05
	0.05		60,000,000	(2)	12/31/2020		0.05
	0.25		332,200		04/2016 – 07/2017		0.25
	0.275		324,000		06/2018 – 03/2019		0.275
	1.00		32,168		10/2015 – 01/2017		1.00
	7.50		3,334		05/2016		7.50
$	9.00		16,668		07/2017		9.00
	Total		87,946,522			$	0.05

The range of Black-Scholes option-pricing model assumption inputs for the six months ended March 31, 2016, were as follows:

	December 23, 2015 through March 31,2016
Annual dividend yield		-
Expected life (years)		5.00
Risk-free interest rate		1.21% ~ 1.74 %
Expected volatility		255.50% ~ 272.56 %

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

6 Months Ended

Mar. 31, 2016

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

Termination of Governance Agreements

Note Purchase Agreement, Notes and Omnibus Amendment and Second Amendment Note & Warrant Agreement

5-Year Extension Warrants with an non-cashless exercise price of $0.05	Secured Convertible Promissory Notes		Warrants to purchase Shares of Common Stock

RSJ Private Equity	$	1,850,000		22,000,000
Robin L. Smith		60,000		1,200,000
John Pappajohn		550,000		6,000,000
Tierney Family Trust		540,000		10,800,000
Oman Ventures		200,000		4,000,000
Follman Family Trust		250,000		5,000,000
Total Secured Convertible Promissory Notes	$	3,450,000		49,000,000

Director and Officer Indemnification Agreement

Transactions with John Pappajohn, Director

On September 6, 2015, Mr. Pappajohn irrevocably assigned $200,000 in principal of his September 2014 Notes to four outside parties in the amount of $50,000 each.

Transactions with Robert J. Follman, Director

Transaction with Robin L. Smith, Chairman

Transaction with Geoffrey E. Harris, Director and Chairman, Audit Committee

Transactions with George Carpenter, President and Chief Executive Officer

Transactions with the SAIL Capital Partners and SAIL Holdings

Transactions with Tierney Family Trust, Greater than 5% Stockholder

Transactions with Mark and Jill Oman, Greater than 5% Stockholder

Transactions with RSJ PE

Michal Votruba joined our Board on July 30, 2015. Mr. Votruba is a director of RSJ PE, which acted as the lead investor in the private placement financing of September 2014 Notes.

XML 23 R13.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE

6 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

LOSS PER SHARE

7. LOSS PER SHARE

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended March 31, 2016 and 2015 is as follows:

	Three months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(142,700	)	$	(696,300	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.00	)	$	(0.01	)

Basic and Diluted weighted average shares outstanding		102,669,022			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		83,271,628			1,892,742
Warrants		80,938,825			781,833
Options		14,230,011			12,645,994

	Six months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(3,594,000	)	$	(1,570,900	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.04	)	$	(0.02	)

Basic and Diluted weighted average shares outstanding		102,543,215			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		73,234,048			1,771,371
Warrants		43,892,108			871,027
Options		14,230,011			12,531,746

XML 24 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES

6 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES

8.	COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

A trial date had originally been set for May 2014. However, plaintiffs’ counsel requested a continuance until August 2014, to which the Company agreed. On June 18, 2014, at plaintiffs’ counsel’s request, the Company entered into a Standstill and Tolling Agreement, whereby the parties agreed to seek a stay of the litigation and plaintiffs agreed to provide the Company with an executed dismissal of all the claims without prejudice, with the ability to re-file the third amended complaint, without change, on or before June 18, 2015. The Company had the right to file the executed stipulation of dismissal if the Court lifted the stay. On May 7, 2015, the parties agreed to continue the Standstill and Tolling Agreement untill May 6, 2016, on the same terms. On May 12, 2015, the Court agreed to stay the case for another six months. On November 4, 2015 the Court lifted the stay, and set the case for trial on March 7, 2016. On February 3, 2016, the Company filed the executed stipulation of dismissal, thereby ending the current action in Orange County. The parties recently entered into extensions of the Standstill and Tolling Agreement that permit Mr. Brandt to start a new action and re-file the third amended complaint, without change, on or before May 23, 2016. The Company continues to believe that Mr. Brandt's allegations set forth in the third amended complaint, like the prior complaints, are without merit. The Company has not accrued any amounts related to this matter. The just-dismissed action was captioned Leonard J. Brandt and Brandt Ventures, GP v. CNS Response, Inc., Sail Venture Partners and David Jones, case no. 30-2011-00465655-CU-WT-CJC.

Lease Commitments

	Payments due by period
Contractual Obligations	Total		Less than 1 year		1 to 3 years		3 to 5 years		More than 5 years

Operating Lease Obligations	$	140,400	$	75,100	$	65,300	$	-	$	-
Capital Lease Obligations		8,400		2,200		4,800		1,400		-
Total	$	148,800	$	77,300	$	70,100	$	1,400	$	-

XML 25 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

6 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

9.	SUBSEQUENT EVENTS

Subsequent to March 31, 2016, the Company issued multiple Notes and Note Warrants pursuant to the Second Amended Note and Warrant Purchase Agreement to affiliates of the Company as follows:

•

XML 26 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Cash

Cash

Derivative Liabilities

Derivative Liabilities

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company also analyzes all financial instruments with features of both liabilities and equity under ASC 480-10, ASC 815-10 and ASC 815-40.

•

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets;

•

Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

	March 31, 2016			September 30, 2015
Annual dividend yield		-			-
Expected life (years)		1.75			0.5
Risk-free interest rate		0.73	%		0.08	%
Expected volatility		225.53	%		48	%

	Carrying Value		Fair Value Measurements at
	As of		March 31, 2016
	March 31,		Using Fair Value Hierarchy
	2016		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		1,441,700		-		-		1,441,700
Total	$	1,441,700	$	-	$	-	$	1,441,700

	Carrying Value		Fair Value Measurements at
	As of		September 30, 2015
	September 30,		Using Fair Value Hierarchy
	2015		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		833,000		-		-		833,000
Total	$	833,000	$	-	$	-	$	833,000

For a roll-forward analysis of embedded derivative liabilities refer to Note 4. Derivative Liabilities

Accounts Receivable

Accounts Receivable

Furniture and Equipment

Furniture and Equipment

Long-Lived Assets

Long-Lived Assets

Intangible Assets

Intangible Assets

Accounts Payable

Accounts Payable

Accounts payable consists of trade payables of which $405,700 and $476,900 are for legal services at March 31, 2016 and 2015 respectively.

Deferred Revenue

Deferred Revenue

Revenues

Revenues

Research and Development Expenses

Research and Development Expenses

The Company charges all research and development expenses to operations as incurred.

Advertising Expenses

Advertising Expenses

The Company charges all advertising expenses to operations as incurred. For the six months ended March 31, 2016 and 2015 advertising expenses were $85,100 and $29,000 respectively.

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Earnings (Loss) per Share

Earnings (Loss) per Share

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Apart from the below-mentioned recent accounting pronouncements, there are no new accounting pronouncements that are currently applicable to the Company.

XML 27 R17.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2016

Accounting Policies [Abstract]

Schedule of fair value inputs liabilities

	March 31, 2016			September 30, 2015
Annual dividend yield		-			-
Expected life (years)		1.75			0.5
Risk-free interest rate		0.73	%		0.08	%
Expected volatility		225.53	%		48	%

Schedule of fair value measurements, recurring and nonrecurring

	Carrying Value		Fair Value Measurements at
	As of		March 31, 2016
	March 31,		Using Fair Value Hierarchy
	2016		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		1,441,700		-		-		1,441,700
Total	$	1,441,700	$	-	$	-	$	1,441,700

	Carrying Value		Fair Value Measurements at
	As of		September 30, 2015
	September 30,		Using Fair Value Hierarchy
	2015		Level 1		Level 2		Level 3
Liabilities
Embedded derivative liabilities		833,000		-		-		833,000
Total	$	833,000	$	-	$	-	$	833,000

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Tables)

6 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of convertable debt

The table below provides additional detail regarding the Notes as of March 31, 2016, with respect to the carrying value and discount on the Balance Sheet.

		As of March 31, 2016
Note Type and Investor	Due Date	Balance		Discount			Carrying Value
Senior Secured 5% Notes Convertible at $0.05 (the “Notes”)		($)		($)			($)
Related Parties:
RSJ Private Equity	12/31/2017	$	1,850,000	$	(211,100	)	$	1,638,900
John Pappajohn	12/31/2017		800,000		(147,300	)		652,700
Tierney Family Trust	12/31/2017		540,000		-			540,000
Follman Family Trust	12/31/2017		250,000		-			250,000
Oman Ventures	12/31/2017		200,000		-			200,000
Robin L. Smith	12/31/2017		60,000		-			60,000
Geoffrey E. Harris	12/31/2017		10,000		(4,700	)		5,300
Total Related Parties			3,710,000		(363,100	)		3,346,900
Others:
11 Accredited Investors	12/31/2017		650,000		(30,700	)		619,300
Total Secured Convertible Promissory Notes		$	4,360,000	$	(393,800	)	$	3,966,200

XML 29 R19.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Tables)

6 Months Ended

Mar. 31, 2016

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of black-scholes option-pricing model assumption inputs

The range of Black-Scholes option-pricing model assumption inputs for all the valuation dates are in the table below:

	September 30, 2015 through to March 31, 2016 Low			September 30, 2015 through to March 31, 2016 High
Annual dividend yield		—			—
Expected life (years)		0.2			2.00
Risk-free interest rate		0.08	%		1.06	%
Expected volatility		47.83	%		225.32	%

Schedule of changes in the derivative valuation

The following tables include a roll-forward of liabilities classified within Levels 1, 2 and 3:

	Six Months Ended March 31, 2016
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2015	$	-	$	-	$	833,000
$3M of convertible debt prior to amendment		-		-		(772,800	)
$3M of convertible debt as amended		-		-		962,300
Issuance of warrants and other derivatives		-		-		444,600
Change in fair value		-		-		(25,400	)
Stock warrant and other derivative liabilities at March 31, 2016	$	-	$	-	$	1,441,700

	Six Months Ended March 31, 2015
	Level 1		Level 2		Level 3

Stock warrant and other derivative liabilities at September 30, 2014	$	-	$	-	$	153,100
Change in fair value		-		-		(67,300	)
Stock warrant and other derivative liabilities at March 31, 2015	$	-	$	-	$	85,800

XML 30 R20.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Tables)

6 Months Ended

Mar. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of stock-based compensation expense

Stock-based compensation expense included in the accompanying statements of operations for the three and six months ended March 31, 2016 and 2015 is as follows:

	For the three months ended March 31,
	2016		2015
Research		10,400		10,400
Product Development		7,700		15,500
Sales and marketing		14,900		53,400
General and administrative		7,200		20,500
Total	$	40,200	$	99,800

	For the six months ended March 31,
	2016		2015
Research		20,800		20,800
Product Development		16,800		34,000
Sales and marketing		14,900		63,300
General and administrative		18,400		44,100
Total	$	70,900	$	162,200

Schedule of stock option activity

A summary of stock option activity is as follows:

	Number of Shares		Weighted Average Exercise Price
Outstanding at September 30, 2015		14,230,011	$	0.75
Granted		-
Exercised		-		-
Forfeited		-
Outstanding at March 31, 2016		14,230,011	$	0.75

Schedule of the status of options outstanding

Following is a summary of the status of options outstanding at March 31, 2016:

Exercise Price ($)		Number of Shares		Expiration Date	Weighted Average Exercise Price ($)

$	0.055		1,750,000	08/2025	$	0.055
	0.04718		8,795,308	12/2022 – 01/2023		0.04718
	0.25		2,715,109	03/2023 – 01/2025		0.25
	0.26		425,000	07/2024		0.26
	3.00		42,670	03/2022		3.00
	3.60		28,648	08/2016		3.60
	3.96		32,928	08/2016		3.96
	9.00		4,525	11/2016		9.00
	12.00		28,535	03/2019 – 07/2020		12.00
	14.10		10,000	03/2021		14.10
	15.30		1,373	09/2018		15.30
	16.50		262,441	03/2020		16.50
	17.70		953	08/2016		17.70
	24.00		4,667	12/2017		24.00
	26.70		32,297	09/2017		26.70
	28.80		11,767	04/2018		28.80
	32.70		83,790	08/2017		32.70
$	Total		14,230,011	Average	$	0.75

Schedule of share-based compensation warrants

The warrant activity for the period starting October 1, 2015, through March 31, 2016, is described as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding at September 30, 2015		781,524		$	0.53
Granted		87,200,000			0.05
Exercised		-			-
Expired		(35,002	)		1.00
Outstanding at March 31, 2016		87,946,522		$	0.05

Schedule of the status of warrants outstanding

Following is a summary of the status of warrants outstanding at March 31, 2016:

Exercise Price		Number of Shares			Expiration Date	Weighted Average Exercise Price

$	0.04718		38,152		03/2018	$	0.04718
	0.05		27,200,000	(1)	12/31/2020		0.05
	0.05		60,000,000	(2)	12/31/2020		0.05
	0.25		332,200		04/2016 – 07/2017		0.25
	0.275		324,000		06/2018 – 03/2019		0.275
	1.00		32,168		10/2015 – 01/2017		1.00
	7.50		3,334		05/2016		7.50
$	9.00		16,668		07/2017		9.00
	Total		87,946,522			$	0.05

Schedule of black-scholes option-pricing model assumption inputs

The range of Black-Scholes option-pricing model assumption inputs for the six months ended March 31, 2016, were as follows:

	December 23, 2015 through March 31,2016
Annual dividend yield		-
Expected life (years)		5.00
Risk-free interest rate		1.21% ~ 1.74 %
Expected volatility		255.50% ~ 272.56 %

XML 31 R21.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

6 Months Ended

Mar. 31, 2016

Schedule of extension warrants issued to affiliates

Extension warrants were issued to affiliates as follows:

5-Year Extension Warrants with an non-cashless exercise price of $0.05	Secured Convertible Promissory Notes		Warrants to purchase Shares of Common Stock

RSJ Private Equity	$	1,850,000		22,000,000
Robin L. Smith		60,000		1,200,000
John Pappajohn		550,000		6,000,000
Tierney Family Trust		540,000		10,800,000
Oman Ventures		200,000		4,000,000
Follman Family Trust		250,000		5,000,000
Total Secured Convertible Promissory Notes	$	3,450,000		49,000,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE (Tables)

6 Months Ended

Mar. 31, 2016

Earnings Per Share [Abstract]

Schedule of earnings per share

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three months ended March 31, 2016 and 2015 is as follows:

	Three months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(142,700	)	$	(696,300	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.00	)	$	(0.01	)

Basic and Diluted weighted average shares outstanding		102,669,022			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		83,271,628			1,892,742
Warrants		80,938,825			781,833
Options		14,230,011			12,645,994

	Six months ended March 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(3,594,000	)	$	(1,570,900	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.04	)	$	(0.02	)

Basic and Diluted weighted average shares outstanding		102,543,215			101,667,409

The weighted average of anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		73,234,048			1,771,371
Warrants		43,892,108			871,027
Options		14,230,011			12,531,746

XML 33 R23.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

6 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of contractual obligations

As of March 31, 2016 the remaining lease obligation is $7,800, of the remaining lease obligation is 2016 $1,600; with $1,200 for the years 2017-2020; 2021 $1,400.

	Payments due by period
Contractual Obligations	Total		Less than 1 year		1 to 3 years		3 to 5 years		More than 5 years

Operating Lease Obligations	$	140,400	$	75,100	$	65,300	$	-	$	-
Capital Lease Obligations		8,400		2,200		4,800		1,400		-
Total	$	148,800	$	77,300	$	70,100	$	1,400	$	-

XML 34 R24.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015	Dec. 23, 2015
Accumulated deficit	$ (66,186,900)		$ (66,186,900)		$ (62,592,900)
Net loss from operations	(690,000)	$ (780,100)	(1,314,700)	$ (1,560,200)
Net cash used in operating activities			1,339,900	$ 1,343,700
October 2012 Note [Member] \| Twenty Accredited Investors [Member]
Gross proceeds from issuance of common stock and convertible debt					1,350,000
Proceeds from convertible debt			1,360,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Secured convertible debt	3,710,000		3,710,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Original Note Purchase Agreement [Member]
Secured convertible debt	$ 4,360,000		$ 4,360,000		$ 3,000,000	$ 3,121,900

XML 35 R25.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended	12 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2016	Sep. 30, 2015
Accounting Policies [Abstract]
Annual dividend yield
Expected life (years)	1 year 9 months	6 months
Risk-free interest rate	0.73%	0.08%
Expected volatility	225.53%	48.00%

XML 36 R26.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Mar. 31, 2016	Sep. 30, 2015
Carrying Value [Member]
Liabilities
Embedded derivative liabilities	$ 1,441,700	$ 833,000
Total	$ 1,441,700	$ 833,000
Level 1 [Member]
Liabilities
Embedded derivative liabilities
Total
Level 2 [Member]
Liabilities
Embedded derivative liabilities
Total
Level 3 [Member]
Liabilities
Embedded derivative liabilities	$ 1,441,700	$ 833,000
Total	$ 1,441,700	$ 833,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015	Sep. 30, 2015
Cash, FDIC insured amount	$ 190,200		$ 190,200
Depreciation and amortization			2,700	$ 4,400
Deferred revenue	45,900	$ 45,900	45,900	45,900	$ 45,900
Advertising expense	85,100	29,000
Derivative liabilities	1,441,700		1,441,700		833,000
Gain on change in fair value of derivative liability	798,200	99,300
Allowance for doubtful accounts	1,200		1,200		1,200
Accounts payable consists of trade payables	405,700	$ 476,900	405,700	476,900
Furniture and Equipment [Member]
Depreciation and amortization			2,700	$ 4,400
Accumulated depreciation and amortization	74,900		$ 74,900		$ 82,600
Furniture and Equipment [Member] \| Minimum [Member]
Useful life			3 years
Furniture and Equipment [Member] \| Maximum [Member]
Useful life			10 years
Computer Software development [Member]
Useful life			3 years
Capitalized software development costs	$ 9,000		$ 9,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details) - USD ($)	6 Months Ended	11 Months Ended
	Mar. 31, 2016	Sep. 13, 2015	Dec. 23, 2015	Sep. 30, 2015	Sep. 15, 2015	Jul. 03, 2015	Jun. 03, 2015	Jun. 02, 2015	Mar. 18, 2015	Mar. 17, 2015	Jan. 08, 2015	Sep. 26, 2014	Sep. 22, 2014
Eleven Accredited Investors [Member]
Discount	$ 30,700			$ 28,900
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Balance	3,710,000
Discount	(363,100)
Carrying Value	3,346,900
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Original Note Purchase Agreement [Member]
Due Date		Mar. 21, 2016
Balance	4,360,000		$ 3,121,900	$ 3,000,000
Discount	(393,800)
Carrying Value	$ 3,966,200
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Due Date	Dec. 31, 2017
Balance	$ 1,850,000
Discount	(211,100)
Carrying Value	1,638,900
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Original Note Purchase Agreement [Member]
Balance	$ 750,000											$ 750,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Due Date	Dec. 31, 2017
Balance	$ 800,000
Discount	(147,300)
Carrying Value	652,700
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member] \| Original Note Purchase Agreement [Member]
Balance	$ 400,000				$ 100,000			$ 100,000	$ 100,000				$ 200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Due Date	Dec. 31, 2017
Balance	$ 540,000
Discount
Carrying Value	$ 540,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| Original Note Purchase Agreement [Member]
Balance	$ 540,000					$ 25,000	$ 100,000			$ 115,000	$ 100,000		200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member]
Due Date	Dec. 31, 2017
Balance	$ 250,000
Discount
Carrying Value	$ 250,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member] \| Original Note Purchase Agreement [Member]
Balance	$ 100,000									$ 100,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member]
Due Date	Dec. 31, 2017
Balance	$ 200,000
Discount
Carrying Value	$ 200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member] \| Original Note Purchase Agreement [Member]
Balance	$ 200,000												$ 200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robin L. Smith [Member]
Due Date	Dec. 31, 2017
Balance	$ 60,000
Discount
Carrying Value	$ 60,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Geoffrey E. Harris [Member]
Due Date	Dec. 31, 2017
Balance	$ 10,000
Discount	(4,700)
Carrying Value	$ 5,300
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Eleven Accredited Investors [Member]
Due Date	Dec. 31, 2017
Balance	$ 650,000
Discount	(30,700)
Carrying Value	$ 619,300

XML 39 R29.htm IDEA: XBRL DOCUMENT

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Narrative)			6 Months Ended	11 Months Ended
	Dec. 23, 2015 USD ($) Number $ / shares shares	Apr. 14, 2015 USD ($)	Mar. 31, 2016 USD ($) Number shares	Sep. 13, 2015	Feb. 24, 2016 USD ($) Number $ / shares shares	Dec. 28, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Sep. 24, 2015 USD ($) Number	Sep. 15, 2015 USD ($)	Sep. 14, 2015 USD ($) $ / shares	Jul. 03, 2015 USD ($)	Jun. 03, 2015 USD ($)	Jun. 02, 2015 USD ($)	Mar. 18, 2015 USD ($)	Mar. 17, 2015 USD ($)	Jan. 08, 2015 USD ($)	Sep. 26, 2014 USD ($)	Sep. 22, 2014 USD ($)
John Pappajohn [Member] \| Note Warrant [Member]
Face amount			$ 250,000
Number of shares called \| shares			5,000,000
Three Accredited Investor [Member] \| Note Warrant [Member]
Face amount			$ 360,000
Number of shares called \| shares			7,200,000
Geoffrey E. Harris [Member] \| Note Warrant [Member]
Number of purchasers \| Number					2
Face amount					$ 10,000
Number of shares called \| shares					200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note			$ 3,710,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note			$ 1,850,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Purchase of convertible note			$ 800,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Purchase of convertible note			$ 540,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note			$ 250,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member]
Purchase of convertible note			$ 200,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robin L. Smith [Member]
Purchase of convertible note			$ 60,000
Maturity date of the notes			Dec. 31, 2017
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Geoffrey E. Harris [Member]
Purchase of convertible note			$ 10,000
Maturity date of the notes			Dec. 31, 2017
Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| John Pappajohn [Member]
Description of conversion terms			The September 2015 Notes are convertible into share of Common Stock (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price, such that the conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock)
Amendment Note Purchase Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Description of conversion terms			Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| John Pappajohn [Member]
Description of conversion terms			Pursuant to the Omnibus Amendment, the Notes are convertible into shares of Common Stock at $0.055 per share: (i) automatically upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robert Follman (Follman Family Trust) [Member]
Description of conversion terms			Pursuant to the Omnibus Amendment, these Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robin L. Smith [Member]
Description of conversion terms			Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount		$ 3,000,000
Issuance of debt		$ 500,000
Conversion price (in dollars per share) \| $ / shares										$ 0.05
Description of conversion terms			Conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the “Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.
Description of collateral			Secured by a security interest in the Company’s intellectual property, as detailed in a security agreement.
Description of repayment priority			Upon a change of control of the Company, the holder of a Note had the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note								$ 350,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| John Pappajohn [Member]
Purchase of convertible note								100,000	$ 100,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note								$ 150,000	150,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Six Accredited Investors [Member]
Number of accredited investors \| Number								6
Face amount								$ 710,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Robin L. Smith [Member]
Purchase of convertible note								$ 60,000		$ 60,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Geoffrey E. Harris [Member]
Purchase of convertible note					$ 10,000
Exercise price (in dollars per share) \| $ / shares					$ 0.05
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount			$ 2,290,000															$ 2,500,000
Conversion price (in dollars per share) \| $ / shares							$ 0.25
Purchase of convertible note	$ 3,121,900		4,360,000				$ 3,000,000
Maturity date of the notes				Mar. 21, 2016
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note			$ 750,000														$ 750,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Number of secured notes issued \| Number			3
Purchase of convertible note			$ 400,000						$ 100,000				$ 100,000	$ 100,000				200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Number of secured notes issued \| Number			5
Description of conversion terms			Pursuant to the Omnibus Amendment, all such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note			$ 540,000								$ 25,000	$ 100,000			$ 115,000	$ 100,000		200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note			$ 100,000												$ 100,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member]
Description of conversion terms			Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note			$ 200,000															$ 200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity & Nine Accredited Investors [Member]
Number of accredited investors \| Number			9
Number of secured notes issued \| Number			15
Face amount			$ 2,270,000
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares	$ 0.25
Number of shares called \| shares	60,000,000
Exercise price (in dollars per share) \| $ / shares	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares						$ 0.25
Number of shares called \| shares						15,000,000
Exercise price (in dollars per share) \| $ / shares						$ 0.05
Second Amended Note & Warrant Agreement [Member] \| John Pappajohn [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares	$ 0.25
Number of shares called \| shares	16,000,000
Exercise price (in dollars per share) \| $ / shares	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares	0.05
Second Amended Note & Warrant Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares	0.05
Second Amended Note & Warrant Agreement [Member] \| Mr. George Carpenter [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares	0.05
Second Amended Note & Warrant Agreement [Member] \| Robin L. Smith [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Sixteen Accredited Investors [Member]
Number of accredited investors \| Number	16
Number of secured notes issued \| Number	16
Purchase of convertible note	$ 6,000,000
Maturity date of the notes	Dec. 31, 2017
Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note						$ 750,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Face amount	$ 1,000,000		$ 27,200,000
Description of conversion terms			Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.
Description of collateral			Secured by a security interest in the Company's intellectual property, as detailed in the amended and restated security agreement.
Description of repayment priority			Upon a change of control of the Company (as described in the Notes), the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Face amount						$ 750,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member] \| John Pappajohn [Member]
Face amount	$ 250,000
Number of shares called \| shares	5,000,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details)	3 Months Ended	6 Months Ended	12 Months Ended
DERIVATIVE LIABILITIES (Details)	Mar. 31, 2016	Mar. 31, 2016	Sep. 30, 2015
Annual dividend yield
Expected life	1 year 9 months		6 months
Risk-free interest rate	0.73%		0.08%
Expected volatility	225.53%		48.00%
Minimum [Member]
Annual dividend yield
Expected life		2 months
Risk-free interest rate		0.08%
Expected volatility		47.83%
Maximum [Member]
Annual dividend yield
Expected life		2 years
Risk-free interest rate		1.06%
Expected volatility		225.32%

XML 41 R31.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details 1) - USD ($)	6 Months Ended
DERIVATIVE LIABILITIES (Details 1) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Stock warrant and other derivative liabilities at beginning
$3M of convertible debt prior to amendment
$3M of convertible debt as amended
Issuance of warrants and other derivatives
Change in fair value
Stock warrant and other derivative liabilities at ending
Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Stock warrant and other derivative liabilities at beginning
$3M of convertible debt prior to amendment
$3M of convertible debt as amended
Issuance of warrants and other derivatives
Change in fair value
Stock warrant and other derivative liabilities at ending
Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Stock warrant and other derivative liabilities at beginning	$ 833,000	$ 153,100
$3M of convertible debt prior to amendment	(772,800)
$3M of convertible debt as amended	962,300
Issuance of warrants and other derivatives	444,600
Change in fair value	(25,400)	(67,300)
Stock warrant and other derivative liabilities at ending	$ 1,441,700	$ 85,800

XML 42 R32.htm IDEA: XBRL DOCUMENT

DERIVATIVE LIABILITIES (Details Narrative)			3 Months Ended		6 Months Ended		11 Months Ended	12 Months Ended
DERIVATIVE LIABILITIES (Details Narrative)	Dec. 23, 2015 USD ($) Number $ / shares	Dec. 22, 2015 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Sep. 13, 2015	Sep. 30, 2015 USD ($) $ / shares	Sep. 22, 2014 USD ($)
Derivative liability			$ 1,441,700		$ 1,441,700			$ 833,000
Gain (loss) on derivative liabilities			$ 786,900		798,200	$ 67,300
Gains (losses) on extinguishment of debt, total					(2,337,400)
Three Accredited Investor [Member] \| Note Warrant [Member]
Face amount			$ 360,000		360,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Secured convertible debt			3,710,000		3,710,000
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares	$ 0.25
Second Amended Note & Warrant Agreement [Member] \| Sixteen Accredited Investors [Member]
Secured convertible debt	$ 6,000,000
Number of accredited investors \| Number	16
Maturity date	Dec. 31, 2017
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Derivative liability			1,441,700		1,441,700
Gain (loss) on derivative liabilities					786,900
Gains (losses) on extinguishment of debt, total					786,900
Face amount	$ 1,000,000		27,200,000		27,200,000
Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Derivative liability		$ 60,200
Gains (losses) on extinguishment of debt, total		772,800
Derivative liability write down		$ 786,900
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Secured convertible debt	3,121,900		4,360,000		4,360,000			$ 3,000,000
Conversion price (in dollars per share) \| $ / shares								$ 0.25
Derivative liability								$ 833,000
Gain (loss) on derivative liabilities								$ 162,800
Gains (losses) on extinguishment of debt, total	962,300
Face amount			$ 2,290,000		$ 2,290,000				$ 2,500,000
Aggregate derivative liability	1,022,400
Maturity date							Mar. 21, 2016
Accrued interest	$ 121,900

XML 43 R33.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details) - USD ($)	3 Months Ended		6 Months Ended
STOCKHOLDERS' DEFICIT (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Total	$ 40,200	$ 99,800	$ 70,900	$ 162,200
Research [Member]
Total	10,400	10,400	20,800	20,800
Product Development [Member]
Total	7,700	15,500	16,800	34,000
Sales And Marketing [Member]
Total	14,900	53,400	14,900	63,300
General And Administrative [Member]
Total	$ 7,200	$ 20,500	$ 18,400	$ 44,100

XML 44 R34.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details 1)	6 Months Ended
STOCKHOLDERS' DEFICIT (Details 1)	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding, beginning \| shares	14,230,011
Granted \| shares
Exercised \| shares
Forfeited \| shares
Outstanding, ending \| shares	14,230,011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning \| $ / shares	$ 0.75
Granted \| $ / shares
Exercised \| $ / shares
Forfeited \| $ / shares
Outstanding, ending \| $ / shares	$ 0.75

XML 45 R35.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details 2) - $ / shares	6 Months Ended
STOCKHOLDERS' DEFICIT (Details 2) - $ / shares	Mar. 31, 2016	Sep. 30, 2015
Exercise Price	$ 0.75	$ 0.75
Option [Member]
Number of Shares	14,230,011
Weighted Average Exercise Price	$ 0.75
Option [Member] \| $0.055 [Member]
Exercise Price	$ 0.055
Number of Shares	1,750,000
Expiration Date	2025-08
Weighted Average Exercise Price	$ 0.055
Option [Member] \| $0.04718 [Member]
Exercise Price	$ 0.04718
Number of Shares	8,795,308
Weighted Average Exercise Price	$ 0.04718
Option [Member] \| $0.04718 [Member] \| Maximum [Member]
Expiration Date	2023-01
Option [Member] \| $0.04718 [Member] \| Minimum [Member]
Expiration Date	2022-12
Option [Member] \| $0.25 [Member]
Exercise Price	$ 0.25
Number of Shares	2,715,109
Weighted Average Exercise Price	$ 0.25
Option [Member] \| $0.25 [Member] \| Maximum [Member]
Expiration Date	2025-01
Option [Member] \| $0.25 [Member] \| Minimum [Member]
Expiration Date	2023-03
Option [Member] \| $0.26 [Member]
Exercise Price	$ 0.26
Number of Shares	425,000
Expiration Date	2024-07
Weighted Average Exercise Price	$ 0.26
Option [Member] \| $3.00 [Member]
Exercise Price	$ 3
Number of Shares	42,670
Expiration Date	2022-03
Weighted Average Exercise Price	$ 3.00
Option [Member] \| $3.60 [Member]
Exercise Price	$ 3.6
Number of Shares	28,648
Expiration Date	2016-08
Weighted Average Exercise Price	$ 3.60
Option [Member] \| $3.96 [Member]
Exercise Price	$ 3.96
Number of Shares	32,928
Expiration Date	2016-08
Weighted Average Exercise Price	$ 3.96
Option [Member] \| $9.00 [Member]
Exercise Price	$ 9
Number of Shares	4,525
Expiration Date	2016-11
Weighted Average Exercise Price	$ 9.00
Option [Member] \| $12.00 [Member]
Exercise Price	$ 12
Number of Shares	28,535
Weighted Average Exercise Price	$ 12.00
Option [Member] \| $12.00 [Member] \| Maximum [Member]
Expiration Date	2020-07
Option [Member] \| $12.00 [Member] \| Minimum [Member]
Expiration Date	2019-03
Option [Member] \| $14.10 [Member]
Exercise Price	$ 14.1
Number of Shares	10,000
Expiration Date	2021-03
Weighted Average Exercise Price	$ 14.10
Option [Member] \| $15.30 [Member]
Exercise Price	$ 15.3
Number of Shares	1,373
Expiration Date	2018-09
Weighted Average Exercise Price	$ 15.30
Option [Member] \| $16.50 [Member]
Exercise Price	$ 16.5
Number of Shares	262,441
Expiration Date	2020-03
Weighted Average Exercise Price	$ 16.50
Option [Member] \| $17.70 [Member]
Exercise Price	$ 17.7
Number of Shares	953
Expiration Date	2016-08
Weighted Average Exercise Price	$ 17.70
Option [Member] \| $24.00 [Member]
Exercise Price	$ 24
Number of Shares	4,667
Expiration Date	2017-12
Weighted Average Exercise Price	$ 24.00
Option [Member] \| $26.70 [Member]
Exercise Price	$ 26.7
Number of Shares	32,297
Expiration Date	2017-09
Weighted Average Exercise Price	$ 26.70
Option [Member] \| $28.80 [Member]
Exercise Price	$ 28.8
Number of Shares	11,767
Expiration Date	2018-04
Weighted Average Exercise Price	$ 28.80
Option [Member] \| $32.70 [Member]
Exercise Price	$ 32.7
Number of Shares	83,790
Expiration Date	2017-08
Weighted Average Exercise Price	$ 32.70

XML 46 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details 3) - Warrant [Member]	6 Months Ended
STOCKHOLDERS' DEFICIT (Details 3) - Warrant [Member]	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning \| shares	781,524
Granted \| shares	87,200,000
Exercised \| shares
Expired \| shares	(35,002)
Outstanding, ending \| shares	87,946,522
Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning \| $ / shares	$ 0.53
Granted \| $ / shares	$ 0.05
Exercised \| $ / shares
Expired \| $ / shares	$ 1
Outstanding, ending \| $ / shares	$ 0.05

XML 47 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details 4) - $ / shares

6 Months Ended

Mar. 31, 2016

Sep. 30, 2015

Exercise Price

$ 0.75

Warrant [Member]

Number of Shares

87,946,522

Weighted Average Exercise Price

$ 0.05

Warrant [Member] | $0.04718 [Member]

Exercise Price

$ 0.04718

Number of Shares

38,152

Expiration Date

2018-03

Weighted Average Exercise Price

$ 0.04718

Warrant [Member] | $0.05 [Member]

Exercise Price

$ 0.05

Number of Shares

^[1]

27,200,000

Weighted Average Exercise Price

$ 0.05

Expiration Date

Dec. 31, 2020

Warrant [Member] | $0.05 [Member]

Exercise Price

$ 0.05

Number of Shares

^[2]

60,000,000

Weighted Average Exercise Price

$ 0.05

Expiration Date

Dec. 31, 2020

Warrant [Member] | $0.25 [Member]

Exercise Price

$ 0.25

Number of Shares

332,200

Weighted Average Exercise Price

$ 0.25

Warrant [Member] | $0.25 [Member] | Maximum [Member]

Expiration Date

2017-07

Warrant [Member] | $0.25 [Member] | Minimum [Member]

Expiration Date

2016-04

Warrant [Member] | $0.275 [Member]

Exercise Price

$ 0.275

Number of Shares

324,000

Weighted Average Exercise Price

$ 0.275

Warrant [Member] | $0.275 [Member] | Maximum [Member]

Expiration Date

2019-03

Warrant [Member] | $0.275 [Member] | Minimum [Member]

Expiration Date

2018-06

Warrant [Member] | $1.00 [Member]

Exercise Price

$ 1

Number of Shares

32,168

Weighted Average Exercise Price

$ 1

Warrant [Member] | $1.00 [Member] | Maximum [Member]

Expiration Date

2017-01

Warrant [Member] | $1.00 [Member] | Minimum [Member]

Expiration Date

2015-10

Warrant [Member] | $7.50 [Member]

Exercise Price

$ 7.5

Number of Shares

3,334

Expiration Date

2016-05

Weighted Average Exercise Price

$ 7.5

Warrant [Member] | $9.00 [Member]

Exercise Price

$ 9

Number of Shares

16,668

Expiration Date

2017-07

Weighted Average Exercise Price

$ 9

[1]

[2]

XML 48 R38.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details 5) - Warrant [Member]	3 Months Ended
STOCKHOLDERS' DEFICIT (Details 5) - Warrant [Member]	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual dividend yield
Expected life	5 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.21%
Expected volatility	255.50%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.74%
Expected volatility	272.56%

XML 49 R39.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)				3 Months Ended	6 Months Ended
STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)	Jan. 15, 2016	Aug. 20, 2015	Jan. 08, 2015	Mar. 31, 2016	Mar. 31, 2016	Sep. 30, 2015	Mar. 26, 2013	Dec. 10, 2012	Mar. 22, 2012	Aug. 03, 2006
Common stock authorized				500,000,000	500,000,000	500,000,000
Common and preferred stock authorized				515,000,000	515,000,000
Blank-check preferred stock authorized				15,000,000	15,000,000
Blank-check preferred stock par value (in dollars per share)				$ 0.001	$ 0.001
Common stock issued				102,717,409	102,717,409	102,417,409
Common stock outstanding				102,717,409	102,717,409	102,417,409
Number of options outstanding				14,230,011	14,230,011	14,230,011
Number of options exercised
Common stock exercise price (in dollars per share)				$ 0.75	$ 0.75	$ 0.75
Number of stock options granted
Total unrecognized stock-based compensation				$ 145,443	$ 145,443
Consulting Agreement [Member] \| Dian Griesel International [Member]
Monthly professional fees	$ 5,000
Consulting Agreement [Member] \| Dian Griesel International [Member]
Aggregate intrinsic value of awarded shares	$ 6,900
Number of shares issued upon services	300,000
Warrant [Member]
Number of equity instruments other than options outstanding				87,946,522	87,946,522
Description of warrant term				The warrants expire at various times starting 2016 through 2020.
Minimum [Member] \| Warrant [Member]
Common stock exercise price (in dollars per share)				$ 0.04718	$ 0.04718
Maximum [Member] \| Warrant [Member]
Common stock exercise price (in dollars per share)				$ 9.00	$ 9.00
2006 Stock Incentive Plan [Member]
Number of shares reserved for future issuance										667,667
Number of options outstanding				501,924	501,924
Number of options exercised					70,825
2006 Stock Incentive Plan [Member] \| Minimum [Member]
Common stock exercise price (in dollars per share)										$ 3.6
2006 Stock Incentive Plan [Member] \| Maximum [Member]
Common stock exercise price (in dollars per share)										$ 32.7
2012 Omnibus Incentive Compensation Plan [Member]
Number of shares reserved for future issuance				521,913	521,913
Number of options outstanding				13,728,087	13,728,087
Common stock exercise price (in dollars per share)			$ 0.25
Number of options authorized							15,000,000	5,500,000	333,334
Number of stock options granted			250,000
Description of vesting rights			The option vesting is contingent upon the achievement of agreed upon goals.
Restricted Stock [Member] \| 2006 Stock Incentive Plan [Member]
Number of equity instruments other than options outstanding				6,132	6,132
Restricted Stock [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of equity instruments other than options outstanding				750,000	750,000
Option [Member]
Number of shares				14,230,011	14,230,011
Option [Member] \| $0.055 [Member]
Common stock exercise price (in dollars per share)				$ 0.055	$ 0.055
Number of shares				1,750,000	1,750,000
Robin L. Smith [Member] \| Restricted Stock [Member]
Weighted exercise price of awarded shares (in dollars per share)		$ 0.055
Number of awarded shares		750,000
Aggregate intrinsic value of awarded shares		$ 41,250
Issuance date		Oct. 30, 2015
Management [Member] \| Option [Member] \| $0.055 [Member]
Common stock exercise price (in dollars per share)		$ 0.055
Number of shares		1,750,000
Expiration period		36 months

XML 50 R40.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' DEFICIT (Details Narrative 1) - Second Amended Note & Warrant Agreement [Member]		6 Months Ended
	Dec. 23, 2015 USD ($) Number shares	Mar. 31, 2016 USD ($)
Note Warrant [Member]
Number of shares called	60,000,000
Number of extension warrants	49,000,000
Extinguishment of Debt expense \| $	$ 1,196,000
One Accredited Investor [Member] \| Note Warrant [Member]
Number of shares called	2,000,000
Ten Accredited Investors [Member] \| Note Warrant [Member]
Number of extension warrants	11,000,000
Number of accredited investors \| Number	10
Directors And Affiliates [Member] \| Note Warrant [Member]
Number of extension warrants	49,000,000
Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Face amount \| $	$ 1,000,000	$ 27,200,000
Description of conversion terms		Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.

XML 51 R41.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Dec. 23, 2015	Mar. 31, 2016	Dec. 28, 2015
John Pappajohn [Member] \| Note Warrant [Member]
Face amount		$ 250,000
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Number of additional shares called after extension	49,000,000
Exercise price (in dollars per share)	$ 0.05
Warrant term	5 years
Second Amended Note & Warrant Agreement [Member] \| John Pappajohn [Member] \| Note Warrant [Member]
Number of additional shares called after extension	6,000,000
Exercise price (in dollars per share)	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| Note Warrant [Member]
Number of additional shares called after extension	10,800,000
Exercise price (in dollars per share)	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Note Warrant [Member]
Number of additional shares called after extension			22,000,000
Exercise price (in dollars per share)			$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Robin L. Smith [Member] \| Note Warrant [Member]
Number of additional shares called after extension	1,200,000
Exercise price (in dollars per share)	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Mr. George Carpenter [Member] \| Note Warrant [Member]
Number of additional shares called after extension	4,000,000
Exercise price (in dollars per share)	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| Note Warrant [Member]
Number of additional shares called after extension	10,000,000
Exercise price (in dollars per share)	$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member]
Face amount	$ 3,450,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| John Pappajohn [Member]
Face amount	550,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Face amount	540,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Face amount	1,850,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| Robin L. Smith [Member]
Face amount	60,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| Mr. George Carpenter [Member]
Face amount	200,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes [Member] \| Robert Follman (Follman Family Trust) [Member]
Face amount	$ 250,000

XML 52 R42.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative)		6 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative)	Apr. 14, 2015 USD ($)	Mar. 31, 2016 USD ($) Number $ / shares shares	Feb. 24, 2016 USD ($) $ / shares shares	Dec. 28, 2015 USD ($) $ / shares shares	Dec. 23, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Sep. 24, 2015 USD ($) Number	Sep. 15, 2015 USD ($)	Sep. 14, 2015 USD ($) $ / shares	Jul. 03, 2015 USD ($)	Jun. 03, 2015 USD ($)	Jun. 02, 2015 USD ($)	Mar. 28, 2015 Number	Mar. 18, 2015 USD ($)	Mar. 17, 2015 USD ($)	Jan. 08, 2015 USD ($)	Sep. 26, 2014 USD ($)	Sep. 22, 2014 USD ($)
Exercise price (in dollars per share) \| $ / shares
Number of stock options granted \| shares
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 3,710,000
John Pappajohn [Member] \| Note Warrant [Member]
Face amount		$ 250,000
Number of shares called \| shares		5,000,000
John Pappajohn [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 800,000
John Pappajohn [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Description of conversion terms		The September 2015 Notes are convertible into share of Common Stock (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price, such that the conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock)
Robert Follman (Follman Family Trust) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 250,000
Thomas Tierney (Tierney Family Trust) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		540,000
Mr. George Carpenter [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		200,000
Robin L. Smith [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		60,000
RSJ Private Equity (Michal Votruba) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		1,850,000
Three Accredited Investor [Member] \| Note Warrant [Member]
Face amount		$ 360,000
Number of shares called \| shares		7,200,000
Geoffrey E. Harris [Member] \| Note Warrant [Member]
Face amount			$ 10,000
Number of shares called \| shares			200,000
Geoffrey E. Harris [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 10,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		4,360,000			$ 3,121,900	$ 3,000,000
Conversion price (in dollars per share) \| $ / shares						$ 0.25
Face amount		$ 2,290,000																$ 2,500,000
Original Note Purchase Agreement [Member] \| RSJ Private Equity & Nine Accredited Investors [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Number of accredited investors \| Number		9
Number of secured notes issued \| Number		15
Face amount		$ 2,270,000
Original Note Purchase Agreement [Member] \| Michal Votruba [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 750,000
Original Note Purchase Agreement [Member] \| John Pappajohn [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Number of secured notes issued \| Number		3
Purchase of convertible note		$ 400,000						$ 100,000				$ 100,000		$ 100,000				200,000
Original Note Purchase Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 100,000													$ 100,000
Original Note Purchase Agreement [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Number of secured notes issued \| Number		5
Description of conversion terms		Pursuant to the Omnibus Amendment, all such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note		$ 540,000								$ 25,000	$ 100,000				$ 115,000	$ 100,000		200,000
Original Note Purchase Agreement [Member] \| Mr. George Carpenter [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Description of conversion terms		Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note		$ 200,000																$ 200,000
Original Note Purchase Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note		$ 750,000															$ 750,000
Amendment Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Description of conversion terms		Conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the “Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.
Description of collateral		Secured by a security interest in the Company’s intellectual property, as detailed in a security agreement.
Description of repayment priority		Upon a change of control of the Company, the holder of a Note had the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
Proceeds from issuance of debt	$ 500,000
Conversion price (in dollars per share) \| $ / shares									$ 0.05
Face amount	$ 3,000,000
Amendment Note Purchase Agreement [Member] \| John Pappajohn [Member]
Description of conversion terms		Pursuant to the Omnibus Amendment, the Notes are convertible into shares of Common Stock at $0.055 per share: (i) automatically upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| John Pappajohn [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Purchase of convertible note							$ 100,000	100,000
Amendment Note Purchase Agreement [Member] \| Robert Follman (Follman Family Trust) [Member]
Description of conversion terms		Pursuant to the Omnibus Amendment, these Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Purchase of convertible note							$ 150,000	$ 150,000
Amendment Note Purchase Agreement [Member] \| Six Accredited Investors [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Number of accredited investors \| Number							6
Face amount							$ 710,000
Amendment Note Purchase Agreement [Member] \| Robin L. Smith [Member]
Description of conversion terms		Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robin L. Smith [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Purchase of convertible note							60,000		$ 60,000
Amendment Note Purchase Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Description of conversion terms		Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Purchase of convertible note							$ 350,000
Amendment Note Purchase Agreement [Member] \| Geoffrey E. Harris [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member]
Purchase of convertible note			$ 10,000
Exercise price (in dollars per share) \| $ / shares			$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares					$ 0.25
Number of shares called \| shares					60,000,000
Exercise price (in dollars per share) \| $ / shares					$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Description of conversion terms		Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.
Description of collateral		Secured by a security interest in the Company's intellectual property, as detailed in the amended and restated security agreement.
Description of repayment priority		Upon a change of control of the Company (as described in the Notes), the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
Face amount		$ 27,200,000			$ 1,000,000
Second Amended Note & Warrant Agreement [Member] \| John Pappajohn [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares					$ 0.25
Number of shares called \| shares					16,000,000
Exercise price (in dollars per share) \| $ / shares					$ 0.05
Second Amended Note & Warrant Agreement [Member] \| John Pappajohn [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Face amount					$ 250,000
Number of shares called \| shares					5,000,000
Second Amended Note & Warrant Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares					$ 0.05
Second Amended Note & Warrant Agreement [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares					0.05
Second Amended Note & Warrant Agreement [Member] \| Mr. George Carpenter [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares					0.05
Second Amended Note & Warrant Agreement [Member] \| Robin L. Smith [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares					$ 0.05
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares				$ 0.25
Number of shares called \| shares				15,000,000
Exercise price (in dollars per share) \| $ / shares				$ 0.05
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note				$ 750,000
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Face amount				$ 750,000
Termination Agreements With SAIL Capital Partners [Member] \| Governance Agreements [Member]
Number of directors nominated under agreement \| Number													3
Termination Agreements With Equity Dynamics,Inc [Member] \| Governance Agreements [Member]
Number of directors nominated under agreement \| Number													4

XML 53 R43.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative 1)					6 Months Ended	8 Months Ended	11 Months Ended	23 Months Ended
RELATED PARTY TRANSACTIONS (Details Narrative 1)	Sep. 06, 2015 USD ($) Number	Jan. 08, 2015 USD ($) $ / shares shares	Jan. 05, 2015 USD ($)	Jun. 14, 2013 $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares	Mar. 31, 2016 USD ($) $ / shares shares	Jul. 08, 2014 USD ($) $ / shares shares	Mar. 25, 2015 USD ($)	Feb. 24, 2016 USD ($) $ / shares shares	Dec. 28, 2015 USD ($) $ / shares shares	Dec. 23, 2015 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Sep. 24, 2015 USD ($)	Sep. 15, 2015 USD ($)	Sep. 14, 2015 USD ($) $ / shares	Jul. 03, 2015 USD ($)	Jun. 03, 2015 USD ($)	Jun. 02, 2015 USD ($)	Apr. 14, 2015 USD ($)	Mar. 18, 2015 USD ($)	Mar. 17, 2015 USD ($)	Sep. 26, 2014 USD ($)	Sep. 22, 2014 USD ($)	Oct. 19, 2012 USD ($)
Number of shares issued upon new issue, value					$ 6,900
Marketing expense due					$ 744,200	$ 744,200						$ 852,000
Number of stock options granted \| shares
Exercise price (in dollars per share) \| $ / shares
John Pappajohn [Member] \| Note Warrant [Member]
Face amount					$ 250,000	$ 250,000
Number of shares called \| shares					5,000,000	5,000,000
Robert Follman (Follman Family Trust) [Member] \| Private Placement [Member] \| Unregistered Stock [Member]
Proceeds from issuance of private placement							$ 100,000
Share price (in dollars per share) \| $ / shares					$ 0.25	$ 0.25	$ 0.25
Number of shares issued upon new issue, value					$ 500,000		$ 100,000
Number of shares issued upon new issue \| shares					2,000,000		400,000
Geoffrey E. Harris [Member] \| Note Warrant [Member]
Face amount									$ 10,000
Number of shares called \| shares									200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note					$ 3,710,000	$ 3,710,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Purchase of convertible note					800,000	800,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note					250,000	250,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robin L. Smith [Member]
Purchase of convertible note					60,000	60,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Geoffrey E. Harris [Member]
Purchase of convertible note					10,000	10,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Purchase of convertible note					540,000	540,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member]
Purchase of convertible note					200,000	200,000
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note					$ 1,850,000	1,850,000
Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| John Pappajohn [Member]
Description of conversion terms					The September 2015 Notes are convertible into share of Common Stock (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price, such that the conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock)
October 2012 Note [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note																								$ 200,000
Number of shares issued upon debt conversion \| shares				4,491,310
Conversion price (in dollars per share) \| $ / shares				$ 0.04718
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Purchase of convertible note					$ 4,360,000	4,360,000					$ 3,121,900	$ 3,000,000
Conversion price (in dollars per share) \| $ / shares												$ 0.25
Face amount					2,290,000	2,290,000																	$ 2,500,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Purchase of convertible note					400,000	400,000								$ 100,000				$ 100,000		$ 100,000			200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member] \| Private Placement [Member]
Proceeds from issuance of private placement	$ 50,000
Number of accredited investors \| Number	4
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note					$ 100,000	100,000															$ 100,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Thomas Tierney (Tierney Family Trust) [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, all such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note		$ 100,000			$ 540,000	540,000										$ 25,000	$ 100,000				$ 115,000		200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| Mr. George Carpenter [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Purchase of convertible note					$ 200,000	200,000																	$ 200,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note					$ 750,000	750,000																$ 750,000
Amendment Note Purchase Agreement [Member] \| John Pappajohn [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, the Notes are convertible into shares of Common Stock at $0.055 per share: (i) automatically upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robert Follman (Follman Family Trust) [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, these Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| Robin L. Smith [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Description of conversion terms					Pursuant to the Omnibus Amendment, such Notes are convertible into shares of Common Stock at $0.05 per share: (i) automatically, upon the closing of a qualified offering of not less than $5 million, or (ii) voluntarily, within 15 days prior to maturity.
Amendment Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Description of conversion terms					Conversion price of all notes will be $0.05 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the “Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntary, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.
Conversion price (in dollars per share) \| $ / shares															$ 0.05
Face amount																			$ 3,000,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| John Pappajohn [Member]
Purchase of convertible note													$ 100,000	100,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Robert Follman (Follman Family Trust) [Member]
Purchase of convertible note													150,000	$ 150,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Robin L. Smith [Member]
Purchase of convertible note													60,000		$ 60,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Geoffrey E. Harris [Member]
Purchase of convertible note									$ 10,000
Exercise price (in dollars per share) \| $ / shares									$ 0.05
Number of additional shares called after extension \| shares									200,000
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note													$ 350,000
Marketing Services Consulting Agreement [Member] \| Decision Calculus Associates (Jill Carpenter) [Member]
Marketing expense paid								$ 280,000
Marketing expense due					$ 70,000	70,000
Marketing expense paid per month						10,000
Three-Month Long Consulting Engagement With Dr. Eric Warner [Member]
Total professional fees			$ 30,000
Number of stock options granted \| shares		250,000
Exercise price (in dollars per share) \| $ / shares		$ 0.25
Fair value of option		$ 28,300
Monthly professional fees			$ 10,000
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares											$ 0.25
Number of shares called \| shares											60,000,000
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											49,000,000
Second Amended Note & Warrant Agreement [Member] \| John Pappajohn [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares											$ 0.25
Number of shares called \| shares											16,000,000
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											6,000,000
Second Amended Note & Warrant Agreement [Member] \| Robert Follman (Follman Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											10,000,000
Second Amended Note & Warrant Agreement [Member] \| Robin L. Smith [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											1,200,000
Second Amended Note & Warrant Agreement [Member] \| Thomas Tierney (Tierney Family Trust) [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											10,800,000
Second Amended Note & Warrant Agreement [Member] \| Mr. George Carpenter [Member] \| Note Warrant [Member]
Exercise price (in dollars per share) \| $ / shares											$ 0.05
Number of additional shares called after extension \| shares											4,000,000
Second Amended Note & Warrant Agreement [Member] \| RSJ Private Equity (Michal Votruba) [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares										$ 0.25
Number of shares called \| shares										15,000,000
Exercise price (in dollars per share) \| $ / shares										$ 0.05
Number of additional shares called after extension \| shares										22,000,000
Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note										$ 750,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Description of conversion terms					Pursuant to the Second Amended and Restated Note and Warrant Agreement, all Notes: (i) mature on December 31, 2017 (subject to earlier conversion or prepayment), (ii) earn interest at a rate of 5% per annum with interest payable at maturity, and (iii) are convertible into shares of Common Stock (a) automatically upon the closing of a qualified offering of no less than $5 million, at a conversion price of $0.05 per share or (b) voluntarily, within 15 days prior to maturity, at a conversion price of $0.05 per share.
Face amount					$ 27,200,000	$ 27,200,000					$ 1,000,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member] \| John Pappajohn [Member]
Face amount											$ 250,000
Number of shares called \| shares											5,000,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Face amount										$ 750,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

LOSS PER SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
LOSS PER SHARE (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$ (142,700)	$ (696,300)	$ (3,594,000)	$ (1,570,900)
Basic and Diluted net loss per share:
Basic net loss per share (in dollars per share)	$ 0.00	$ (0.01)	$ (0.04)	$ (0.02)
Basic and Diluted weighted average shares outstanding (in shares)	102,669,022	101,667,409	102,543,215	101,667,409
Convertible Debt [Member]
Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Anti-dilutive common equivalent shares	83,271,628	1,892,742	73,234,048	1,771,371
Option [Member]
Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Anti-dilutive common equivalent shares	14,230,011	12,645,994	14,230,011	12,531,746
Warrant [Member]
Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Anti-dilutive common equivalent shares	80,938,825	781,833	43,892,108	871,027

XML 55 R45.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES (Details)	Mar. 31, 2016 USD ($)
Operating Lease Obligations
Operating Lease Obligations, Less than 1 year	$ 75,100
Operating Lease Obligations, 1 to 3 years	$ 65,300
Operating Lease Obligations, 3 to 5 years
Operating Lease Obligations, More than 5 years
Operating Lease Obligations, Total	$ 140,400
Capital Lease Obligations
Capital Lease Obligations, Less than 1 year	2,200
Capital Lease Obligations, 1 to 3 years	4,800
Capital Lease Obligations, 3 to 5 years	$ 1,400
Capital Lease Obligations, More than 5 years
Capital Lease Obligations, Total	$ 8,400
Total Lease Obligations
Total, Less than 1 year	77,300
Total, 1 to 3 years	70,100
Total, 3 to 5 years	$ 1,400
Total, More than 5 years
Total	$ 148,800

XML 56 R46.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)						3 Months Ended		6 Months Ended		72 Months Ended
	Feb. 02, 2016 USD ($) ft²	Jan. 20, 2016 USD ($)	Apr. 24, 2013 USD ($)	Mar. 06, 2013 USD ($)	Jan. 26, 2013 USD ($)	Mar. 31, 2016 USD ($) ft²	Mar. 31, 2015 USD ($)	Mar. 31, 2016 USD ($) ft²	Mar. 31, 2015 USD ($)	Jan. 22, 2016
Loss Contingencies [Line Items]
Operating leases monthly lease payments	$ 1,856							$ 4,580
Operating leases rent expense						$ 16,200	$ 12,200	28,400	$ 24,400
Capital leases future minimum payments due						8,400		8,400
Capital leases future minimum payments due for 2016						1,600		1,600
Capital leases future minimum payments due for 2017-2020						1,200		1,200
Capital leases future minimum payments due for 2021						$ 1,400		1,400
EEG Equipment [Member]
Loss Contingencies [Line Items]
Operating leases term of contract	23 months 15 days
Operating leases monthly lease payments	$ 928		$ 325
Operating leases rent expense	$ 1,911
Proceeds from long-term capital lease obligations			$ 8,900
Capital lease term			36 months
Area of land \| ft²	1,092
Capital leases future minimum payments due			$ 600
Commence period	Feb. 15, 2016
Expiration period	Jan. 31, 2018
Headquarters and Neurometric Services [Member]
Loss Contingencies [Line Items]
Operating leases term of contract										24 months
Operating leases monthly lease payments								2,290
Operating leases rent expense								$ 4,809
Area of land \| ft²						2,290		2,290
Commence period								Feb. 01, 2016
Expiration period								Jan. 31, 2018
Canon Copier [Member]
Loss Contingencies [Line Items]
Operating leases term of contract		60 months
Operating leases monthly lease payments		$ 135
Capital leases future minimum payments due						$ 7,800		$ 7,800
Financial lease to acquire		$ 6,700
Leonard J. Brandt and Brandt Ventures, GP v. CNS Response, Inc., Sail Venture Partners and David Jones [Member]
Loss Contingencies [Line Items]
Damages sought value				$ 170,000	$ 9,000,000			$ 250,000

XML 57 R47.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			6 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 05, 2016	Jan. 08, 2015	Mar. 31, 2016	May. 04, 2016	Apr. 21, 2016	Apr. 11, 2016	Apr. 07, 2016	Feb. 24, 2016	Dec. 28, 2015	Dec. 23, 2015
Number of stock options granted
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Number of shares called										60,000,000
2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted		250,000
Description of vesting rights		The option vesting is contingent upon the achievement of agreed upon goals.
Geoffrey E. Harris [Member] \| Note Warrant [Member]
Face amount								$ 10,000
Number of shares called								200,000
RSJ Private Equity (Michal Votruba) [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Number of shares called									15,000,000
John Pappajohn [Member] \| Note Warrant [Member]
Face amount			$ 250,000
Number of shares called			5,000,000
John Pappajohn [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Number of shares called										16,000,000
SubsequentEventMember \| Robin L. Smith [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Share price (in dollars per share)					$ 0.05
Number of shares called					800,000
SubsequentEventMember \| Robin L. Smith [Member] \| Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount					$ 40,000
SubsequentEventMember \| Robin L. Smith [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	1,000,000
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Geoffrey E. Harris [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	500,000
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Five Directors [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	25,000
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Mr. George Carpenter [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	1,000,000
Description of vesting rights	50% of these shares vested on the date of grant with the remaining 50% vesting pro-rata over 12 months starting on the date of grant, respectively.
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Mr. Paul Buck [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	1,000,000
Description of vesting rights	50% of these shares vested on the date of grant with the remaining 50% vesting pro-rata over 12 months starting on the date of grant, respectively.
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Staff Members [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	1,450,000
Description of vesting rights	These shares vest pro-rata over 12 months starting on the date of grant.
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| Decision Calculus Associates (Jill Carpenter) [Member] \| 2012 Omnibus Incentive Compensation Plan [Member]
Number of stock options granted	200,000
Description of vesting rights	These shares vest pro-rata over 12 months starting on the date of grant.
Share price (in dollars per share)	$ 0.0255
SubsequentEventMember \| RSJ Private Equity (Michal Votruba) [Member] \| Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount							$ 200,000
SubsequentEventMember \| Robert Follman (Follman Family Trust) [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Share price (in dollars per share)							$ 0.05
Number of shares called							4,000,000
SubsequentEventMember \| John Pappajohn [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Share price (in dollars per share)						$ 0.05
Number of shares called						5,000,000
SubsequentEventMember \| John Pappajohn [Member] \| Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount						$ 250,000
SubsequentEventMember \| Mr. George Carpenter & His Wife Jill [Member] \| Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Share price (in dollars per share)					$ 0.05
Number of shares called					1,000,000
SubsequentEventMember \| Mr. George Carpenter & His Wife Jill [Member] \| Second Amended Note & Warrant Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount				$ 50,000

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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